Compounds and methods for stabilizing phenylalanine hydroxylase mutations
By providing a stable PAH mutant protein compound or a pharmaceutical composition thereof, the problem of difficult to obtain and maintain a therapeutically effective amount of protein in existing PKU treatments is solved, and the control of phenylalanine level is improved and the quality of life of patients is improved.
Patent Information
- Application Number
- CN202380036612.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-28
- Filing Date
- 2023-02-27
- Publication Date
- 2024-12-06
AI Technical Summary
Existing treatments for phenylketonuria (PKU), such as Phe-restricted diet and drug treatment, are difficult to persist for a long time and have problems with the acquisition and maintenance of effective protein doses, especially enzyme replacement therapy, which is not effective due to rapid protein degradation. .
Provides a stable compound or pharmaceutical composition of a phenylalanine hydroxylase (PAH) mutant protein, or a pharmaceutical composition thereof, by contacting the mutant PAH protein, to reduce the phenylalanine level, including the specific compound structure and its pharmaceutically acceptable salts are used to treat PKU patients.
It improves the ability of patients to increase natural protein intake, extends the maintenance time of therapeutically effective amounts, improves the control of phenylalanine levels in blood and brains of PKU patients, and reduces the complexity and cost of treatment.
Smart Images

Figure CN119095854A_ABST
Abstract
Description
[0001] Related applications
[0002] This application claims priority to U.S. Provisional Application No. 63 / 314,580, filed February 28, 2022, the entire contents of which are incorporated herein by reference. Technical Field
[0003] This application relates to compounds that stabilize phenylalanine hydroxylase (PAH) mutations, pharmaceutical compositions comprising these compounds, and methods of treating phenylketonuria using these compounds. Background Technology
[0004] Phenylketonuria (PKU) is an autosomal recessive genetic disorder affecting approximately 1 in 10,000 people worldwide (approximately 1 in 15,000–1 in 20,000 in the United States). The global incidence varies by region. PKU occurs in individuals with a mutation in the gene encoding phenylalanine hydroxylase (PAH), the enzyme responsible for converting phenylalanine to tyrosine. PAH is a tetrameric enzyme expressed in the liver and requires the BH4 cofactor to function. Reduced or absent PAH activity leads to the toxic accumulation of phenylalanine (Phe) in the blood and brain. High levels of Phe can damage brain white matter and interfere with neurotransmitter production. If left untreated, high levels of Phe can lead to intellectual disability and decreased IQ in children, as well as neurocognitive and psychiatric problems in adults, such as executive function deficits (e.g., difficulty with attention, memory, flexible thinking, and organization / time management), psychological problems (e.g., depression, anxiety, and mood swings), mental and / or behavioral problems (e.g., attention deficit hyperactivity disorder, self-harm, schizophrenia, agoraphobia, and agitation), and neurological abnormalities (e.g., spasms, tremors, gait disorders, and epilepsy).
[0005] PKU phenotypes can range from mild hyperphenylalaninemia (HPA) to more severe phenotypes, the latter resulting in untreated blood Phe concentrations exceeding 1200 μM. US medical guidelines currently recommend maintaining blood Phe concentrations between 120 and 360 μM for adults and children under 12 years of age. European medical guidelines currently recommend maintaining blood Phe concentrations below 360 μM for children under 12 years of age and pregnant women, and below 600 μM for non-pregnant patients over 12 years of age.
[0006] The standard of care for PKU is a Phe-restricted diet, which strictly limits the intake of natural protein. This diet is very strict and difficult to adhere to. Currently, two medications are approved for the treatment of PKU, each with its own challenges. Kuvan (saproptorelin dihydrochloride), a synthetic BH4 cofactor, was approved in 2007 for use from infants to adults. Kuvan is not effective in all PKU patients, and current guidelines recommend testing for response unless the patient is known to have two nullipotent mutations. Pegvaliase, an enzyme replacement therapy, was approved in 2018 for adults with blood Phe concentrations greater than 600 μM, although previous treatment options were available. Pegvaliase typically involves injecting a purified, PEGylated form of phenylalanine aminolyase, which reduces Phe by converting it to ammonia and trans-cinnamic acid instead of tyrosine. One of the major challenges of enzyme replacement therapy is obtaining and maintaining a therapeutically effective amount of protein in the body due to the rapid degradation or inactivation of the infused protein. Current methods to overcome this problem involve multiple expensive, high-dose injections.
[0007] There is a need for medications that can increase patients' intake of natural proteins. Summary of the Invention
[0008] In some aspects, the present invention provides compounds of formula I:
[0009]
[0010] Or a pharmaceutically acceptable salt thereof, wherein:
[0011] m is 1 or 2;
[0012] R 1 for
[0013] x is between 0 and 5;
[0014] Each R a Independent of halogen, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy or C 1-6 Halogenated alkoxy groups;
[0015] R 2 C 1-4 Alkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl;
[0016] R 3 For H or C 1-6 alkyl;
[0017] R 4 For H or C 1-6 alkyl;
[0018] or R 3 and R 4 Together with the atoms they are attached to, they form C 3-6 cycloalkyl;
[0019] R 5 For H or D;
[0020] R 5A It is H or D; and
[0021] L represents a bond, carbonyl group, or C with optional substitution. 1-6 Alkylene, optionally substituted C 1-6 alkylene carbonyl, optionally substituted C 2-6 imide carbonyl, optionally substituted C 1-6 Halogenated alkylene carbonyl, or optionally substituted -C(O)NR b (C 1-6 alkylene)-, wherein the carbon atom of the carbonyl group is attached to N in formula I; and
[0022] R b For H or C 1-6 alkyl.
[0023] In other respects, the present invention provides compounds of the formula IA, IB, IC, ID, IE, IF, IG, IH, II, IJ, IK, IL, or IM, or pharmaceutically acceptable salts thereof:
[0024]
[0025] Stereoisomers and mixtures of stereoisomers of compounds of formulas I, IA, IB, IC, ID, IE, IF, IG, IH, II, IJ, IK, IL, and IM, as well as their pharmaceutical salts, are also described.
[0026] In other respects, the present invention provides pharmaceutical compositions comprising one or more compounds described herein or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients.
[0027] In other aspects, the present invention provides a method for stabilizing a mutant PAH protein, comprising contacting the protein with one or more compounds described herein or pharmaceutically acceptable salts thereof. In some embodiments, the mutant PAH protein comprises at least one R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation. In other embodiments, the mutant PAH protein comprises at least one R408W, Y414C, I65T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation.
[0028] In other respects, the present invention provides a method for reducing phenylalanine levels in subjects suffering from phenylketonuria, comprising administering a therapeutically effective amount of one or more of the compounds described herein or a pharmaceutically acceptable salt thereof.
[0029] Detailed Description of Exemplary Implementations
[0030] definition
[0031] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. The terminology used in this specification is for describing particular embodiments only and is not intended to limit the scope of this disclosure.
[0032] As used in the structure of this article It indicates the connection point between a specific delineated structure or substituent and the appropriate atom in the rest of the molecule.
[0033] Unless the context clearly indicates otherwise, the articles “a” and “an” used herein and in the appended claims refer to one or more (e.g., at least one) of the grammatical objects of the article. For example, “an element” means one or more elements.
[0034] "Pharmaceutical acceptable" means approved or permitted by a federal or state regulatory agency or a corresponding agency in a country outside the United States, or listed in the United States Pharmacopeia or other generally recognized pharmacopoeia for use in animals (e.g., humans).
[0035] "Pharmaceutically acceptable salt" refers to the salt of the compound of the present invention, which is pharmaceutically acceptable and has the desired pharmacological activity of the parent compound. Specifically, such salt is non-toxic and can be an inorganic or organic acid addition salt and a base addition salt. Specifically, such salt includes: (1) acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc.; or acid addition salts formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chloro Benzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheponic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfate, gluconic acid, glutamic acid, hydroxynaphthenic acid, salicylic acid, stearic acid, mucoconic acid, etc.; or (2) salts formed when the acidic protons in the parent compound are replaced by metal ions (e.g., alkali metal ions, alkaline earth ions or aluminum ions) or coordinated with organic bases (e.g., ethanolamine, diethanolamine, triethanolamine, N-methylglucosamine, etc.). Salts also include (by example only) sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, etc.; and when the compound contains a basic functional group, salts of non-toxic organic or inorganic acids, such as hydrochloride, hydrobromide, fumarate, tartrate, methanesulfonate, acetate, maleate, oxalate, etc.
[0036] "Pharmaceutical acceptable excipients" are substances that are nontoxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as inert substances, added to a pharmacological composition or otherwise used as a medium, carrier, or diluent to facilitate the administration of the drug and are compatible with it.
[0037] The term "alkyl," when used alone or as part of a substituent, refers to a straight-chain or branched hydrocarbon group having 1 to 12 carbon atoms ("C12") in the group. 1-12 For example, 1 to 6 carbon atoms (“C”) 1-6 Examples of alkyl groups include methyl (C1), ethyl (C2), propyl (C3) (e.g., n-propyl, isopropyl), butyl (C4) (e.g., n-butyl, tert-butyl, sec-butyl, isobutyl), pentyl (C5) (e.g., n-pentyl, 3-pentyl, pentyl, neopentyl, 3-methyl-2-butyl, tert-pentyl), hexyl (C6) (e.g., n-hexyl), heptyl (C7) (e.g., n-heptyl), octyl (C8) (e.g., n-octyl), etc. In some embodiments, the alkyl group is C1. 1-6 Alkyl; in other embodiments, it is C10. 1-4Alkyl; and in other embodiments, it is C10. 1-3 alkyl.
[0038] The term "alkylene," when used alone or as part of a substituent, refers to an alkyl dienym, i.e., a straight-chain or branched hydrocarbon group attached to two other groups. For example, one embodiment of a C2 alkylene is dienym-CH2CH2-. In some embodiments, the alkylene is C2-. 1-6 Alkylene; in other embodiments, it is C 1-4 Alkylene.
[0039] When this article uses the carbon atom range, such as C 1-6 This includes all ranges and the number of individual carbon atoms. For example, "C 1-3 "Including C" 1-3 C 1-2 C 2-3 C1, C2 and C3.
[0040] The term "cycloalkyl," when used alone or as part of a substituent, refers to a non-aromatic cyclic hydrocarbon group having 3 to 10 carbon atoms ("C10"). 3-10 For example, 3 to 7 carbon atoms (“C”) 3-7 Examples of cycloalkyl groups include cyclopropyl (C3), cyclobutyl (C4), cyclopentyl (C5), cyclohexyl (C6), cycloheptyl (C7), etc. In some embodiments, the cycloalkyl group is C6. 3-4 Cycloalkyl; in other embodiments, it is C10. 3-6 Cycloalkyl; and in other embodiments, it is C10. 3-8 Cycloalkyl group. The cycloalkyl group may be unsubstituted or substituted. In some embodiments, the cycloalkyl group is substituted with two substituents. In other embodiments, the cycloalkyl group is substituted with one substituent. In other embodiments, the cycloalkyl group is substituted with three substituents. In other embodiments, the cycloalkyl group is unsubstituted.
[0041] When used alone or as part of a substituent, the term "aryl" also refers to a monocyclic or bicyclic aromatic ring structure having 6 or 10 carbon atoms, wherein one or more carbon atoms in the ring are optionally substituted. The term "aryl" also includes a monocyclic or bicyclic aromatic ring structure having 6 or 10 carbon atoms, wherein two adjacent carbon atoms in the ring are optionally substituted, such that the two adjacent carbon atoms and their respective substituents form a cycloalkyl or heterocyclic ring. Examples of aryl groups include phenyl, indenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, etc. Aryl groups can be unsubstituted or substituted. In other embodiments, the optionally substituted phenyl has four substituents. In other embodiments, the optionally substituted phenyl has three substituents. In other embodiments, the optionally substituted phenyl has two substituents. In other embodiments, the optionally substituted phenyl has one substituent. In other embodiments, the optionally substituted phenyl is unsubstituted.
[0042] As described herein, the term "alkenyl" refers to a straight-chain or branched group having 2 to 12 carbon atoms ("C2") in the group. 2-12 The alkenyl group comprises at least one carbon-carbon double bond. Examples of alkenyl groups include vinyl (-CH=CH2; C2 alkenyl), allyl (-CH2-CH=CH2; C3 alkenyl), propenyl (-CH=CHCH3; C3 alkenyl), isopropenyl (-C(CH3)=CH2; C3 alkenyl), butenyl (-CH=CHCH2CH3; C4 alkenyl), sec-butenyl (-C(CH3)=CHCH3; C4 alkenyl), isobutenyl (-CH=C(CH3)2; C4 alkenyl), 2-butenyl (-CH2CH=CHCH3; C4 alkyl), pentenyl (-CH=CHCH2CH2CH3; C5 alkenyl), etc. In some embodiments, the alkenyl group is C 2-6 Alkenyl; in other embodiments, it is C 2-4 Alkenyl group.
[0043] As described herein, the term "alkynyl" refers to a straight-chain or branched group having 2 to 12 carbon atoms ("C2") in the group. 2-12 The group comprises at least one carbon-carbon triple bond. Examples of alkynyl groups include ethynyl (-C≡CH; C2 alkynyl), propynyl (-CH2-C≡CH; C3 alkynyl), propynyl (-C≡CCH3; C3 alkynyl), butynyl (-C≡CCH2CH3; C4 alkynyl), pentylyl (-C≡CCH2CH2CH3; C5 alkynyl), etc. In some embodiments, the alkynyl group is C 2-6 Alkyne group; in other embodiments, it is C 2-4 Alkyne group.
[0044] The term "carbonyl" refers to C(O) or C(=O), whether used on its own or as part of another group.
[0045] The term "alkyl carbonyl," whether used alone or as part of another group, refers to an alkyl group as defined above, wherein at least one carbon atom is bonded to an oxo group. For example, one embodiment of a C3 alkyl carbonyl is -CH2C(O)CH3. In some embodiments, the alkyl carbonyl is C... 1-6 Alkyl carbonyl group.
[0046] The term "alkenyl carbonyl," whether used alone or as part of another group, refers to a -C(O)-(alkenyl) group, where the alkenyl group is an alkylene diene, i.e., a straight-chain or branched hydrocarbon group containing at least one carbon-carbon double bond attached to two other groups. For example, one embodiment of the -C(O)-C2 alkenyl group is -C(O)-CH=CH-. In some embodiments, the alkenyl group of the alkenyl carbonyl group is C 2-6 alkenyl group; in other embodiments, the alkenyl group is C 2-4 Alkenyl group.
[0047] The term “halogen” or “halogen”, whether used on its own or as part of another group, refers to a fluorine, chlorine, bromine, or iodine atom.
[0048] As used herein, the term "halogenated alkyl" refers to an alkyl group in which one or more hydrogen atoms are substituted by one or more halogen atoms, which may be the same or different. In some embodiments, the alkyl group is substituted by at least one halogen. In other embodiments, the alkyl group is substituted by one, two, or three F and / or Cl. Examples of halogenated alkyl groups include fluoromethyl (CH2F), 1-fluoroethyl (CH(CH3)F), 2-fluoroethyl, difluoromethyl (CHF2), trifluoromethyl (CF3), pentafluoroethyl, 1,1-difluoroethyl (C(CH3)F2), 2,2-difluoroethyl (CH2CHF2), 2,2,2-trifluoroethyl (CH2CF3), 2-fluoropropyl-2-yl (C(CH3)2F), 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, trichloromethyl, etc. In some embodiments, the halogenated alkyl group is C 1-6 Halogenated alkyl; in other embodiments, it is C10. 1-4 Halogenated alkyl; and in other embodiments, it is C10. 1-3 Halogenated alkyl groups.
[0049] The term "haloalkylene carbonyl," whether used alone or as part of another group, refers to a -C(O)-(haloalkylene) group, wherein the haloalkylene refers to a haloalkyl dienym. For example, one embodiment of a -C(O)-C1 haloalkylene is -C(O)-CF2-. In some embodiments, the haloalkylene is C 1-6 Alkyl halide; in other embodiments, it is C10. 1-4 Alkyl halide; and in other embodiments, it is C10. 1-3 Alkyl halides.
[0050] When the term "cyanoalkyl" is used alone or as part of another group, it means that an alkyl group as defined herein is substituted with one or more CN groups. In some embodiments, the alkyl group is substituted with at least one CN group. In other embodiments, the alkyl group is substituted with one, two, or three CN groups. In other embodiments, the cyanoalkyl group is C10. 1-6 Cyanoalkyl. In other embodiments, the cyanoalkyl group is C10. 1-4 Cyanoalkyl groups. Examples of cyanoalkyl groups include CH2CN, CH2CH2CN, CH(CN)CH3, CH2CH2CH2CN, C(CH3)2CN, CH2CH(CN)CH3, CH(CN)CH2CH3, etc.
[0051] When used alone or as part of another group, the term "hydroxyalkyl" refers to an alkyl group as defined herein, wherein one or more hydrogen atoms are replaced by one or more hydroxyl groups (i.e., -OH). In some embodiments, the hydroxyalkyl group contains one OH group. In other embodiments, the hydroxyalkyl group contains two OH groups. In further embodiments, the hydroxyalkyl group contains three OH groups. Examples of hydroxyalkyl groups include hydroxymethyl, hydroxyethyl (e.g., 1-hydroxyethyl, 2-hydroxyethyl), 1,2-dihydroxyethyl, hydroxypropyl (e.g., 2-hydroxypropyl, 3-hydroxypropyl), hydroxybutyl (e.g., 3-hydroxybutyl, 4-hydroxybutyl), 2-hydroxy-1-methylpropyl, 1,3-dihydroxypropyl-2-yl, etc. In some embodiments, the hydroxyalkyl group is C10. 1-6 Hydroxyalkyl; in other embodiments, it is C 1-4 Hydroxyalkyl; and in other embodiments, it is C 1-3 Hydroxyalkyl.
[0052] When used alone or as part of another group, the term "cycloalkylsulfonyl" refers to a cycloalkyl group as defined herein, bonded to a sulfonyl group (i.e., -SO2-), with the sulfonyl group forming a connection point with the remainder of the molecule. In some embodiments, the cycloalkylsulfonyl group is C 3-8 Cycloalkylsulfonyl; in other embodiments, it is C3-6 Cycloalkylsulfonyl groups. Examples of cycloalkylsulfonyl groups include -SO2-cyclopropyl, -SO2-cyclobutyl, -SO2-cyclopentyl, etc.
[0053] The term "alkylsulfonyl," when used alone or as part of another group, refers to an alkyl group as defined herein, bonded to a sulfonyl group (i.e., -SO2-), and the sulfonyl group forms a connection point with the remainder of the molecule. In some embodiments, the alkylsulfonyl group is C 1-6 Alkyl sulfonyl group; in other embodiments, it is C 1-4 Alkyl sulfonyl group. Examples of alkyl sulfonyl groups include -SO2CH3, -SO2CH2CH3, etc.
[0054] The term "alkylsulfonyl (alkylene)" as used on its own or as part of another group refers to an alkylene group as defined herein, bonded to the sulfonyl group of an alkylsulfonyl group. Examples of alkylsulfonyl (alkylene) groups include -C(CH3)2SO2CH3, -CH2SO2CH3, -CH(CH3)SO2CH3, etc.
[0055] The term "alkoxy," whether used alone or as part of another group, refers to an oxygen group linked to an alkyl group by a single bond. Examples of alkoxy groups include methoxy (OCH3), ethoxy (OCH2CH3), and propoxy (e.g., -O). n Pr, -O i Pr), or butoxy group (e.g., -O) n Bu、-O i Bu、-O s Bu、-O t Bu), etc. In other embodiments, the alkoxy group is C. 1-6 Alkyl group. In other embodiments, the alkoxy group is C. 1-4 Alkyl group.
[0056] The term "alkoxy (alkylene)" as used on its own or as part of another group refers to an alkylene group as defined herein, bonded to an alkoxy group. Examples of alkoxy (alkylene) groups include -CH2OCH3, -CH2CH2OCH3, etc.
[0057] The term "haloalkoxy," whether used alone or as part of another group, refers to an oxygen group linked to a haloalkyl group by a single bond, wherein the haloalkyl group is as defined above. Examples of haloalkoxy groups include fluoromethoxy (OCH2F), 2-fluoroethoxy, difluoromethoxy (OCHF2), trifluoromethoxy (OCF3), pentafluoroethoxy, 1,1-difluoroethoxy (OC(CH3)F2), 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy (OCH2CF3), 3,3,3-trifluoropropoxy, 4,4,4-trifluorobutoxy, trichloromethoxy, etc. In some embodiments, the haloalkoxy group is C 1-6 Haloalkoxy; in other embodiments, it is C 1-4 Haloalkoxy; and in other embodiments, it is C 1-3 Halogenated alkoxy groups.
[0058] When the term "haloalkoxy (alkylene)" is used alone or as part of another group, it refers to an alkylene group as defined herein, in combination with a haloalkoxy group. Examples of haloalkoxy (alkylene) groups include -CH2OCF3, etc.
[0059] The term "heteroaryl," used alone or as part of a substituent, refers to a monocyclic or bicyclic aromatic ring structure comprising a carbon atom and up to four heteroatoms, each of which is independently nitrogen, oxygen, or sulfur. A heteroaryl ring may comprise a total of 5, 6, 9, or 10 ring atoms. In some embodiments, the heteroaryl ring is characterized by the number of ring atoms in the heteroaryl group. For example, a 6-membered heteroaryl refers to a heteroaryl group having 6 ring atoms. Similarly, a 5-membered heteroaryl refers to a heteroaryl group having 5 ring atoms. The heteroaryl portion may be unsubstituted, or one or more carbon or nitrogen atoms in the ring may be substituted. Examples of heteroaryl groups include thienyl, benzo[b]thienyl, furanyl, benzofuranyl, pyranyl, thienyl, isobenzofuranyl, benzoxazinyl, chromenyl, xanthyl, 2H-pyrroleyl, pyrroleyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, 3H-indolyl, indolyl, indazoleyl, purinel, isoquinolinyl, quinolinyl, quinoxalinyl, phthalazinyl, naphthinyl, cinolinyl, triazolyl. Tetraazolyl, thiadiazolyl, oxadiazolyl, quinazolinyl, pteridinyl, pyrimidinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, furazolyl, pyrazolo[1,5-a]pyridinyl, benzoisothiazolyl, imidazole[1,5-a]pyridinyl, pyrrolo[1,2]pyridazinyl, benzo[d]thiazolyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzoisoxazolyl, isothiazolyl, tetrahydropyrazolo[1,5-a]pyridinyl, etc.In some embodiments, the heteroaryl group is thiophene (e.g., thiophene-2-yl and thiophene-3-yl), furanyl (e.g., 2-furanyl, 3-furanyl, 4-furanyl), pyrroloyl (e.g., pyrrolo-2-yl, pyrrolo-3-yl), imidazolyl (e.g., imidazo-2-yl, imidazo-4-yl), pyrazolyl (e.g., pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl), pyridinyl (e.g., pyridin-1-yl, pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl), pyrimidinyl (e.g., pyrimidin-2-yl, pyrimidin-4-yl, and pyrimidin-5-yl), or thiazolyl (e.g., Thiazol-2-yl, thiazolyl, and thiazolyl-5-yl), isothiazolyl (e.g., isothiazol-3-yl, isothiazol-4-yl, and isothiazol-5-yl), oxazolyl (e.g., oxazol-2-yl, oxazol-4-yl, and oxazol-5-yl), isoxazolyl (e.g., isoxazol-3-yl, isoxazol-4-yl, and isoxazol-5-yl), pyrazinyl (e.g., pyrazin-2-yl, pyrazin-3-yl, pyrazin-5-yl, and pyrazin-6-yl), triazolyl (e.g., 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, and 1,2,4-triazol-5-yl), thiadiazolyl (e.g., 1,2,3- Thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl), oxadiazolyl (e.g., 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl), indazoleyl (e.g., indazole-3-yl), pyrazolo[1,5-a]pyridinyl (e.g., pyrazolo[1,5-a]pyridin-3-yl), imidazole[1,5-a]pyridinyl (e.g., imidazole[1,5-a]pyridin-1-yl), pyrrolo[1,2]pyridazinyl (e.g., pyrrolo[1,2]pyridazin-5-yl, pyrrolo[1,2]pyridazinyl) The terms "heteroaryl" include N-oxides. Heteroaryl groups can be unsubstituted or substituted. In some embodiments, the heteroaryl group is substituted with two substituents. In other embodiments, the heteroaryl group has one substituent. In other embodiments, the heteroaryl group has three substituents. In a further embodiment, the heteroaryl group is unsubstituted.Substitution can occur on any available carbon or heteroatom (e.g., nitrogen), or both, as long as the valence of the substituent allows it.
[0060] In some embodiments, the heteroaryl group is a 5- or 6-membered heteroaryl group. In some embodiments, the heteroaryl group is a 5-membered heteroaryl group, meaning it is a monocyclic aromatic ring system having 5 ring atoms, wherein at least one carbon atom of the ring is independently substituted by a heteroatom selected from nitrogen, oxygen, and sulfur. Examples of 5-membered heteroaryl groups include thiophene, furanyl, pyrrole, oxazolyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, and isoxazolyl. In other embodiments, the heteroaryl group is a 6-membered heteroaryl group, for example, a monocyclic aromatic ring system having 6 ring atoms, wherein at least one carbon atom of the ring is substituted by a nitrogen atom. Examples of 6-membered heteroaryl groups include pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, and others.
[0061] The term "heterocyclic group," used alone or as part of another group, refers to a non-aromatic, saturated, or partially unsaturated cyclic group, such as one or two double bonds, containing one, two, or three rings, having three to fourteen ring members, i.e., a 3-14 membered heterocyclic group, in which at least one carbon atom of one ring is replaced by a heteroatom. Each heteroatom is independently selected from oxygen, sulfur (including sulfoxides and sulfones), and / or nitrogen atoms, and may be oxidized or quaternized. The term "heterocyclic group" also includes groups in which the ring -CH2- is replaced by -C(O)-. The term "heterocyclic group" also includes groups having fused, optionally substituted aryl groups, such as indolinyl or chroman-4-yl, and groups having fused, optionally substituted cycloalkyl groups, such as 6-azaspiro[2.5]octyl. In some embodiments, the heterocyclic group is C 4-6 A heterocyclic group, i.e., a 4-, 5-, or 6-membered cyclic group, contains one ring and one or two oxygen and / or nitrogen atoms. In other embodiments, the heterocyclic group is a C-shaped group containing one ring and one nitrogen atom. 4-6Heterocyclic groups. Heterocyclic groups can optionally be attached to the remainder of the molecule via any available carbon or heteroatom, resulting in a stable structure. Examples of heterocyclic groups include azirrocyclobutane, dioxacyclohexane, tetrahydropyranyl, pyrroliyl, piperidinyl, morpholinyl, piperazine, pyrroliyl, indololinyl, oxacyclobutane, tetrahydrofuranyl, tetrahydrothiophenyl, azirrocycloheptane, acridineyl, dioxacyclopentane, imidazoalkyl, pyrazolyl, thiohexane, dithiaalkyl, thiomorpholinyl, oxacycloheptane, oxacyclopropane, tetrahydropyranyl, etc. In some embodiments, the heterocyclic group includes azirrocyclobutane, pyrroliyl, piperidinyl, piperazine, morpholinyl, and 6-azispiro[2.5]octyl. The heterocyclic group can be unsubstituted or substituted. In some embodiments, the heterocyclic group is substituted with two substituents. In other embodiments, the heterocyclic group is substituted with one substituent. In other embodiments, the heterocyclic group is substituted with three substituents. In other embodiments, the heterocyclic group is unsubstituted.
[0062] When the term “(heterocyclic)alkylene” is used alone or as part of another group, it refers to an alkylene group as defined herein that is combined with a heterocyclic group as defined herein.
[0063] The term "optional substitution" used in this document to describe the chemical parts defined herein means that the part may, but does not necessarily, be substituted with one or more suitable functional groups or other substituents provided herein. For example, substituents may be optionally substituted with one or more of the following: halogen, cyano, -NO2, -N3, -OH, -SH, C 1-6 Alkyl, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkoxy (alkylene), C 1-6 Halogenated alkoxy groups, C 1-6 Halogenated alkoxy (alkylene), C 1-6 alkyl carbonyl, C 1-6 Cyanoalkyl, C 1-6 Hydroxyalkyl, C 1-6 alkylene thioyl, (CR v R x ) p NR y R z (where R) v and R x Independently H or C 1-6 Alkyl; R y and R z Independently H, C 1-6 Alkyl, C3-6 cycloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy (alkylene) or C(O)OC 1-6 Alkyl group (with p = 0, 1, 2 or 3), -C(O)NH2, -C(O)NHC 1-6 Alkyl, -C(O)N(C) 1-6 Alkyl)2、-C(O)NHC 3-6 Cycloalkyl, -C(O)N(C 3-6 cycloalkyl)2, -COOH, -C 1-6 Alkylene COOH, -C 3-6 cycloalkyl COOH, -C 1-6 Alkylene CONH2, C 3-6 cycloalkyl group CONH2, -C 1-6 Alkylene CONHC 1-6 Alkyl, -C 1-6 Alkylene CON(C) 1-6 Alkyl)2、-C(O)OC 1-6 Alkyl group, -NHCO(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(O)(C 1-6 Alkyl), -S(O)C 1-6 Alkyl, -S(O)C 3-6 cycloalkyl, C 1-6 alkylsulfonyl, C 3-8 Cycloalkylsulfonyl, C 1-6 Alkylsulfonyl (alkylene), oxo (=O), 3-7-membered heterocyclic, heterocyclic (alkylene), aryl, aryl (alkylene), or heteroaryl groups. In some embodiments, the C of any of the substituents in this paragraph... 1-6 Alkyl group is C 1-4 Alkyl; in other embodiments, it is C10. 1-3 Alkyl group. In some embodiments, the C10 of any of the substituents in this paragraph... 1-6 Alkylene is C 1-4 Alkylene. In some embodiments, the C 1-6 The alkyl halosubstituted group is C 1-4 Halogenated alkyl; in other embodiments, it is C10. 1-3 Halogenated alkyl group. In some embodiments, the C... 3-6 The cycloalkyl substituent is C 3-4 Cycloalkyl substituents. In some embodiments, the C... 1-6 The alkoxy substituent is C 1-3 Alkyl group; in other embodiments, it is C 1-4Alkyl group. In some embodiments, the C... 1-6 The haloalkoxy substituent is C 1-3 Haloalkoxy; in other embodiments, it is C 1-4 Halogenated alkoxy groups.
[0064] In some embodiments, the substituents may optionally be replaced with one or more of the following: C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, halogen, CN, C 1-6 Cyanoalkyl, C 1-6 Haloalkyl, OH, optional substituted C 3-8 cycloalkyl, optionally substituted C 3-8 Cycloalkenyl, optionally substituted aryl, optionally substituted aryl (alkylene), optionally substituted heteroaryl, optionally substituted heterocyclic, optionally substituted heterocyclic (alkylene), C 1-6 Hydroxyalkyl, C 1-6 Halogenated alkoxy groups, C 1-6 Halogenated alkoxy (alkylene), C 1-6 Alkoxy, C 1-6 Alkoxy (alkylene), C 1-6 Deuterated alkoxy (alkylene), C 1-6 alkyl carbonyl, C 3-8 Cycloalkylsulfonyl, C 1-6 alkylsulfonyl (alkylene), (CR) v R x ) p NR y R z (where R) v and R x Independently H or C 1-6 Alkyl; R y and R z Independently H and C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy (alkylene) or C(O)OC 1-6 Alkyl groups, and p is 0, 1, 2 or 3) and C(O)NR y2 R z2 (where R) y2 and R z2 Independently H and C 1-6 Alkyl, or C 3-6 (cycloalkyl).
[0065] The term "nitrogen protecting group" refers to a portion attached to a nitrogen atom to prevent a reaction from occurring at that nitrogen atom. Nitrogen protecting groups are known to those skilled in the art and include those described in Wuts, PG, Greene's Protective Groups in Organic Synthesis, Wiley; 5th edition (October 27, 2014), which is incorporated herein by reference.
[0066] Unless otherwise stated herein, the expressions of numerical ranges herein are intended as a shorthand for each individual value within a range, and each individual value is incorporated into the specification as if it were expressed separately. Unless otherwise stated, the use of any and all examples or exemplary language (e.g., “for example”) provided herein is intended to better illustrate the disclosure and does not limit its scope. No language in the specification should be construed as indicating that any unstated element is essential to the practice of the disclosure.
[0067] When the term “about” is used in conjunction with a numerical value or range of values, it indicates that the numerical value or range may deviate from what is considered reasonable by a person skilled in the art.
[0068] The compounds described herein may contain one or more asymmetric centers and therefore may exist in a variety of stereoisomeric forms, such as enantiomers and / or diastereomers. For example, the compounds described herein may be in the form of a single enantiomer, diastereomer, or geometric isomer, or in the form of a mixture of stereoisomers, including racemic mixtures and mixtures rich in one or more stereoisomers. Isomers may be separated from the mixture by methods known to those skilled in the art, including supercritical fluid chromatography (SFC), chiral high-performance liquid chromatography (HPLC), and the formation and crystallization of chiral salts; or preferred isomers may be prepared by asymmetric synthesis. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, EL Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, SHTables of Resolving Agents and OpticalResolutions p. 268 (EL Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972).
[0069] The exemplary compounds disclosed herein include a chiral center, which may be described herein as having a specific stereochemistry, but whose absolute stereochemistry has not yet been obtained. The absolute configuration can be obtained using methods known in the art.
[0070] As used herein, the term “stereoisomer” refers to compounds that have the same chemical composition and connectivity but differ in the spatial arrangement of atoms or groups, such as enantiomers or diastereomers.
[0071] When the stereochemical configuration at the chiral center in a compound having one or more chiral centers is indicated by its chemical name (e.g., where the configuration is represented by "R" or "S" in the chemical name) or structure (e.g., the configuration is represented by a dashed line or wedge bond), the indicated configuration has an enrichment of greater than 50%, 60%, 70%, 80%, 90%, 99%, or 99.9% relative to the opposite configuration. "Enrichment of the indicated configuration relative to the opposite configuration" is a molar percentage, determined by dividing the number of compounds having the indicated chiral center stereochemical configuration by the total number of all compounds in the mixture having the same or opposite stereochemical configurations.
[0072] When a disclosed compound is named or described by structure without indicating stereochemistry, it should be understood that the name or structure contains one of the possible stereoisomers or geometric isomers without other isomers, or contains a mixture of stereoisomers or geometric isomers.
[0073] It should be understood that some compounds disclosed herein may exist in tautomeric forms. Such forms are incorporated as part of this disclosure. Therefore, when a compound is represented by a structural formula or designated by a chemical name, all possible tautomeric forms of that compound are included in the structural formula.
[0074] When the compounds described herein contain alkene double bonds or other geometrically asymmetric centers, they include E and Z geometric isomers unless otherwise stated.
[0075] In some embodiments, the compounds described herein are isotopically enriched compounds, for example, isotopic bodies. The term "isotopically enriched" refers to an atom having an isotopic composition different from that of its natural abundance. "Isotopically enriched" can also refer to a compound containing at least one such atom having an isotopic composition different from that of its natural abundance. In isotopic bodies, "isotopic enrichment" refers to the percentage of a given atom in a molecule where a specific isotope replaces the natural isotopic composition of that atom. For example, 1% deuterium enrichment at a given position means that 1% of the molecules in a given sample contain deuterium at that specified position. Since the natural distribution of deuterium is about 0.0156%, deuterium enrichment at any position in a compound synthesized using non-enriched starting materials would be about 0.0156%. In one embodiment, one or more hydrogen atoms on the compound may be replaced by deuterium.
[0076] Therefore, as used herein, unless otherwise specified, the term "isotope enrichment factor" refers to the ratio between the isotopic composition of a specified isotope and the natural isotopic composition.
[0077] Regarding the compounds presented in this article, the position of a specific atom is referred to as having deuterium or "D" or "...". 2 When H is mentioned, it should be understood that the deuterium abundance at that location is substantially greater than the natural abundance of deuterium (approximately 0.015%). In specific embodiments, the minimum isotopic enrichment factor typically present at each designated deuterium atom, referred to as the location with deuterium, is at least 1000 (15% deuterium doping), at least 2000 (30% deuterium doping), at least 3000 (45% deuterium doping), at least 3500 (52.5% deuterium doping), at least 4000 (60% deuterium doping), and at least 5000 (75% deuterium doping). The isotopic enrichment and isotopic enrichment factor of the compounds provided herein can be determined using conventional analytical methods (including mass spectrometry and nuclear magnetic resonance spectroscopy) known to those skilled in the art.
[0078] Throughout this specification, the term "patient" or "subject" is used to describe an animal, preferably a human or domestic animal, to which treatment, including preventative treatment, is administered according to the compounds or compositions of this disclosure. For the treatment of conditions or disease states specific to a particular animal (e.g., a human patient), the term "patient" refers to that particular animal, including domestic animals (e.g., dogs or cats) or farm animals (e.g., horses, cattle, sheep, etc.). Generally, in this disclosure, the term "patient" refers to a human patient unless the context of its use implies otherwise.
[0079] The terms "therapeuticly effective amount" or "effective amount" refer to the amount or dose of the disclosed compound (or a pharmaceutically acceptable salt thereof) sufficient to produce the desired therapeutic benefit in a subject requiring treatment of a specified disease or condition. Furthermore, a therapeutically effective amount of the disclosed compound refers to the amount of a therapeutic agent, alone or in combination with other therapies, that provides therapeutic benefit in the treatment or prevention of a disease.
[0080] In one embodiment, “treatment” or “curing” for any disease or condition means improving the disease or condition (e.g., preventing or reducing the development of the disease or at least one of its clinical symptoms). In another embodiment, “treatment” or “curing” means improving at least one bodily parameter that may not be identifiable to the subject. In yet another embodiment, “treatment” or “curing” means regulating the disease or condition, whether physical (e.g., stabilizing identifiable symptoms), physiological (e.g., stabilizing bodily parameters), or both. In yet another embodiment, “treatment” or “curing” means delaying the onset of the disease or condition.
[0081] The terms “prevention”, “protection”, and “avoidance” refer to the prevention of the onset, recurrence, or spread of a subject’s disease by administering a prophylactic or therapeutic agent.
[0082] compound
[0083] This invention provides compounds of formula I or pharmaceutically acceptable salts thereof:
[0084]
[0085] In Equation I, m is 1 or 2. In some embodiments, m is 1. In other embodiments, m is 2.
[0086] In equation I, R 1 for
[0087] In R 1In the structure, x ranges from 0 to 5. In some embodiments, x is 0. In other embodiments, x is 1. In other embodiments, x is 2. In other embodiments, x is 3. In other embodiments, x is 4. In other embodiments, x is 5.
[0088] In other implementation schemes, R 1 for And x is 0 or 1, such as In other implementation schemes, R 1 for In other implementation schemes, R 1 for In other implementation schemes, R 1 for In other implementation schemes, R 1 for In other implementation schemes, R 1 for In other implementation schemes, R 1 for
[0090] In some embodiments, the compound is a single enantiomer and R 1 Partially alpha (α) configured. In some embodiments, the compound is a single enantiomer and R 1 Part of it is a beta (β) configuration.
[0091] In R 1 In the structure, each R a Independent of halogen, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy or C 1-6 Halogenated alkoxy groups. In some embodiments, R... a It is a halogen such as F, Cl, Br, or I. In other embodiments, R a It is F, Br, or Cl. In other embodiments, R a For F. In other implementations, R a For Br. In other embodiments, R a For Cl. In other implementations, R a For I. In other implementations, R a C 1-6 Alkyl groups such as methyl, ethyl, propyl, butyl, pentyl, or hexyl. In other embodiments, R a It is methyl, ethyl, or isopropyl. In other embodiments, R a It is methyl. In other embodiments, R is...a C 3-6 Cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In other embodiments, R a It is cyclopropyl. In other embodiments, R a C 1-6 Haloalkyl groups such as CF3, CHF2, CH2F, CH2CF3, C(CH3)2F, or C(CH3)F2. In other embodiments, R a It is CF3 or CHF2. In other embodiments, R a C 1-6 Alkyl groups, such as methoxy, ethoxy, propoxy, butoxy, pentoxy, or hexoxy. In other embodiments, R a It is methoxy or ethoxy. In other embodiments, R a C 1-6 Halogenated alkoxy groups such as OCF3 or OCH2CF3. In other embodiments, an R a It is halogen and the second R a C 1-6 Alkoxy or C 1-6 alkyl.
[0092] In equation I, R 2 C 1-4 Alkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments, R 2 C is an optional replacement 3-8 Cycloalkyl, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl. In other embodiments, R 2 For unreplaced C 3-8 Cycloalkyl, unsubstituted heterocyclic, unsubstituted aryl, or unsubstituted heteroaryl. In other embodiments, R 2 To replace C 3-8 Cycloalkyl, substituted heterocyclic, substituted aryl, or substituted heteroaryl. In some embodiments, R 2 C 1-4 Alkyl groups such as methyl, ethyl, propyl, butyl, or tert-butyl. In other embodiments, R 2 C is an optional replacement 3-8 Cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl. In other embodiments, R 2 The substituted heterocyclic group is an optional heterocyclic group such as a nitrogen-containing heterocyclic butyl group. In other embodiments, R 2 The substituted aryl group is, for example, phenyl. In other embodiments, R... 2The substituted heteroaryl group is such as pyridyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, furanyl, thiophenyl, pyrimidinyl, pyrazinyl, indazoleyl, pyrazolo[1,5-a]pyridyl, imidazole[1,5-a]pyridyl, pyrrolo[1,2-b]pyridazinyl, benzo[d]thiazolyl, benzo[d]isothiazolyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]isoxazolyl, or benzo[d]isothiazolyl.
[0093] In equation I, R 3 For H or C 1-6 Alkyl group. In some embodiments, R 3 For H. In other implementations, R 3 C 1-6 Alkyl groups such as methyl, ethyl, propyl, butyl, pentyl, or hexyl. In other embodiments, R 3 It is methyl. In other embodiments, R is... 3 It is ethyl. In other embodiments, R 3 It is propyl. In other embodiments, R 3 It is butyl. In other embodiments, R 3 It is pentyl. In other embodiments, R 3 For oneself.
[0094] In equation I, R 4 For H or C 1-6 Alkyl group. In some embodiments, R 4 For H. In other implementations, R 4 C 1-6 Alkyl groups such as methyl, ethyl, propyl, butyl, pentyl, or hexyl. In other embodiments, R 4 It is methyl. In other embodiments, R is... 4 It is ethyl. In other embodiments, R 4 It is propyl. In other embodiments, R 4 It is butyl. In other embodiments, R 4 It is pentyl. In other embodiments, R 4 For oneself.
[0095] Or, R 3 and R 4 Together with the atoms they are connected to, they form C 3-6 Cycloalkyl. In some embodiments, R 3 and R 4 Together they form a cyclopropyl group. In other embodiments, R 3 and R 4 Together they form a cyclobutyl group. In other embodiments, R 3 and R4 Together they form a cyclopentyl group. In other embodiments, R 3 and R 4 Together they form a cyclohexyl group.
[0096] In some implementation schemes, R 3 and R 4 Both are H. In other implementations, R 3 For methyl and R 4 For H. In other implementations, R 3 and R 4 Both are methyl groups.
[0097] In equation I, R 5 For H or D. In some implementations, R 5 For H. In other implementations, R 5 The answer is D.
[0098] In equation I, R 5A For H or D. In some implementations, R 5A For H. In other implementations, R 5A The answer is D.
[0099] In formula I, L represents a bond, carbonyl group, or optionally substituted C. 1-6 Alkylene, optionally substituted C 1-6 alkylene carbonyl, optionally substituted C 2-6 imide carbonyl, optionally substituted C 1-6 Halogenated alkylene carbonyl, or optionally substituted -C(O)NR b (C 1-6 (alkylene)-, wherein the carbon atom of the carbonyl group is attached to N in Formula I. In some embodiments, L is a bond. In other embodiments, L is a carbonyl group (where the carbon atom of the carbonyl group is attached to N in Formula I). In other embodiments, L is an optionally substituted C 1-6 Alkylenes, such as methylene, ethylene, propylene, butylene, pentylene, or hexylene. In other embodiments, L is a C1 alkylene. In other embodiments, L is a C2 alkylene. In other embodiments, L is a C3 alkylene. In other embodiments, L is a C4 alkylene. In other embodiments, L is a C5 alkylene. In other embodiments, L is a C6 alkylene. In other embodiments, L is an optionally substituted C 1-6An alkylene carbonyl group (where the carbonyl carbon atom is attached to N in Formula I). In other embodiments, L is a -C1 alkylene-C(O)-. In other embodiments, L is a -C2 alkylene-C(O)-. In other embodiments, L is a -C3 alkylene-C(O)-. In other embodiments, L is a -C4 alkylene-C(O)-. In other embodiments, L is a -C5 alkylene-C(O)-. In other embodiments, L is a -C6 alkylene-C(O)-. In other embodiments, L is an optionally substituted C 2-6 An alkenyl carbonyl group (where the carbonyl carbon atom is attached to N in Formula I). In other embodiments, L is -C2 alkenyl-C(O)-. In other embodiments, L is -C3 alkenyl-C(O)-. In other embodiments, L is -C4 alkenyl-C(O)-. In other embodiments, L is -C5 alkenyl-C(O)-. In other embodiments, L is -C6 alkenyl-C(O)-. In other embodiments, L is an optionally substituted C 1-6 A haloalkylene carbonyl group (where the carbonyl carbon atom is attached to N in Formula I). In other embodiments, L is a -C1 haloalkylene-C(O)-. In other embodiments, L is a -C2 haloalkylene-C(O)-. In other embodiments, L is a -C3 haloalkylene-C(O)-. In other embodiments, L is a -C4 haloalkylene-C(O)-. In other embodiments, L is a -C5 haloalkylene-C(O)-. In other embodiments, L is a -C6 haloalkylene-C(O)-. In other embodiments, L is a -C(O)NR b (C 1-6 Alkylene)- (wherein the carbonyl carbon atom is attached to N in Formula I). In other embodiments, L is -C(O)NR b C1 alkylene-. In other embodiments, L is -C(O)NR. b C2 alkylene-. In other embodiments, L is -C(O)NR. b C3 alkylene-. In other embodiments, L is -C(O)NR. b C4 alkylene-. In other embodiments, L is -C(O)NR. b C5 alkylene-. In other embodiments, L is -C(O)NR. b C6 alkylene-.
[0100] In the structure of L, R b For H or C 1-6 Alkyl group. In some embodiments, R b For H. In other implementations, R b C 1-6Alkyl groups, such as methyl, ethyl, propyl, butyl, pentyl, or hexyl. In other embodiments, R b It is methyl. In other embodiments, R is... b It is ethyl. In other embodiments, R b It is propyl. In other embodiments, R b It is butyl. In other embodiments, R b It is pentyl. In other embodiments, R b For oneself.
[0101] In some implementations, L represents a bond, -C(O)-, -C(O)CH2-, -C(O)CH2CH2-, -C(O)CH2CH2CH2-, -C(O)CF2-, -C(O)CHF-, -C(O)C(CH3)2-, -C(O)CH=CH-, -C(O)NHCH2-, -CH2-, or -CH2CH2-. In other embodiments, L is a bond, -C(O)-, -C(O)CH2-, or -C(O)CF2.
[0102] In some implementation schemes, R 2 It is cyclopentyl, cyclobutyl, cyclopropyl, aziridine, phenyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazolo[1,5-a]pyridinyl, indazole, thiazolyl, imidazole[1,5-a]pyridinyl, pyrrolo[1,2]pyridazinyl, thiophene, isoxazolyl, isothiazolyl, benzo[d]thiazolyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]isooxazolyl, benzo[d]isothiazolyl, furanyl, or pyrazinyl, each of which may be optionally substituted.
[0103] In other implementation schemes, R 2 It is cyclopentyl, cyclobutyl, cyclopropyl, cyclohexyl, aziridine, phenyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrazolo[1,5-a]pyridinyl, indazole, thiazolyl, imidazole[1,5-a]pyridinyl, pyrrolo[1,2]pyridazinyl, thiophene, isoxazolyl, isothiazolyl, benzo[d]thiazolyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]isooxazolyl, benzo[c]isooxazolyl, benzo[d]isothiazolyl, furanyl, pyrazinyl or quinolinyl, each of which may be optionally substituted.
[0104] In other implementation schemes, R 2It is cyclopentyl, cyclobutyl, cyclopropyl, aziridine, phenyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazolo[1,5-a]pyridinyl, indazole, thiazolyl, imidazole[1,5-a]pyridinyl, pyrrolo[1,2]pyridazinyl, thiophene, isoxazolyl, isothiazolyl, benzo[d]thiazolyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]isooxazolyl, benzo[d]isothiazolyl, furanyl, or pyrazinyl, none of which is substituted.
[0105] In other implementation schemes, R 2 It is cyclopentyl, cyclobutyl, cyclopropyl, cyclohexyl, aziridine, phenyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazolo[1,5-a]pyridinyl, indazole, thiazolyl, imidazole[1,5-a]pyridinyl, pyrrolo[1,2]pyridazinyl, thiophene, isoxazolyl, isothiazolyl, benzo[d]thiazolyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]isooxazolyl, benzo[c]isooxazolyl, benzo[d]isothiazolyl, furanyl, pyrazinyl or quinolinyl, none of which are substituted.
[0106] In other implementation schemes, R 2 The cyclopentyl group is optionally substituted. In other embodiments, R... 2 The substituted cyclobutyl group is optional. In other embodiments, R... 2 The cyclopropyl group is optionally substituted. In other embodiments, R... 2 The substituted cyclohexyl group is used. In other embodiments, R... 2 It is an optionally substituted nitrogen-containing heterocyclic butyl group. In other embodiments, R 2 The phenyl group is optionally substituted. In other embodiments, R... 2 The pyrazolyl group is optionally substituted. In other embodiments, R 2 The oxazolyl group is optionally substituted. In other embodiments, R 2 The thiazole group is optionally substituted. In other embodiments, R 2 The triazole group is optionally substituted. In other embodiments, R... 2 The substituted oxadiazole group is optionally present. In other embodiments, R... 2 The pyridyl group is optionally substituted. In other embodiments, R... 2 The pyrimidinyl group is optionally substituted. In other embodiments, R 2 The pyrazolo[1,5-a]pyridyl group is optionally substituted. In other embodiments, R 2 The indazole group is optionally substituted. In other embodiments, R... 2 The thiadiazole group is optionally substituted. In other embodiments, R...2 The substituted imidazole [1,5-a]pyridyl group is used. In other embodiments, R 2 The pyrrolo[1,2]pyridazinyl group is optionally substituted. In other embodiments, R 2 The thiophene group is optionally substituted. In other embodiments, R 2 The isoxazolyl group is optionally substituted. In other embodiments, R 2 The isothiazol group is optionally substituted. In other embodiments, R 2 The substituted benzo[d]thiazolyl group is optionally used. In other embodiments, R 2 The substituted benzo[d]imidazolium group is optionally used. In other embodiments, R 2 The substituted benzo[d]oxazolyl group is optionally used. In other embodiments, R 2 It is benzo[d]isoxazolyl. In other embodiments, R 2 The substituted benzo[c]isoxazolyl group is optionally used. In other embodiments, R 2 The substituted benzo[d]isothiazolyl group is optionally used. In other embodiments, R 2 The furanyl group is optionally substituted. In other embodiments, R... 2 The pyrazinyl group is optionally substituted. In other embodiments, R 2 The quinolinyl group is optionally substituted.
[0107] In other implementation schemes, R 2The following are listed: aziridine-1-yl, aziridine-3-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,2,3-triazol-5-yl, 1,3,4-oxadiazol-2-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, pyrazolo[1,5-a]pyridin-3-yl, indazole-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, 1,3,4-thiadiazol-2-yl, pyridin-1-yl The following are substituted: pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, imidazole[1,5-a]pyridin-1-yl, pyrrolo[1,2]pyridazin-5-yl, pyrrolo[1,2]pyridazin-6-yl, thiophene-2-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, benzo[d]thiazol-2-yl, benzo[d]thiazol-3-yl, benzo[d]imidazol-2-yl, benzo[d]oxazol-2-yl, benzo[d]isoxazol-3-yl, benzo[d]isothiazol-3-yl, furan-3-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, or pyrazin-2-yl, each of which may be optionally substituted.
[0108] In other implementation schemes, R 2 The following are listed: aziridine-1-yl, aziridine-3-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,2,3-triazol-5-yl, 1,3,4-oxadiazol-2-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, pyrazolo[1,5-a]pyridin-3-yl, indazole-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, 1,3,4-thiadiazol-2-yl, pyridin-1-yl, pyridin-2-yl, pyridine The following are substituted: pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, imidazole[1,5-a]pyridin-1-yl, pyrrolo[1,2]pyridazin-5-yl, pyrrolo[1,2]pyridazin-6-yl, thiophene-2-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, benzo[d]thiazol-2-yl, benzo[d]thiazol-3-yl, benzo[d]imidazol-2-yl, benzo[d]oxazol-2-yl, benzo[d]isoxazol-3-yl, benzo[d]isothiazol-3-yl, furan-3-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, pyrazin-2-yl, benzo[c]isoxazol-3-yl, or quinoline-3-yl, each of which may be optionally substituted.
[0109] In other implementation schemes, R 2 C 3-8 Cycloalkyl, heterocyclic, aryl, or heteroaryl, each substituted by one or more of the following: C 1-6 Alkyl, optionally substituted C 2-6 alkenyl, halogen, CN, C 1-6 Cyanoalkyl, C 1-6 Halogenated alkyl, OH, optional substituted C 3-8 cycloalkyl, optionally substituted C 3-8 Cycloalkyl (alkylene), optionally substituted C 3-8 Cycloalkenyl, optionally substituted aryl, optionally substituted aryl (alkylene), optionally substituted heteroaryl, optionally substituted heterocyclic, optionally substituted heterocyclic (alkylene), C 1-6 Hydroxyalkyl, C 1-6 Halogenated alkoxy groups, C 1-6 Halogenated alkoxy (alkylene), C 1-6 Alkoxy, C 1-6 Alkoxy (alkylene), C 1-6 Deuterated alkoxy (alkylene), C 1-6 alkyl carbonyl, C 3-8 Cycloalkylsulfonyl, C 1-6 alkylsulfonyl, C 1-6 Alkylsulfonyl (alkylene),
[0110] (CR v R x ) p NR y R z (where R) v and R x Independently H or C 1-6 Alkyl; R y and R z Independently H and C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy (alkylene) or C(O)OC 1-6 Alkyl group (where p is 0, 1, 2, or 3), or C(O)NR y2 R z2 (where R) y2 and R z2 Independently H and C 1-6 Alkyl, or C 3-6 (Cycloalkyl). In other embodiments, R 2 C can be arbitrarily replaced 1-6Alkyl groups, such as methyl, ethyl, propyl, isopropyl, or tert-butyl. In other embodiments, R 2 C can be arbitrarily replaced 2-6 Alkenyl groups such as CH=CH2, CH=CHC(CH3)2OH, or CH=CH-cyclopropyl. In other embodiments, R 2 Optional substitutions include halogens such as Br, Cl, or F. In other embodiments, R... 2 CN can be optionally replaced. In other embodiments, R... 2 C can be arbitrarily replaced 1-6 Cyanoalkyl groups, such as C(CH3)2CN. In other embodiments, R... 2 C can be arbitrarily replaced 1-6 Haloalkyl groups, such as CF3, CHF2, CH2F, CH(CH3)F, CH2CF3, C(CH3)2F, C(CH3)F2, or CH2CHF2. In other embodiments, R 2 Optional substitution includes OH. In other embodiments, R... 2 Optional substitution of C 3-8 Cycloalkyl groups, such as optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, or optionally substituted cyclohexyl. In other embodiments, R 2 Optional substitution of C 3-8 Cycloalkyl (alkylene) such as optionally substituted cyclopropyl (alkylene) or optionally substituted cyclobutyl (alkylene). In other embodiments, R 2 Optional substitution of C 3-8 Cycloalkenyl, such as optionally substituted cyclohexenyl. In other embodiments, R 2 Optional substitution includes substituted aryl groups such as substituted phenyl groups. In other embodiments, R 2 Optional substitutions include optionally substituted aryl (alkylene) groups, such as optionally substituted benzyl groups. In other embodiments, R... 2 Optional substitutions include optional substituted heteroaryl groups, such as optional substituted pyrazolyl, optional substituted imidazolyl, optional substituted pyridyl, optional substituted pyrimidinyl, or optional substituted pyrazinyl. In other embodiments, R 2 Optional substitutions include optional substituted heteroaryl groups, such as optional substituted pyrazolyl, optional substituted imidazolyl, optional substituted pyridyl, optional substituted pyrimidinyl, optional substituted pyrazinyl, or optional substituted pyridazinyl. In other embodiments, R 2 Optional substitutions include optional substituted heterocyclic groups such as optional substituted aza-butyl, optional substituted piperidinyl, optional substituted piperazine, optional substituted pyrrolidinyl, optional substituted morpholinyl, or optional substituted 6-azaspiro[2.5]octyl-6-yl. In other embodiments, R 2Optional substitutions include substituted morpholinyl (alkylene), substituted piperidinyl (alkylene), substituted piperazine (alkylene), or substituted azacyclic butyl (alkylene). In other embodiments, R 2 C can be arbitrarily replaced 1-6 Hydroxyalkyl groups such as C(CH3)2OH, CH(CH3)OH, C(CH3)2CH2OH, CH2C(CH3)2OH, or CH(CH2CH3)OH. In other embodiments, R 2 C can be arbitrarily replaced 1-6 Halogenated alkoxy groups such as OCF3, OCH2CF3, or OCH2CH2CF3. In other embodiments, R 2 C can be arbitrarily replaced 1-6 Halogenated alkoxy (alkylene oxide) such as CH2OCF3. In other embodiments, R 2 C can be arbitrarily replaced 1-6 Alkyl groups, such as methoxy or ethoxy. In other embodiments, R 2 C can be arbitrarily replaced 1-6 Alkyl (alkylene) compounds, such as C(CH3)2OCH3, CH2OCH3, or (CH2)2OCH3. In other embodiments, R 2 C can be arbitrarily replaced 1-6 Deuterated alkoxy (alkylene oxide) such as CH2OCD3. In other embodiments, R 2 C can be arbitrarily replaced 1-6 Alkyl carbonyl, such as C(=O)CH3 or CH2C(=O)CH3. In other embodiments, R 2 C can be arbitrarily replaced 3-8 Cycloalkylsulfonyl groups, such as cyclopropylsulfonyl, cyclobutylsulfonyl, or cyclopentylsulfonyl. In other embodiments, R 2 C can be arbitrarily replaced 1-6 Alkyl sulfonyl groups, such as methyl sulfonyl, ethyl sulfonyl, or propyl sulfonyl. In other embodiments, R 2 C can be arbitrarily replaced 1-6 Alkyl sulfonyl (alkylene), such as C(CH3)2SO2CH3. In other embodiments, R 2 Optional replacements include (CR) v R x ) p NR y R z , where R v R x R y R zAnd p as defined above, such as NH2, NHcyclopropyl, NHCH3, N(CH3)2, CH2N(CH3)2, (CH2)2N(CH3)2, CH2N(CH3)(CH2CH3), C(CH3)2NH(CH3), C(CH3)2N(CH3)2, CH2N(CH3)cyclobutyl, or CH2N(CH3)(C(O)O tert-butyl). In some embodiments, p is 0. In other embodiments, p is 1. In other embodiments, p is 2. In other embodiments, p is 3. In some embodiments, R v and R x Independently hydrogen or methyl. In other embodiments, R y and R z Independently, it is hydrogen, methyl, ethyl, cyclopropyl, cyclobutyl, C(O)Omethyl, C(O)Oethyl, C(O)Opropyl, or C(O)O tert-butyl. In other embodiments, R 2 For C(O)NR y2 R z2 , where R y2 and R z2 As defined above, such as C(O)N(CH3)2 or C(O)NH cyclopropyl. In other embodiments, R y2 and R z2 Independently hydrogen, methyl, or cyclopropyl. In other embodiments, R 2Substituted by one or more of the following: methyl, ethyl, propyl, isopropyl, tert-butyl, CH=CH2, CH=CHC(CH3)2OH, CH=CH-cyclopropyl, Br, Cl, F, CN, C(CH3)2CN, CF3, CHF2, CH2F, CH(CH3)F, CH2CF3, C(CH3)2F, C(CH3)F2, CH2CHF2, OH, optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, optionally substituted cyclohexyl, optionally substituted cyclohexenyl. Optionally substituted cyclopropyl (alkylene), optionally substituted cyclobutyl (alkylene), optionally substituted phenyl, optionally substituted benzyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted pyridyl, optionally substituted pyrimidinyl, optionally substituted pyrazinyl, optionally substituted azacyclobutane, optionally substituted piperidinyl, optionally substituted piperazinyl, optionally substituted pyrrolidinyl, optionally substituted morpholinyl, optionally substituted 6-azaspiro[2.5]octyl-6-yl, optionally substituted morpholinyl (alkylene), optionally substituted piperidinyl (alkylene), optionally substituted Optional substituted piperazine (alkylene) or optionally substituted azacyclic butyl (alkylene), C(CH3)2OH, CH(CH3)OH, C(CH3)2CH2OH, CH2C(CH3)2OH, CH(CH2CH3)OH, OCH2CH2CF3, OCF3, OCH2CF3, CH2OCF3, methoxy, ethoxy, C(CH3)2OCH3, CH2OCH3, (CH2)2OCH3, CH2OCD3, C(=O)CH3, CH2C(=O)CH3 Cyclopropylsulfonyl, cyclobutylsulfonyl, cyclopentylsulfonyl, C(CH3)2SO2CH3, NH2, NHcyclopropyl, NHCH3, N(CH3)2, CH2N(CH3)2, (CH2)2N(CH3)2, CH2N(CH3)(CH2CH3), C(CH3)2NH(CH3), C(CH3)2N(CH3)2, CH2N(CH3)cyclobutyl, CH2N(CH3)(C(O)O tert-butyl), C(O)N(CH3)2, or C(O)NHcyclopropyl.
[0111] In other implementation schemes, R 2 for In other implementation schemes, R 2 for In other implementation schemes, R 2 for
[0112] In some implementation schemes, R 2It is a heterocyclic group, optionally substituted with one or more of the following: halogen, C 1-6 Halogenated alkyl groups, or optionally substituted heteroaryl groups. In other embodiments, R 2 for In other implementation schemes, R 2 It is a heterocyclic group, and its substitutions include one or more of the following: halogen, C 1-6 Halogenated alkyl groups, or optionally substituted heteroaryl groups. In other embodiments, R 2 for In other implementation schemes, R 2 for
[0113] In some implementation schemes, R 2 C 3-8 Cycloalkyl, optionally substituted with one or more of the following: halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl or OH. In other embodiments, R 2 C 3-8 Cycloalkyl, optionally substituted with one or more of the following: halogen or OH. In other embodiments, R 2 Unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted cyclopentyl, unsubstituted cyclohexyl In other implementation schemes, R 2 C 3-8 Cycloalkyl groups, which are substituted with one or more of the following: halogens, C 1-6 Alkyl, C 1-6 Halogenated alkyl or OH. In other embodiments, R 2 for In other implementation schemes, R 2 for
[0114] In some implementation schemes, R 2 It is aryl, optionally substituted with one or more of the following: halogen or C 1-6 Alkyl group. In other embodiments, R 2 It is an unsubstituted phenyl group. In other implementation schemes, R 2 It is aryl, and its substitutions include one or more of the following: halogen or C. 1-6 Alkyl group. In other embodiments, R 2 for
[0115] In some implementation schemes, R 2The pyridyl, pyrimidinyl, or pyrazinyl group may be optionally substituted. In other embodiments, the pyridyl, pyrimidinyl, or pyrazinyl group may be substituted with one or more of the following: halogen, C 1-6 Halogenated alkyl, cyano, or NR y R z , where R y and R z Independently H or C 1-6 alkyl.
[0116] In other implementation schemes, R 2 It is a heteroaryl group, and its substitutions include one or more of the following: C 1-6 Alkyl, C 1-6 Cyanoalkyl, C 1-6 Halogenated alkyl, or C 1-6 Hydroxyalkyl. In other embodiments, R 2 It is a heteroaryl group, and its substitutions include one or more of the following: C 1-6 Alkyl group. In other embodiments, R 2 It is a heteroaryl group, and its substitutions include one or more of the following: C 1-6 Cyanoalkyl. In other embodiments, R 2 It is a heteroaryl group, and its substitutions include one or more of the following: C 1-6 Haloalkyl. In other embodiments, R 2 It is a heteroaryl group, and its substitutions include one or more of the following: C 1-6 Fluoroalkyl. In other embodiments, R 2 It is a heteroaryl group, and its substitutions include one or more of the following: C 1-6 Hydroxyalkyl. In other embodiments, R 2 It is a heteroaryl group, substituted with one or more of the following: methyl, ethyl, isopropyl, tert-butyl, C(CH3)2CN, CH(CH3)OH, C(CH3)2OH, C(CH3)2CH2OH, CH(CH2CH3)OH, CH2C(CH3)2OH, CH2F, CHF2, CF3, CH2CF3, CH2CHF2, CH(CH3)F, C(CH3)F2, or C(CH3)2F. In other embodiments, R 2 It is a heteroaryl group, substituted with one or more of the following: methyl, isopropyl, tert-butyl, C(CH3)2CN, CH(CH3)OH, C(CH3)2OH, CHF2, CF3, CH2CF3, CH(CH3)F, or C(CH3)2F. In other embodiments, R 2 It is a heteroaryl group, substituted with a methyl group. In other embodiments, R 2 It is a heteroaryl group, substituted with an isopropyl group. In other embodiments, R2 It is a heteroaryl group, substituted with tert-butyl. In other embodiments, R 2 It is a heteroaryl group, substituted with C(CH3)2CN. In other embodiments, R 2 It is a heteroaryl group, substituted with CH(CH3)OH. In other embodiments, R 2 It is a heteroaryl group, substituted with C(CH3)2OH. In other embodiments, R 2 It is a heteroaryl group, substituted with CHF2. In other embodiments, R 2 It is a heteroaryl group, substituted with CF3. In other embodiments, R 2 It is a heteroaryl group, substituted with CH2CF3. In other embodiments, R 2 It is a heteroaryl group, substituted with CH(CH3)F. In other embodiments, R 2 It is a heteroaryl group, and its substitution is C(CH3)2F.
[0117] In other implementation schemes, R 2 It is a heteroaryl group, and its substitutions include C. 3-8 cycloalkyl, wherein the C 3-8 The cycloalkyl group itself may be optionally substituted with one or more of the following: halogen, OH, C 1-6 Haloalkyl, C 1-6 Alkyl or C 1-6 Alkyl group. In other embodiments, R 2 It is a heteroaryl group, with unsubstituted C atoms. 3-8 Cycloalkyl groups, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In other embodiments, R 2 It is a heteroaryl group, substituted with cyclopropyl or cyclobutyl groups. In other embodiments, R 2 It is a heteroaryl group, and its substitutions include C. 3-8 cycloalkyl groups, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, wherein the C 3-8 The cycloalkyl group itself is substituted by one or more of the following: halogen, OH, C 1-6 Haloalkyl, C 1-6 Alkyl or C 1-6 Alkyl group. In some embodiments, the substituted C 3-8 The cycloalkyl substituent has OH. In other embodiments, the substituted C 3-8 The cycloalkyl group is substituted with one or more of the following: halogens, such as F, Cl, or Br. In other embodiments, the substituted C... 3-8 Cycloalkyl substitution has C 1-6 Alkyl groups, such as methyl, ethyl, or propyl. In other embodiments, the substituted C 3-8 Cycloalkyl substitution has C 1-6Halogenated alkyl groups, such as CF3, CH2CF3, or CHF2. In other embodiments, the substituted C 3-8 Cycloalkyl substitution has C 1-6 Alkyl groups, such as methoxy, ethoxy, or propoxy. In other embodiments, the substituted C... 3-8 The cycloalkyl group is cyclopropyl or cyclobutyl, each substituted with one or more of the following: F, OH, or methyl. In other embodiments, R 2 It is a heteroaryl group, and its substitutions include In other implementation schemes, R 2 It is a heteroaryl group, and its substitutions include
[0118] In other implementation schemes, R 2 It is a heteroaryl group, which is substituted with an aryl group, wherein the aryl group is optionally substituted with one or more of the following: halogen, C 1-6 Haloalkyl, C 1-6 Alkyl, or C 3-8 Cycloalkyl. In other embodiments, R 2 It is a heteroaryl group, substituted with an unsubstituted phenyl group. In other embodiments, R 2 It is a heteroaryl group, substituted with aryl groups, such as phenyl, wherein the aryl group itself is substituted with one or more of the following: halogen, C 1-6 Haloalkyl, C 1-6 Alkyl, or C 3-8 Cycloalkyl. In some embodiments, the substituted aryl group is substituted with one or more of the following: halogens, such as F, Cl, or Br. In other embodiments, the substituted aryl group is substituted with C. 1-6 Halogenated alkyl groups, such as CF3, CH2CF3, or CHF2. In other embodiments, the substituted aryl group has a C20 substitution. 1-6 Alkyl groups, such as methyl, ethyl, or propyl. In other embodiments, the substituted aryl group has a C-substituted alkyl group. 3-8 Cycloalkyl groups, such as cyclopropyl, cyclobutyl, or cyclopentyl. In other embodiments, the substituted aryl group is a phenyl group substituted with one or more of the following: F, methyl, or CF3. In other embodiments, R 2 It is a heteroaryl group, and its substitutions include In other implementation schemes, R 2 It is a heteroaryl group, and its substitutions include
[0119] In other implementation schemes, R 2The heteroaryl group is a heteroaryl group, which is optionally substituted with other heteroaryl groups. In some embodiments, the optionally substituted heteroaryl group is an optionally substituted pyridyl group, an optionally substituted pyrazinyl group, an optionally substituted pyrazolyl group, an optionally substituted imidazolyl group, or an optionally substituted pyrimidinyl group. In other embodiments, the optional substitution on the heteroaryl group is one or more of the following: halogen, C 1-6 Haloalkyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl or C 3-8 Cycloalkylsulfonyl. In other embodiments, the optionally substituted heteroaryl group is substituted with one or more of the following: halogens, such as F, Cl, or Br. In other embodiments, the optionally substituted heteroaryl group is substituted with one or more of the following: C 1-6 Halogenated alkyl groups, such as CF3, CH2CF3, CH2CHF2, or CHF2. In other embodiments, the optionally substituted heteroaryl group is substituted with one or more of the following: C 1-6 Alkyl groups, such as methyl, ethyl, propyl, or isopropyl. In other embodiments, the optionally substituted heteroaryl group is substituted with one or more of the following: C 1-6 Alkyl groups, such as methoxy, ethoxy, or propoxy. In other embodiments, the optionally substituted heteroaryl group is substituted with one or more of the following: C 1-6 Haloalkoxy groups, such as OCF3. In other embodiments, the optionally substituted heteroaryl group is substituted with one or more of the following: C 3-8 Cycloalkyl groups, such as cyclopropyl, cyclobutyl, or cyclopentyl. In other embodiments, the optionally substituted heteroaryl group is substituted with one or more of the following: C 3-8 Cycloalkylsulfonyl groups, such as cyclopropylsulfonyl, cyclobutylsulfonyl, or cyclopentylsulfonyl. In other embodiments, the optionally substituted heteroaryl group is substituted with one or more of the following: F, CF3, CH2CHF2, CHF2, methyl, methoxy, cyclobutyl, or cyclopropylsulfonyl.
[0120] In other implementation schemes, R 2 It is a heteroaryl group, substituted with pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl, pyrazin-3-yl, pyrazin-4-yl, pyrazin-5-yl, imidazole-4-yl, or imidazole-5-yl, each of which may be optionally substituted. In other embodiments, R 2The substitutions include pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl, pyrazin-3-yl, pyrazin-4-yl, pyrazin-5-yl, imidazole-4-yl, imidazole-5-yl, pyridazin-3-yl, and pyridazin-4-yl, each optionally substituted. In other embodiments, R 2 The pyrazole-1- group is optionally substituted. In other embodiments, R 2 The pyrazole-3- group is optionally substituted. In other embodiments, R 2 The pyrazole-4- group is optionally substituted. In other embodiments, R 2 The pyridin-2-yl group is optionally substituted. In other embodiments, R 2 The pyridine-3-yl group is optionally substituted. In other embodiments, R 2 The pyridine-4-yl group is optionally substituted. In other embodiments, R 2 The substituted imidazole-4- group is optionally replaced. In other embodiments, R 2 The substituted imidazole-5-yl group is optionally substituted. In other embodiments, R 2 The pyrimidin-2-yl group is optionally substituted. In other embodiments, R 2 The pyrimidin-4-yl group is optionally substituted. In other embodiments, R 2 The pyrimidin-5-yl group is optionally substituted. In other embodiments, R 2 The pyrazin-2-yl group is optionally substituted. In other embodiments, R 2 The alternative is a pyridazine-3-yl group with optional substitution. In other embodiments, R 2 The alternative is pyridazine-4-yl with optional substitution.
[0121] In some implementation schemes, R 2 It is a heteroaryl group, and its substitutions include In other implementation schemes, R 2 It is a heteroaryl group, and its substitutions include In other implementation schemes, R 2 It is a heteroaryl group, and its substitutions include
[0122] In some implementation schemes, R 2 It is a heteroaryl group, and its substitutions include In other implementation schemes, R 2 It is a heteroaryl group, and its substitutions include In other implementation schemes, R 2 It is a heteroaryl group, and its substitutions include
[0123] In other implementation schemes, R 2 It is a heteroaryl group, substituted with a heterocyclic group or a heterocyclic (alkylene) group, wherein the heterocyclic group and the heterocyclic (alkylene) group are each optionally substituted with one or more of the following: halogen, OH, C. 1-6 Haloalkyl, C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C(O)O(C 1-6 Alkyl), or C 3-8 Cycloalkyl. In other embodiments, R 2 It is a heteroaryl group, substituted with an unsubstituted heterocyclic group such as azirrobutyl, pyrrolidinyl, piperidinyl, piperazine, morpholinyl, or 6-azaspiro[2.5]octyl-6-yl, or an unsubstituted heterocyclic (alkylene) group such as azirrobutyl (alkylene), pyrrolidinyl (alkylene), piperidinyl (alkylene), piperazine (alkylene), or morpholinyl (alkylene). In other embodiments, R 2 It is a heteroaryl group, substituted with a heterocyclic group, such as aziridine, pyrrolidinyl, piperidinyl, piperazine, or morpholinyl, or a heterocyclic (alkylene) group, such as aziridine (alkylene), pyrrolidinyl (alkylene), piperidinyl (alkylene), piperazine (alkylene), or morpholinyl (alkylene), wherein the heterocyclic group and the heterocyclic (alkylene) group are each substituted by one or more of the following: halogen, OH, C. 1-6 Haloalkyl, C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C(O)O(C 1-6 Alkyl), or C 3-8 Cycloalkyl. In other embodiments, the substituted heterocyclic group or substituted heterocyclic (alkylene) is substituted with one or more of the following: halogen, such as F, Cl, or Br. In other embodiments, the substituted heterocyclic group or substituted heterocyclic (alkylene) is substituted with one or more of the following: OH. In other embodiments, the substituted heterocyclic group or substituted heterocyclic (alkylene) is substituted with one or more of the following: C 1-6Halogenated alkyl groups, such as CF3, CH2CF3, or CHF2. In other embodiments, the substituted heterocyclic group or substituted heterocyclic (alkylene) group is substituted with one or more of the following: C 1-6 Alkyl groups, such as methyl, ethyl, or propyl. In other embodiments, the substituted heterocyclic group or substituted heterocyclic (alkylene) is substituted with one or more of the following: C 1-6 Hydroxyalkyl groups such as C(CH3)2OH or CH(CH3)OH. In other embodiments, the substituted heterocyclic group or substituted heterocyclic (alkylene) group is substituted by one or more of the following: C 1-6 Alkoxy groups, such as methoxy, ethoxy, or propoxy. In other embodiments, the substituted heterocyclic group or substituted heterocyclic (alkylene) group is substituted with one or more of the following: C(O)O(C 1-6 Alkyl groups, such as C(O)O methyl, C(O)O ethyl, C(O)O propyl, or C(O)O tert-butyl. In other embodiments, the substituted heterocyclic group or substituted heterocyclic group (alkylene group) is substituted by one or more of the following: C 3-8 Cycloalkyl groups, such as cyclopropyl, cyclobutyl, or cyclopentyl. In other embodiments, the substituted heterocyclic group or substituted heterocyclic (alkylene) group is substituted with one or more of the following: F, OH, or methyl. Wherein R 2 In other embodiments of the heteroaryl group, R 2 Replace In which R 2 In other embodiments of the heteroaryl group, R 2 Replace
[0124] In other implementation schemes, R 2 for In other implementation schemes, R 2 for In other implementation schemes, R 2 for, In other implementation schemes, R 2 for In other implementation schemes, R 2 for In other implementation schemes, R 2 for In other implementation schemes, R 2 for In other implementation schemes, R 2for In other implementation schemes, R 2 for In other implementation schemes, R 2 for In other implementation schemes, R 2 for In other implementation schemes, R 2 for In other implementation schemes, R 2 for In other implementation schemes, R 2 for In other implementation schemes, R 2 for In other implementation schemes, R 2 for In other implementation schemes, R 2 for In other implementation schemes, R 2 for In other implementation schemes, R 2 for In other implementation schemes, R 2 for In other implementation schemes, R 2 for In other implementation schemes, R 2 for In other implementation schemes, R 2 for In other implementation schemes, R 2 for
[0125] In R 2 In these structures, R 6 and R 7 Each is independently H, CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Cyanoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkoxy (alkylene), C 1-6 Halogenated alkoxy groups, C 1-6 Halogenated alkoxy (alkylene), C 1-6 Deuterated alkoxy (alkylene), halogen, (CR) v R x ) p NR y R z C(O)NR y2 R z2 C1-6 Alkyl carbonyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted heterocyclic, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C 2-6 alkenyl, optionally substituted C 3-8 Cycloalkenyl, optionally substituted (C 3-8 Cycloalkyl)alkylene, optionally substituted (aryl)alkylene, optionally substituted (heterocyclic)alkylene, or C 1-6 alkylsulfonyl; R 8 For H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy (alkylene), C 1-6 alkyl carbonyl, C 1-6 Hydroxyalkyl, (CR) v R x ) p NR y R z Optional substitution of C 3-8 Cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted (C 3-8 cycloalkyl)alkylene; R v and R x Independently H or C 1-6 Alkyl; R y and R z Independently for H and C 1-6 Alkyl, C 1-6 alkoxy (alkylene), or C 3-6 cycloalkyl; R y2 and R z2 Independently for H and C 1-6 Alkyl, or C 3-6 Cycloalkyl; and p is 0, 1, 2, or 3. In some embodiments, R 6 R 7 and R 8 For H.
[0126] In other implementation schemes, R 6 C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Cyanoalkyl, or C 1-6 Hydroxyalkyl. In other embodiments, R 6 C 1-6 Alkyl groups such as methyl, ethyl, isopropyl, or tert-butyl. In other embodiments, R 6 C 1-6Haloalkyl groups such as CF3, CHF2, CH2F, CH2CF3, CH(CH3)F, C(CH3)F2, or C(CH3)2F. In other embodiments, R 6 C 1-6 Cyanoalkyl groups, such as C(CH3)2CN. In other embodiments, R... 6 C 1-6 Hydroxyalkyl groups such as C(CH3)2OH, CH(CH3)OH, CH(CH2CH3)OH, CH2C(CH3)2OH, or C(CH3)2CH2OH. In other embodiments, R 6 It can be methyl, isopropyl, tert-butyl, CF3, CHF2, C(CH3)F2, C(CH3)2F, C(CH3)2OH or CH(CH3)OH.
[0127] In other implementation schemes, R 6 C 3-6 Cycloalkyl groups, optionally substituted with one or more of the following: halogen, OH, C 1-6 Haloalkyl, C 1-6 Alkyl, or C 1-6 Alkyl group. In other embodiments, R 6 It is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, optionally substituted with one or more of the following: halogen, OH, C 1-6 Haloalkyl, C 1-6 Alkyl, or C 1-6 Alkyl group. In other embodiments, R 6 It is an unsubstituted cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl group. In other embodiments, R... 6 C 3-6 Cycloalkyl groups, substituted with one or more halogens such as F, Cl, or Br. In other embodiments, R 6 C 3-6 Cycloalkyl groups, which are substituted with one or more OH groups. In other embodiments, R 6 C 3-6 cycloalkyl, which is substituted with one or more C atoms 1-6 Halogenated alkyl groups such as CF3, CH2CF3, or CHF2. In other embodiments, R 6 C 3-6 cycloalkyl, which is substituted with one or more C atoms 1-6 Alkyl groups such as methyl, ethyl, or propyl. In other embodiments, R 6 C 3-6 Cycloalkyl groups, which are substituted with C 1-6 Alkyl groups, such as one or more methoxy, ethoxy, or propoxy groups. In other embodiments, R 6It is cyclopropyl, cyclobutyl, or cyclohexyl, each optionally substituted with one or more of the following: F, OH, or methyl. In other embodiments, R 6 for In other implementation schemes, R 6 for
[0128] In other implementation schemes, R 6 It is aryl, and its optional substitutions include one or more of the following: halogen, C 1-6 Haloalkyl, C 1-6 Alkyl or C 3-6 Cycloalkyl. In other embodiments, R 6 It is a phenyl group, which may be optionally substituted with one or more of the following: halogen, C 1-6 Haloalkyl, C 1-6 Alkyl or C 3-6 Cycloalkyl. In other embodiments, R 6 It is an aryl group, optionally substituted with one or more of the following: halogens such as F, Cl, or Br. In other embodiments, R 6 It is aryl, and its optional substitutions include one or more of the following: C 1-6 Halogenated alkyl groups such as CF3, CH2CF3, or CHF2. In other embodiments, R 6 It is aryl, and its optional substitutions include one or more of the following: C 1-6 Alkyl groups such as methyl, ethyl, or propyl. In other embodiments, R 6 It is aryl, and its optional substitutions include one or more of the following: C 3-6 Cycloalkyl groups such as cyclopropyl, cyclobutyl, or cyclopentyl. In other embodiments, R 6 It is aryl (e.g., phenyl), optionally substituted with F, methyl, or CF3. In other embodiments, R 6 for In other implementation schemes, R 6 for
[0129] In other implementation schemes, R 6 It is a heteroaryl group, optionally substituted with one or more of the following: halogen, C 1-6 Haloalkyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-6 cycloalkyl, or C 3-6 Cycloalkylsulfonyl. In other embodiments, R6 It is pyridyl, pyrazolyl, pyrazinyl, imidazoleyl, or pyrimidinyl, each optionally substituted. In other embodiments, R 6 It is pyridyl, pyrazolyl, pyrazinyl, pyridazinyl, imidazoleyl, or pyrimidinyl, each optionally substituted. In other embodiments, R 6 The pyrazinyl group is optionally substituted, such as pyrazin-2-yl, pyrazin-3-yl, pyrazin-4-yl, or pyrazin-5-yl. In other embodiments, R 6 The pyrazolyl group is optionally substituted, such as pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, or pyrazol-5-yl. In other embodiments, R 6 The pyridinyl group is optionally substituted, such as pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl. In other embodiments, R 6 The substituted pyridazinyl group is optionally used, such as pyridazin-3-yl or pyridazin-4-yl. In other embodiments, R 6 The substituted imidazole group is optionally substituted, such as imidazole-4-yl or imidazole-5-yl. In other embodiments, R 6 The substituted pyrimidinyl group is optionally substituted, such as pyrimidin-2-yl, pyrimidin-4-yl, or pyrimidin-5-yl. In other embodiments, R 6 It is pyrazin-2-yl, pyrazin-3-yl, pyrazin-4-yl, pyrazin-5-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, imidazole-4-yl, imidazole-5-yl, pyrimidin-2-yl, pyrimidin-4-yl, or pyrimidin-5-yl, each optionally substituted. In other embodiments, R 6 It is pyrazin-2-yl, pyrazin-3-yl, pyrazin-4-yl, pyrazin-5-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, imidazole-4-yl, imidazole-5-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridazin-3-yl, or pyridazin-4-yl, each optionally substituted. In other embodiments, R 6 It is an unsubstituted pyridin-2-yl, unsubstituted pyridin-3-yl, unsubstituted pyridin-4-yl, unsubstituted pyrimidin-2-yl, unsubstituted pyrimidin-4-yl, unsubstituted pyrimidin-5-yl, or unsubstituted pyrazin-2-yl. In other embodiments, R 6 It is an unsubstituted pyridin-2-yl, unsubstituted pyridin-3-yl, unsubstituted pyridin-4-yl, unsubstituted pyrimidin-2-yl, unsubstituted pyrimidin-4-yl, unsubstituted pyrimidin-5-yl, unsubstituted pyrazin-2-yl, or pyridazin-3-yl. In other embodiments, R 6 Optional substitutions include one or more halogens such as F, Cl, or Br. In other embodiments, R6 Optional substitution with one or more C 1-6 Halogenated alkyl groups such as CF3, CH2CF3, or CHF2. In other embodiments, R 6 Optional substitution with one or more C 1-6 Alkyl groups such as methyl, ethyl, propyl, or isopropyl. In other embodiments, R 6 Optional substitution with one or more C 1-6 Alkyl groups, such as methoxy, ethoxy, or propoxy. In other embodiments, R 6 Optional substitution with one or more C 1-6 Haloalkoxy groups, such as OCF3. In other embodiments, R... 6 Optional substitution with one or more C 3-6 Cycloalkyl groups such as cyclopropyl, cyclobutyl, or cyclopentyl. In other embodiments, R 6 Optional substitution with one or more C 3-6 Cycloalkylsulfonyl groups, such as cyclopropylsulfonyl, cyclobutylsulfonyl, or cyclopentylsulfonyl. In other embodiments, R 6 It is a heteroaryl group, which may be optionally substituted with one or more of the following: F, CF3, CH2CF3, CHF2, methyl, methoxy, OCF3, cyclobutyl, or cyclopropylsulfonyl.
[0130] In other implementation schemes, R 6 It is a five-membered heteroaryl group, optionally substituted with one or more of the following: CF3, CH2CF3, CHF2, methyl, cyclobutyl, or cyclopropylsulfonyl. In other embodiments, R 6 for In other implementation schemes, R 6 for In other implementation schemes, R 6 for In other implementation schemes, R 6 for In other implementation schemes, R 6 for In other implementation schemes, R 6 for In other implementation schemes, R 6 for
[0131] In other implementation schemes, R 6It is a six-membered heteroaryl group, optionally substituted with one or more of the following: F, CF3, methoxy, OCF3, or methyl. In other embodiments, R 6 for In other implementation schemes, R 6 for In other implementation schemes, R 6 for
[0132] In other implementation schemes, R 6 It is a heterocyclic group or a heterocyclic (alkylene) group, each optionally substituted with one or more of the following: halogen, OH, C 1-6 Haloalkyl, C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C(O)O(C 1-6 Alkyl), or C 3-6 Cycloalkyl. In other embodiments, R 6 It can be an optionally substituted azacyclic butyl, optionally substituted pyrrolidinyl, optionally substituted piperidinyl, optionally substituted piperazineyl, or optionally substituted morpholinyl. In other embodiments, R 6 It is an optionally substituted nitrogen-containing heterocyclic butyl group. In other embodiments, R 6 The substituted pyrroleyl group is optional. In other embodiments, R... 6 The piperidinyl group is optionally substituted. In other embodiments, R 6 The piperazine group is optionally substituted. In other embodiments, R... 6 The morpholino group is optionally substituted. In other embodiments, R 6 It can be an optionally substituted morpholinyl (alkylene), optionally substituted piperidinyl (alkylene), optionally substituted piperazine (alkylene), or optionally substituted azacyclic butyl (alkylene). In other embodiments, R 6 It is an unsubstituted nitrogen-containing heterocyclic butyl, pyrrolidinyl, piperidinyl, piperazineyl, or morpholinyl group. In other embodiments, R 6 It is an unsubstituted morpholinyl (alkylene), piperidinyl (alkylene), piperazine (alkylene), or azacyclic butyl (alkylene). In other embodiments, R 6The heterocyclic group is unsubstituted with a morpholino or morpholino (alkylene) group. In other embodiments, the heterocyclic and alkylene groups are optionally substituted with one or more halogens such as F, Cl, or Br. In other embodiments, the heterocyclic and alkylene groups are optionally substituted with one or more OH groups. In other embodiments, the heterocyclic and alkylene groups are optionally substituted with one or more C groups. 1-6 Halogenated alkyl groups such as CF3, CH2CF3, or CHF2. In other embodiments, the heterocyclic and heterocyclic (alkylene) groups are optionally substituted with one or more C24 groups. 1-6 Alkyl groups such as methyl, ethyl, or propyl. In other embodiments, the heterocyclic and heterocyclic (alkylene) groups are optionally substituted with one or more C24 groups. 1-6 Hydroxyalkyl groups, such as C(CH3)2OH. In other embodiments, the heterocyclic and heterocyclic (alkylene) groups are optionally substituted with one or more C... 1-6 Alkoxy groups, such as methoxy, ethoxy, or propoxy. In other embodiments, the heterocyclic and heterocyclic (alkylene) groups are optionally substituted with one or more C(O)O(C) groups. 1-6 Alkyl groups, such as C(O)Omethyl, C(O)Oethyl, C(O)Opropyl, or C(O)O tert-butyl. In other embodiments, the heterocyclic and heterocyclic (alkylene) groups are optionally substituted with one or more C... 3-6 Cycloalkyl groups, such as one or more cyclopropyl, cyclobutyl, or cyclopentyl groups. In other embodiments, R... 6 It is a heterocyclic group and a heterocyclic (alkylene) group, each optionally substituted with one or more of the following: F, OH, C(CH3)2(OH), methyl, C(O)O (tert-butyl), or cyclopropyl.
[0133] In other implementation schemes, R 6 for In other implementation schemes, R 6 for In other implementation schemes, R 6 for In other implementation schemes, R 6 for In other implementation schemes, R 6 for In other implementation schemes, R 6 for In other implementation schemes, R 6 for
[0134] In other implementation schemes, R 6 For H, CN, C 1-6 Alkoxy, C 1-6 Alkoxy (alkylene), C 1-6 Halogenated alkoxy groups, C 1-6 Halogenated alkoxy (alkylene), C 1-6 Deuterated alkoxy (alkylene), halogen, (CR) v R x ) p NR y R z C(O)NR y2 R z2 C 1-6 Alkyl carbonyl, optionally substituted C 2-6 alkenyl, optionally substituted C 3-6 Cycloalkenyl, optionally substituted (C 3-6 Cycloalkyl)alkylene, optionally substituted (aryl)alkylene, or C 1-6 Alkyl sulfonyl group. In other embodiments, R 6 For H. In other implementations, R 6 For CN. In other implementations, R 6 C 1-6 Alkyl groups, such as methoxy groups. In other embodiments, R... 6 C 1-6 Alkoxy (alkylene) compounds such as CH2OCH3, C(CH3)2OCH3, or (CH2)2OCH3. In other embodiments, R 6 C 1-6 Halogenated alkoxy groups such as OCF3, OCHF2, OCH2F, or O(CH2)2CF3. In other embodiments, R 6 C 1-6 Halogenated alkoxy (alkylene oxide) such as CH2OCF3. In other embodiments, R 6 C 1-6 Deuterated alkoxy (alkylene oxide) such as CH2OCD3. In other embodiments, R 6 It is a halogen such as F, Br, or Cl. In other embodiments, R... 6 For (CR) v R x ) p NR y R zSuch as NH2, N(CH3)2, NHCH2CF3, NHCH2CH2OCH3, NH (cyclopropyl), CH2N(CH3)2, (CH2)2N(CH3)2, C(CH3)2NHCH3, C(CH3)2N(CH3)2, CH2NH (cyclopropyl), or CH2CH2NH (cyclopropyl). In other embodiments, R 6 For C(O)NR y2 R z2 Such as C(O)N(CH3)2 or C(O)NH (cyclopropyl). In other embodiments, R 6 C 1-6 Alkyl carbonyl groups, such as C(O)CH3. In other embodiments, R... 6 C is an optional replacement 2-6 Alkenyl groups such as CH=CH2, CH=CH-cyclopropyl, or CH=CHC(CH3)2OH. In other embodiments, R 6 C is an optional replacement 3-6 Cycloalkenyl, such as In other implementation schemes, R 6 For optional replacement (C) 3-6 Cycloalkylene groups, such as CH2-cyclopropyl, CH2CH2-cyclopropyl, or C(CH3)OH-cyclopropyl. In other embodiments, R 6 The substituted (aryl) alkylene group is optionally substituted, such as benzyl. In other embodiments, C 1-6 Alkyl sulfonyl (alkylene) such as C(CH3)2SO2CH3. In other embodiments, R 6 It can be H, CH2OCH3, Cl, NH (cyclopropyl), or C(O)N(CH3)2.
[0135] In some implementation schemes, R 7 For H, CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl groups, halogens, C 3-8 Cycloalkyl, aryl, or heteroaryl. In other embodiments, R 7 For H. In other implementations, R 7 For CN. In other implementations, R 7 C 1-6 Alkyl groups, such as methyl, ethyl, or propyl. In other embodiments, R 7 It is methyl. In other embodiments, R is... 7 C 1-6 Alkyl halogenates, such as CHF2, CH2F, C(CH3)F2, CH2CHF2, or CF3. In other embodiments, R 7 It is CHF2 or CF3. In other embodiments, R7 It is a halogen, such as F, Br, or Cl. In other embodiments, R... 7 It is Br or Cl. In other embodiments, R 7 C 3-6 Cycloalkyl groups, such as cyclopropyl, cyclobutyl, or cyclopentyl. In other embodiments, R 7 It is cyclopropyl. In other embodiments, R 7 It is aryl. In other embodiments, R 7 It is phenyl. In other embodiments, R 7 It is a heteroaryl group. In other embodiments, R 7 It is pyridinyl. In other embodiments, R... 7 The derivative is H, CN, methyl, CF3, CH2F, CHF2, CF2(CH3), CH2CHF2, Br, Cl, cyclopropyl, phenyl, or pyridyl. In other embodiments, R... 7 It can be H, CN, methyl, CHF2, CF3, Br, Cl, cyclopropyl, phenyl, or pyridyl.
[0136] In R 2 In some implementation schemes, R 8 For H. In other implementations, R 8 C 1-6 Alkyl groups such as methyl, ethyl, isopropyl, or tert-butyl. In other embodiments, R 8 C 1-6 Haloalkyl groups such as CF3, CHF2, CH2F, CH2CF3, CH2CHF2, C(CH3)2F, or C(CH3)F2. In other embodiments, R 8 C 1-6 Alkyl (alkylene) compounds, such as CH2CH2OCH3. In other embodiments, R... 8 C 1-6 Alkyl carbonyl groups, such as CH2C(=O)CH3. In other embodiments, R... 8 C 1-6 Hydroxyalkyl groups, such as CH2C(CH3)2OH. In other embodiments, R... 8 For (CR) v R x ) p NR y R z For example, (CH2)2N(CH3)2. In other embodiments, R 8 C is an optional replacement 3-8 Cycloalkyl groups include optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, or optionally substituted cyclohexyl. In other embodiments, R 8The aryl group is optionally substituted, such as an optionally substituted phenyl group. In other embodiments, R 8 The substituted heteroaryl group is optionally substituted, such as an optionally substituted pyridyl group. In other embodiments, R 8 The substituted heteroaryl group is optionally substituted, such as an optionally substituted pyridyl group. In other embodiments, R 8 For optional replacement (C) 3-8 cycloalkyl)alkylene, such as In other implementation schemes, R 8 H, methyl, isopropyl, CHF2, CH2CF3, CF3, cyclopropyl, or
[0137] In some implementation schemes, R v and R x One or both of them are H. In other embodiments, R v and R x One or both of them are C 1-6 Alkyl groups such as methyl, ethyl, propyl, or butyl. In other embodiments, R v and R x One or both of them are methyl groups. In some embodiments, R y and R z One or both of them are H. In other embodiments, R y and R z One or both of them are C 1-6 Alkyl groups such as methyl, ethyl, propyl, or butyl. In other embodiments, R y and R z One or both of them are C 1-6 Alkyl (alkylene) such as CH2OCH3. In other embodiments, R y and R z One or both of them are C 3-6 Cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, R y2 and R z2 One or both of them are H. In other embodiments, R y2 and R z2 One or both of them are C 1-6 Alkyl groups such as methyl, ethyl, propyl, or butyl. In other embodiments, R y2 and R z2 One or both of them are C 3-6 Cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In other embodiments, p is 0. In other embodiments, p is 1. In other embodiments, p is 2. In other embodiments, p is 3.
[0138] In some implementation schemes, R 2 for Where: R 6 For H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Cyanoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkoxy (alkylene), optionally substituted C 3-6 Cycloalkyl, or optionally substituted heteroaryl; and R 7 For H, CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl groups, halogens, C 3-6 Cycloalkyl, aryl, or heteroaryl. In other embodiments, R 6 For H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Cyanoalkyl, C 1-6 Hydroxyalkyl, optionally substituted C 3-6 Cycloalkyl, or optionally substituted heteroaryl; and R 7 For H, CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, halogen, or C 3-6 Cycloalkyl. In other embodiments, R 6 For H. In other implementations, R 6 C 1-6 Alkyl group. In other embodiments, R 6 It is methyl, isopropyl, or tert-butyl. In other embodiments, R 6 C 1-6 Haloalkyl. In other embodiments, R 6 It is CF2H, C(CH3)2F, CH(CH3)F, or CF3. In other embodiments, R 6 C 1-6 Cyanoalkyl. In other embodiments, R 6 It is C(CH3)2CN. In other embodiments, R 6 C 1-6 Hydroxyalkyl. In other embodiments, R 6 It is C(CH3)2OH, CH2C(CH3)2OH, CH(CH2CH3)OH, C(CH3)2(CH2OH), or CH(CH3)OH. In other embodiments, R 6 C 1-6 Alkyl group. In other embodiments, R 6 It is methoxy or ethoxy. In other embodiments, R 6C 1-6 Alkoxy (alkylene oxide). In other embodiments, R 6 It is CH2OCH3 or (CH2)2OCH3. In other embodiments, R 6 C is an optional replacement 3-6 Cycloalkyl. In other embodiments, the optionally substituted C 3-6 The cycloalkyl substituted plant has one or more OH groups. In other embodiments, R 6 for In other implementation schemes, R 6 for In other implementation schemes, R 6 The substituted heteroaryl group is optional. In other embodiments, R 6 The substituted pyridyl, pyrazolyl, pyrazinyl, pyrimidinyl, or imidazoleyl groups may be optionally substituted. In other embodiments, the optionally substituted heteroaryl group has one or more C24 groups. 1-6 Alkyl groups such as methyl, ethyl, or isopropyl. In other embodiments, R 6 for In other implementation schemes, R 6 for In other implementation schemes, R 6 H, methyl, tert-butyl, C(CH3)2F, C(CH3)2CN, C(CH3)2OH, CH(CH3)OH, CH2OCH3, cyclopropyl, In other implementation schemes, R 6 For H, tert-butyl, C(CH3)2F, C(CH3)2CN, C(CH3)2OH, CH(CH3)OH, In other implementation schemes, R 7 For H. In other implementations, R 7 For CN. In other implementations, R 7 C 1-6 Alkyl group. In other embodiments, R 7 It is methyl. In other embodiments, R is... 7 C 1-6 Haloalkyl. In other embodiments, R 7 It is CF2H, CHF2, CH2F, C(CH3)F2, or CF3. In other embodiments, R 7 It is CHF2 or CF3. In other embodiments, R 7 It is a halogen. In other embodiments, R7 It is Br or Cl. In other embodiments, R 7 C 3-6 Cycloalkyl. In other embodiments, R 7 It is cyclopropyl. In other embodiments, R 7 It is aryl. In other embodiments, R 7 It is phenyl. In other embodiments, R 7 It is a heteroaryl group. In other embodiments, R 7 It is pyridinyl. In other embodiments, R... 7 It is H, CN, methyl, CHF2, CF3, Br, Cl, cyclopropyl, phenyl, or pyridyl. In other embodiments, R 7 It can be H, CN, methyl, CHF2, CF3, Br, Cl, or cyclopropyl.
[0139] In other implementation schemes, R 2 for Where: R 6 For H, CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkoxy (alkylene), optionally substituted C 3-6 Cycloalkyl, optionally substituted heteroaryl; and R 7 For H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, halogen or C 3-6 Cycloalkyl. In other embodiments, R 6 For H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, or C 1-6 Hydroxyalkyl; and R 7 For H. In other implementations, R 6 For H. In other implementations, R 6 For CN. In other implementations, R 6 C 1-6 Alkyl group. In other embodiments, R 6 It is methyl, isopropyl, or tert-butyl. In other embodiments, R 6 C 1-6 Haloalkyl. In other embodiments, R 6 It is CHF2, C(CH3)2F, C(CH3)F2, or CF3. In other embodiments, R 6 C 1-6 Hydroxyalkyl. In other embodiments, R 6The form is C(CH3)2OH. In other embodiments, R 6 C 1-6 Alkyl group. In other embodiments, R 6 It is methoxy or ethoxy. In other embodiments, R 6 C 1-6 Alkoxy (alkylene oxide). In other embodiments, R 6 It is CH2OCH3. In other embodiments, R 6 C is an optional replacement 3-6 Cycloalkyl. In other embodiments, R 6 for In other implementation schemes, R 6 The substituted heteroaryl group is optional. In other embodiments, R 6 It is an optionally substituted pyridyl group or an optionally substituted pyrazolyl group. In other embodiments, R 6 for In other implementation schemes, R 6 For H, tert-butyl, C(CH3)2F, C(CH3)F2, C(CH3)2OH, CH2OCH3, In other implementation schemes, R 6 It is H or C(CH3)2F. In other embodiments, R 7 For H. In other implementations, R 7 C 1-6 Alkyl group. In other embodiments, R 7 It is methyl. In other embodiments, R is... 7 C 1-6 Haloalkyl. In other embodiments, R 7 It is CF2H or CF3. In other embodiments, R 7 It is a halogen. In other embodiments, R 7 It is Br or Cl. In other embodiments, R 7 C 3-6 Cycloalkyl. In other embodiments, R 7 It is cyclopropyl. In other embodiments, R 7 It can be H, methyl, CF2H, CF3, Br, Cl or cyclopropyl.
[0140] In other implementation schemes, R 2 for Where R 6 and R 7 Independently for H and C 1-6 Alkyl, C 1-6Haloalkyl, halogen, optional substituted C 3-6 Cycloalkyl, or optionally substituted aryl. In other embodiments, R 6 and R 7 Each is H. In other implementations, R... 6 or R 7 One of them is C 1-6 Alkyl groups, such as methyl. In other embodiments, R... 6 or R 7 One of them is C 1-6 Halogenated alkyl groups such as CF3. In other embodiments, R... 6 or R 7 One of them is a halogen such as Br or Cl. In other embodiments, R 6 or R 7 One of them is C that can be arbitrarily replaced. 3-6 Cycloalkyl groups, such as unsubstituted cyclopropyl groups. In other embodiments, R... 6 or R 7 One of them is an optionally substituted aryl group, such as an unsubstituted phenyl group. In other embodiments, R 6 It is methyl, CF3, Cl, cyclopropyl, or phenyl and R 7 For H. In other implementations, R 7 It is methyl, CF3, Cl, cyclopropyl, or phenyl and R 6 For H.
[0141] In other implementation schemes, R 2 for Where R 6 For H, C 1-6 Alkyl, halogen, or optionally substituted aryl. In other embodiments, R 6 For H. In other implementations, R 6 C 1-6 Alkyl groups, such as methyl, ethyl, isopropyl, or tert-butyl. In other embodiments, R 6 It is methyl or ethyl. In other embodiments, R... 6 It is a halogen, such as F, Br, or Cl. In other embodiments, R... 6 For Br. In other embodiments, R 6 The aryl group is optionally substituted. In other embodiments, R 6 It is phenyl. In other embodiments, R 6 It is H, methyl, ethyl, Br, or phenyl. In other embodiments, R 6 It can be H, methyl, or phenyl.
[0142] In other implementation schemes, R 2 for Where R6 For H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C(O)NR y2 R z2 、(CR v R x ) p NR y R z Optional substitution of C 3-6 Cycloalkyl, optionally substituted aryl, optionally substituted heterocyclic, or optionally substituted heteroaryl; R v and R x Independently H or C 1-6 Alkyl; R y and R z Independently for H and C 1-6 Alkyl, C 1-6 alkoxy (alkylene), or C 3-6 cycloalkyl; R y2 and R z2 Independently for H and C 1-6 Alkyl, or C 3-6 Cycloalkyl; and p is 0, 1, 2, or 3. In other embodiments, R 6 For H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted aryl, optionally substituted heterocyclic, or optionally substituted heteroaryl. In some embodiments, R 6 For H. In other implementations, R 6 C 1-6 Alkyl group. In other embodiments, R 6 It is methyl, ethyl, isopropyl, or tert-butyl. In other embodiments, R 6 It is methyl, isopropyl, or tert-butyl. In other embodiments, R 6 C 1-6 Haloalkyl. In other embodiments, R 6 It is CHF2, CF3, or C(CH3)2F. In other embodiments, R 6 It is CF3, CHF2, C(CH3)F2, or C(CH3)2F. In other embodiments, R 6 C 1-6 Hydroxyalkyl. In other embodiments, R 6 It is C(CH3)2OH or CH(CH3)OH. In other embodiments, R... 6 For C(O)NR y2 Rz2 In other implementations, R 6 It is C(O)N(CH3)2 or C(O)NH (cyclopropyl). In other embodiments, R 6 For (CR) v R x ) p NR y R z In other implementations, R 6 It is NH2, N(CH3)2, NHCH2CF3, NHCH2CH2OCH3, NH (cyclopropyl), CH2N(CH3)2, CH2NH (cyclopropyl), or CH2CH2NH (cyclopropyl). In other embodiments, R 6 C is an optional replacement 3-6 Cycloalkyl. In other embodiments, the optionally substituted C 3-6 The cycloalkyl group is substituted by one or more of the following: halogens such as F or C. 1-6 Alkyl groups, such as methyl. In other embodiments, R... 6 for In other implementation schemes, R 6 The aryl group is optionally substituted. In other embodiments, the optionally substituted aryl group is substituted by one or more of the following: halogens such as F, C. 1-6 Alkyl groups such as methyl, or C 1-6 Halogenated alkyl groups such as CF3. In other embodiments, R... 6 for In other implementation schemes, R 6 The optionally substituted heterocyclic group. In other embodiments, the optionally substituted heterocyclic group is substituted with one or more of the following: halogens such as F or C. 1-6 Alkyl groups, such as methyl. In other embodiments, R... 6 for In other implementation schemes, R 6 for In other implementation schemes, R 6 The optionally substituted heteroaryl group is such as optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted pyridyl, or optionally substituted pyrazinyl. In other embodiments, the optionally substituted heteroaryl group is substituted by one or more of the following: C 1-6 Alkyl groups such as methyl, ethyl, or isopropyl, C 1-6 Alkyl halogens such as CF3, CH2CF3, or CHF2, and halogens such as F and C. 1-6 Alkoxy groups such as methoxy, ethoxy, or propoxy, C 3-6Cycloalkyl groups such as cyclopropyl or cyclobutyl; or C 3-6 Cycloalkylsulfonyl groups, such as cyclopropylsulfonyl, cyclobutylsulfonyl, or cyclopentylsulfonyl. In other embodiments, R 6 for In other implementation schemes, R 6 for In other implementation schemes, R 6 The derivatives are methyl, isopropyl, tert-butyl, CHF2, C(CH3)2F, C(CH3)2OH, CH(CH3)OH, C(O)N(CH3)2, NH (cyclopropyl). phenyl, In other implementation schemes, R 6 The compounds are methyl, isopropyl, tert-butyl, CF3, CHF2, C(CH3)F2, C(CH3)2F, C(CH3)2OH.
[0143] In other implementation schemes, R 2 for Where R 6 and R 7 Independent of H, halogen, C 1-6 Alkyl, or C 1-6 Halogenated alkyl; and R 8 For H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, optionally substituted aryl, or heteroaryl. In other embodiments, R 6 and R 7 Independent of H, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl or NR y R z , where R y and R z Independently H or C 1-6 Alkyl; R 8 For H, C 1-6 Alkyl, C 1-6 Alkyl, C 3-6 Cycloalkyl or heteroaryl. In other embodiments, R 6 and R 7 One or both of them are H. In other embodiments, R 6 or R7 One of them is a halogen. In other embodiments, R 6 or R 7 One of them is Cl or Br. In other embodiments, R 6 or R 7 One of them is Cl. In other embodiments, R 6 or R 7 One of them is C 1-6 Alkyl group. In other embodiments, R 6 or R 7 One of them is a methyl group. In other embodiments, R 6 or R 7 One of them is C 1-6 Haloalkyl. In other embodiments, R 6 or R 7 One of them is CHF2, CH2CF3, CF2H, or CF3. In other embodiments, R 6 or R 7 One of them is CHF2. In other embodiments, R 6 or R 7 One of them is NR y R z , where R y and R z Independently H or C 1-6 Alkyl groups, such as NH2. In other embodiments, R 6 or R 7 One of them is Cl, Br, methyl, CHF2, or CF3. In other embodiments, R 6 or R 7 One of them is Cl, methyl, CHF2, or NH2. In other embodiments, R 6 or R 7 One of them is methyl, Cl, CHF2, or CF3. In some embodiments, R 8 For H. In other implementations, R 8 C 1-6 Alkyl group. In other embodiments, R 8 It is methyl, ethyl, isopropyl, or tert-butyl. In other embodiments, R 8 It is methyl or isopropyl. In other embodiments, R 8 C 1-6 Haloalkyl. In other embodiments, R 8 It is CHF2, CH2CF3, CF2H, CH2CHF2, or CF3. In other embodiments, R 8 It is CHF2, CH2CF3, or CF3. In other embodiments, R 8C 3-6 Cycloalkyl. In other embodiments, R 8 It is cyclopropyl. In other embodiments, R 8 The aryl group is optionally substituted. In other embodiments, R 8 It is phenyl or fluorophenyl. In other embodiments, R 8 It is a heteroaryl group. In other embodiments, R 8 It is pyridinyl. In other embodiments, R... 8 The derivative is H, methyl, isopropyl, tert-butyl, CHF2, CH2CF3, CH2CHF2, CH2C(=O)CH3, CH2C(CH3)2OH, (CH2)2N(CH3)2, cyclopropyl, fluorophenyl, pyridyl, CH2-cyclopropyl, or CH2-cyclobutyl. In other embodiments, R 8 The compounds are methyl, isopropyl, CHF2, CH2CF3, CF3, cyclopropyl, and pyridyl.
[0144] In other implementation schemes, R 2 for Where R 6 For H, C 1-6 Alkyl, halogen, C 1-6 Halogenated alkyl, or C 3-6 cycloalkyl; and R 8 For H, C 1-6 Alkyl, or C 1-6 Haloalkyl. In other embodiments, R 6 For H, C 1-6 Alkyl, halogen, C 1-6 Halogenated alkyl, or C 3-6 cycloalkyl; and R 8 For H or C 1-6 Alkyl group. In other embodiments, R 6 For H. In other implementations, R 6 C 1-6 Alkyl groups, such as methyl groups. In other embodiments, R... 6 It is a halogen such as Cl or Br. In other embodiments, R... 6 For Cl. In other implementations, R 6 C 1-6 Halogenated alkyl groups such as CHF2 or CF3. In other embodiments, R 6 C 3-6 Cycloalkyl groups, such as cyclopropyl groups. In other embodiments, R... 6 It can be H, methyl, Cl, CHF2, CF3, or cyclopropyl. In some embodiments, R 8 For H. In other implementations, R 8 C 1-6Alkyl groups such as methyl, ethyl, or isopropyl. In other embodiments, R 8 C 1-6 Halogenated alkyl groups, such as CF3 or CHF2. In other embodiments, R 8 It is a methyl group.
[0145] In other implementation schemes, R 2 for In these structures, W is either S or NR. 15 W 1 For S, O or NR 15 ;R 10 R 11 R 12 R 13 and R 14 Each independently represents H and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkoxy (alkylene), C 1-6 Hydroxyalkyl, C 1-6 Halogenated alkoxy groups, C 1-6 Halogenated alkoxy (alkylene), C 2-6 Alkenyl, CN, halogen, (CR) v R x ) p NR y R z C(O)NR y2 R z2 Optional substitution of C 3-8 Cycloalkyl, optionally substituted heterocyclic, optionally substituted heterocyclic (alkylene), optionally substituted aryl, or optionally substituted heteroaryl; R v and R x Independently H or C 1-6 Alkyl; R y and R z Independently for H and C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy (alkylene) or C(O)OC 1-6 Alkyl; R y2 and R z2 Independently H and C 1-6 Alkyl, or C 3-6 Cycloalkyl; p is 0, 1, 2 or 3; and R 15 For H or C 1-6 alkyl.
[0146] In some implementations, W stands for S. In other implementations, W stands for NR. 15 In some implementation schemes, W 1 For S. In other implementations, W 1 For O. In other implementations, W 1 For NR 15 In some implementations, R 10 R 11 R 12 R 13 and R 14 For H. In other implementations, R 10 R 11 R 12 and R 13 For H. In other implementations, R 10 R 11 R 12 R 13 and R 14 At least one of them is C 1-6 Alkyl group. In other embodiments, R 10 R 11 R 12 R 13 and R 14 At least one of them is C 1-6 Haloalkyl. In other embodiments, R 10 R 11 R 12 R 13 and R 14 At least one of them is C 1-6 Alkyl group. In other embodiments, R 10 R 11 R 12 R 13 and R 14 At least one of them is C 1-6 Alkoxy (alkylene oxide). In other embodiments, R 10 R 11 R 12 R 13 and R 14 At least one of them is C 1-6 Hydroxyalkyl. In other embodiments, R 10 R 11 R 12 R 13 and R 14 At least one of them is C 1-6 Haloalkoxy group. In other embodiments, R 10 R 11 R 12 R13 and R 14 At least one of them is C 1-6 Haloalkoxy (alkylene). In other embodiments, R 10 R 11 R 12 R 13 and R 14 At least one of them is C 2-6 Alkenyl. In other embodiments, R 10 R 11 R 12 R 13 and R 14 At least one of them is CN. In other embodiments, R 10 R 11 R 12 R 13 and R 14 At least one of them is a halogen. In other embodiments, R 10 R 11 R 12 R 13 and R 14 At least one of them is (CR) v R x ) p NR y R z In other implementations, R 10 R 11 R 12 R 13 and R 14 At least one of them is C(O)NR y2 R z2 In other implementations, R 10 R 11 R 12 R 13 and R 14 At least one of them is an optional substitution of C 3-8 Cycloalkyl. In other embodiments, R 10 R 11 R 12 R 13 and R 14 At least one of them is an optionally substituted heterocyclic group. In other embodiments, R 10 R 11 R 12 R 13 and R 14 At least one of them is an optionally substituted heterocyclic group (alkylene group). In other embodiments, R 10 R 11 R 12 R13 and R 14 At least one of them is an optionally substituted aryl group. In other embodiments, R 10 R 11 R 12 R 13 and R 14 At least one of them is an optionally substituted heteroaryl group. In some embodiments, R v and R x One or both of them are H. In other embodiments, R v and R x One or both of them are C 1-6 Alkyl group. In some embodiments, R y and R z One or both of them are H. In other embodiments, R y and R z One or both of them are C 1-6 Alkyl group. In other embodiments, R y and R z One or both of them are C 3-6 Cycloalkyl. In other embodiments, R y and R z One or both of them are C 1-6 Hydroxyalkyl. In other embodiments, R y and R z One or both of them are C 1-6 Haloalkyl. In other embodiments, R y and R z One or both of them are C(O)OC 1-6 Alkyl group. In some embodiments, R y2 and R z2 One or both of them are H. In other embodiments, R y2 and R z2 One or both of them are C 1-6 Alkyl group. In other embodiments, R y2 and R z2 One or both of them are C 3-6 Cycloalkyl. In some embodiments, p is 0. In other embodiments, p is 1. In other embodiments, p is 2. In other embodiments, p is 3. In some embodiments, R 15 For H. In other implementations, R 15 C 1-6 alkyl.
[0147] In other implementation schemes, R 2 for Where R 10 R11 R 12 R 13 and R 14 Each independently represents H and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkoxy (alkylene), halogen, optionally substituted aryl, optionally substituted heterocyclic, optionally substituted heterocyclic (alkylene), optionally substituted heteroaryl, or (CR) v R x ) p NR y R z In other implementations, R 10 R 11 R 12 R 13 and R 14 Each independently represents H and C. 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkoxy (alkylene), optionally substituted heterocyclic, optionally substituted heterocyclic (alkylene), optionally substituted heteroaryl, or (CR) v R x ) p NR y R z In some implementations, R 10 R 11 R 12 R 13 and R 14 For H. In other implementations, R 10 R 11 R 12 R 13 and R 14 At least one of them is C 1-6 Alkyl groups, such as methyl or ethyl. In other embodiments, R 10 R 11 R 12 R 13 and R 14 At least one of them is C 1-6 Alkyl groups, such as methyl. In other embodiments, R... 10 R 11 R 12 R 13 and R 14 At least one of them is C 1-6 Halogenated alkyl groups such as CF3 or C(CH3)2F. In other embodiments, R 10R 11 R 12 R 13 and / or R 14 At least one of them is C 3-6 Cycloalkyl groups, such as cyclopropyl groups. In other embodiments, R... 10 R 11 R 12 R 13 and R 14 At least one of them is C 1-6 Alkyl groups, such as methoxy groups. In other embodiments, R... 10 R 11 R 12 R 13 and R 14 At least one of them is C 1-6 Alkoxy (alkylene oxide) such as CH2OCH3 or (CH2)2OCH3. In other embodiments, R 10 R 11 R 12 R 13 and R 14 At least one of them is a halogen, such as F, Br, or Cl. In other embodiments, R 10 R 11 R 12 R 13 and R 14 At least one of them is an optionally substituted aryl group, such as an unsubstituted phenyl group. In other embodiments, R 10 R 11 R 12 R 13 and R 14 At least one of them is an optionally substituted heterocyclic group, such as In other implementation schemes, R 10 R 11 R 12 R 13 and R 14 At least one of them is an optionally substituted heterocyclic group, such as In other embodiments, the optionally substituted heterocyclic group is In other implementation schemes, R 10 R 11 R 12 R 13 and R 14 At least one of them is an optionally substituted heterocyclic group (alkylene group). In other embodiments, R 10 R 11 R 12 R 13 and R 14At least one of them is In other implementation schemes, R 10 R 11 R 12 R 13 and R 14 At least one of them is In other implementation schemes, R 10 R 11 R 12 R 13 and R 14 At least one of them is an optionally substituted heteroaryl group, such as an optionally substituted pyridyl, optionally substituted pyrazinyl, optionally substituted pyrimidinyl, or optionally substituted pyrazolyl. In other embodiments, R 10 R 11 R 12 R 13 and R 14 At least one of them is In other implementation schemes, R 10 R 11 R 12 R 13 and R 14 At least one of them is (CR) v R x ) p NR y R z Such as NH2, NH(CH3), N(CH3)2, CH2N(CH3)2, or CH2CH2N(CH3)2. In other embodiments, R 10 R 11 R 12 R 13 and R 14 At least one of them is (CR) v R x ) p NR y R z Such as N(CH3)2, CH2N(CH3)2, or CH2CH2N(CH3)2. In other embodiments, R 10 R 11 R 12 R 13 and R 14 Each of the following can be independently H, methyl, C(CH3)2F, cyclopropyl, methoxy, CH2OCH3, (CH2)2OCH3, Br, F, Cl, phenyl. N(CH3)2, CH2N(CH3)2, or CH2CH2N(CH3)2. In other embodiments, R 10 R 11 R 12 R 13 and R 14 Each is independently H, methyl, cyclopropyl, methoxy, CH2OCH3, (CH2)2OCH3, N(CH3)2, CH2N(CH3)2, or CH2CH2N(CH3)2. In other embodiments, R 10 R 13 and R 14 Each is hydrogen. In other embodiments, R 10 R 13 and R 14 Each is hydrogen; and R 11 It is a halogen.
[0148] In other implementation schemes, R 10 R 11 R 12 R 13 and R 14 At least one of them is a substituted heterocyclic group or a substituted heterocyclic group (alkylene group), and its substitution is one or more of the following: halogen such as F, Cl or Br; C 1-6 Halogenated alkyl groups such as CF3, CH2CF3, or CHF2; C 1-6 Alkyl groups such as methyl, ethyl, or propyl; OH; C 1-6 Hydroxyalkyl groups such as C(CH3)2OH; C 1-6 Alkyl groups such as methoxy, ethoxy, or propoxy; or C 3-6 Cycloalkyl groups such as cyclopropyl, cyclobutyl, or cyclopentyl. In other embodiments, the substituted heterocyclic group or substituted heterocyclic (alkylene) group is substituted with one or more methyl, OH, or F groups.
[0149] In other implementation schemes, R 10 R 11 R 12 R 13 and R 14 At least one of them is a substituted heteroaryl group, and its substitution is one or more of the following: halogen such as F, Cl or Br; C 1-6 Halogenated alkyl groups such as CF3, CH2CF3, or CHF2; C 1-6 Alkyl groups such as methyl, ethyl, propyl, or isopropyl; C 1-6 Alkyl groups such as methoxy, ethoxy, or propoxy; C 1-6 Halogenated alkoxy groups such as OCF3; C 3-6 Cycloalkyl groups such as cyclopropyl, cyclobutyl, or cyclopentyl; or C3-6 Cycloalkylsulfonyl groups, such as cyclopropylsulfonyl, cyclobutylsulfonyl, or cyclopentylsulfonyl. In other embodiments, the substituted heteroaryl group is substituted with one or more of the following: F, CF3, CHF2, or methyl. In other embodiments, the optionally substituted heteroaryl group is pyrazolyl, substituted with one methyl group.
[0150] In other implementation schemes, R 2 for Where R 10 R 11 R 12 and R 13 Each independently represents H and C. 1-6 Alkyl or halogen and R 15 For H or C 1-6 Alkyl group. In other embodiments, R 10 R 11 R 12 and R 13 For H. In other implementations, R 10 R 11 R 12 and R 13 At least one of them is C 1-6 Alkyl group. In other embodiments, R 10 R 11 R 12 and R 13 At least one of them is halogen. In other embodiments, R 10 R 11 R 12 and R 13 At least one of them is Br. In some implementations, R 15 For H. In other implementations, R 15 C 1-6 Alkyl group. In other embodiments, R 15 It is methyl. In other embodiments, R is... 15 It is H or methyl.
[0151] In other implementation schemes, R 2 for Where R 10 R 11 R 12 R 13 and R 14 Each is independently H, halogen, or C. 1-6 Alkyl group. In some embodiments, R 2 for In other implementation schemes, R 2 for In some implementation schemes, R 10R 11 R 12 R 13 and R 14 For H. In other implementations, R 10 R 11 R 12 R 13 and R 14 At least one of them is a halogen. In other embodiments, R 10 R 11 R 12 R 13 and R 14 At least one of them is C 1-6 alkyl.
[0152] In other implementation schemes, R 2 for Where R 10 R 11 R 12 R 13 and R 14 Each is independently H, halogen, or C. 1-6 Alkyl group. In some embodiments, R 10 R 11 R 12 R 13 and R 14 For H. In other implementations, R 10 R 11 R 12 R 13 and R 14 At least one of them is a halogen. In other embodiments, R 10 R 11 R 12 R 13 and R 14 At least one of them is Br. In other embodiments, R 10 R 11 R 12 R 13 and R 14 At least one of them is C 1-6 alkyl.
[0153] In other implementation schemes, R 2 for Where R 10 R 11 R 12 and R 13 Each independently represents H and C. 1-6 Alkyl, or halogen. In some embodiments, R 2 for In other implementation schemes, R 2 for In other implementation schemes, R 2 for In some implementation schemes, R 10 R 11 R 12 and R 13 For H. In other implementations, R 10 R 11 R 12 and R 13 At least one of them is halogen. In other embodiments, R 10 R 11 R 12 and R 13 At least one of them is F. In other embodiments, R 10 R 11 R 12 and R 13 At least one of them is C 1-6 Alkyl group. In other embodiments, R 10 R 11 R 12 and R 13 At least one of them is methyl. In other embodiments, R 10 R 11 R 12 and R 13 Each can be H, methyl, or F independently.
[0154] In other implementation schemes, R 2 for Where R 6 As defined in this article and R 7 For H. In other implementations, R 2 for In other implementation schemes, R 2 for
[0155] In other implementation schemes, R 2 for Where R 6 As defined in this article and R 7 CH3. In other embodiments, R 2 for In other implementation schemes, R 2 for
[0156] In other implementation schemes, R2 for Where R 6 As defined in this article and R 7 It is cyclopropyl. In other embodiments, R 2 for In other implementation schemes, R 2 for
[0157] In other implementation schemes, R 2 for Where R 6 As defined in this article and R 7 For CHF2. In other implementations, R 2 for In other implementation schemes, R 2 for
[0158] In other implementation schemes, R 2 for Where R 6 As defined in this article and R 7 For CF3. In other implementations, R 2 for In other implementation schemes, R 2 for
[0159] In other implementation schemes, R 2 for Where R 6 As defined in this article and R 7 For CN. In other implementations, R 2 for
[0160] In other implementation schemes, R 2 for Where R 6 As defined in this article and R 7 It is Br or Cl. In other embodiments, R 2 for
[0161] In other implementation schemes, R 2 for Where R 6 As defined in this article and R 7 It is phenyl or pyridyl. In other embodiments, R 2 for
[0162] In other implementation schemes, R 2 for Where R 6 As defined in this article and R 7 For H. In other implementations, R 2 for In other implementation schemes, R 2 for
[0163] In other implementation schemes, R 2 for Where R 6 -R 8 As defined herein. In other implementations, R 2 for In other implementation schemes, R 2 for
[0164] In other implementation schemes, R 2 for Where R 6 -R 8 As defined herein. In other implementations, R 2 for In other implementation schemes, R 2 for
[0165] In other implementation schemes, R 2 for Where R 6 The substituted heterocyclic group is optional. In other embodiments, R 2 for In other implementation schemes, R 2 for
[0166] In other implementation schemes, R 2 for Where R 6 The substituted heteroaryl group is optional. In other embodiments, R 2 for In other implementation schemes, R 2 for
[0167]
[0168] In other implementation schemes, R 2 for Where R 6 The aryl group is optionally substituted. In other embodiments, R 2 for
[0169] In other implementation schemes, R 2 for Where R 6 C 1-6 Alkyl, C 1-6 Halogenated alkyl, or C 1-6 Hydroxyalkyl. In other embodiments, R 2 for In other implementation schemes, R 2 for
[0170] In other implementation schemes, R 2 for Where R 6 C is an optional replacement 3-8 Cycloalkyl. In other embodiments, R 2 for
[0171] In other implementation schemes, R 2 for Where R 6 For C(O)NR y2 R z2 or (CR) v R x ) p NR y R z And R y2 R z2 p, R v R x R y and R z As defined herein. In other implementations, R 2 for
[0172] In other implementation schemes, R 2 for Where R 6 For H, C 1-6 Alkyl, or optionally substituted aryl. In other embodiments, R 2 for In other implementation schemes, R 2for
[0173] In other implementation schemes, R 2 for Where R 6 C 1-6 Hydroxyalkyl. In other embodiments, R 2 for
[0174] In other implementation schemes, R 2 for Where R 8 C 1-6 Alkyl and R 6 As defined herein. In other implementations, R 2 for
[0175] In other implementation schemes, R 2 for Where R 10 -R 14 As defined herein. In other implementations, R 2 for In other implementation schemes, R 2 for
[0176] In other implementation schemes, R 2 for Where R 13 For H and R 10 R 11 R 12 R 14 and R 15 As defined herein. In other implementations, R 2 for
[0177] In some embodiments, the compound of formula I is a compound of formula IA or a pharmaceutically acceptable salt thereof:
[0178] Where R 1 R 2 R 5 L and m are as defined herein. In other embodiments, the compound is... Or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is... Or its pharmaceutically acceptable salt.
[0179] In other embodiments, the compound of formula I is of formula IB or a pharmaceutically acceptable salt thereof:
[0180] Where R 1 R 2 R 5 and m as defined herein. In other embodiments, the compound is... Or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is... Or its pharmaceutically acceptable salt.
[0181] In other embodiments, the compound of formula I is of formula IC or a pharmaceutically acceptable salt thereof:
[0182] Where R 1 R 2 R 5 and m as defined herein. In other embodiments, the compound is... IC-1 or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is... IC-2 or a pharmaceutically acceptable salt thereof.
[0183] In other embodiments, the compound of formula I is formula ID or a pharmaceutically acceptable salt thereof:
[0184] Where R 1 R 2 R 5 and m as defined herein. In some embodiments, the compound is... Or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is... Or its pharmaceutically acceptable salt.
[0185] In other embodiments, the compound of formula I is of formula IE or a pharmaceutically acceptable salt thereof:
[0186] Where R 1 R 2 R 5 and m as defined herein. In other embodiments, the compound is... Or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is... Or its pharmaceutically acceptable salt.
[0187] In other embodiments, the compound of formula I is formula IF or a pharmaceutically acceptable salt thereof:
[0188] Where R 1 R 2 R 5 and m as defined herein. In other embodiments, the compound is... Or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is... Or its pharmaceutically acceptable salt.
[0189] In other embodiments, the compound of formula I is formula IG or a pharmaceutically acceptable salt thereof:
[0190] Where R 1 R 2 R 5 and m as defined herein. In other embodiments, the compound is... Or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is... Or its pharmaceutically acceptable salt.
[0191] In other embodiments, the compound of formula I is formula IH or a pharmaceutically acceptable salt thereof:
[0192] Where R 1 R 2 R 5 and m as defined herein. In other embodiments, the compound is... Or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is... Or its pharmaceutically acceptable salt.
[0193] In other embodiments, the compound of formula I is a pharmaceutically acceptable salt of formula II or thereof:
[0194] Where R 1 R 2 R 5 and m as defined herein. In other embodiments, the compound is... Or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is... Or its pharmaceutically acceptable salt.
[0195] In other embodiments, the compound of formula I is a pharmaceutically acceptable salt of formula IJ or thereof:
[0196] Where R 1 R 2 R 5and m as defined herein. In other embodiments, the compound is... Or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is... Or its pharmaceutically acceptable salt.
[0197] In other embodiments, the compound of formula I is formula IK or a pharmaceutically acceptable salt thereof: Where R 1 R 2 R 5 and m as defined herein. In other embodiments, the compound is... Or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is... Or its pharmaceutically acceptable salt.
[0199] In other embodiments, the compound of formula I is formula IL or a pharmaceutically acceptable salt thereof:
[0200] Where R 1 R 2 R 5 L and m are as defined herein. In other embodiments, the compound is... Or its pharmaceutically acceptable salt.
[0201] In other embodiments, the compound of formula I is formula IM or a pharmaceutically acceptable salt thereof:
[0202] Where R 1 R 2 R 5 L and m are as defined herein. In other embodiments, the compound is... Or its pharmaceutically acceptable salt.
[0203] In some embodiments, the compounds of this disclosure are any one or more compounds in Table 1 and their pharmaceutically acceptable salts and / or isotopes. Compounds having Formula I are further disclosed in the examples and are included in this disclosure. This includes their pharmaceutically acceptable salts as well as neutral forms.
[0204] This disclosure further provides racemic mixtures of R-enantiomers, S-enantiomers, or any of the compounds described herein. In some embodiments, the compound is an S-enantiomer. In other embodiments, the compound is an R-enantiomer. In still other embodiments, the compound is a racemic mixture.
[0205] In another embodiment, the compound disclosed herein may be enantiomer-enriched, for example, having an enantiomer excess or an "ee" greater than about 5%, as measured by chiral HPLC. In some embodiments, the ee is greater than about 10%. In other embodiments, the ee is greater than about 20%. In other embodiments, the ee is greater than about 30%. In other embodiments, the ee is greater than about 40%. In other embodiments, the ee is greater than about 50%. In other embodiments, the ee is greater than about 60%. In other embodiments, the ee is greater than about 70%. In other embodiments, the ee is greater than about 80%. In other embodiments, the ee is greater than about 85%. In other embodiments, the ee is greater than about 90%. In other embodiments, the ee is greater than about 91%. In other embodiments, the ee is greater than about 92%. In other embodiments, the ee is greater than about 93%. In other embodiments, the ee is greater than about 94%. In other embodiments, the ee is greater than about 95%. In other embodiments, the ee is greater than about 96%. In other embodiments, the ee is greater than about 97%. In other embodiments, the ee is greater than about 98%. In other embodiments, the ee is greater than about 99%.
[0206] This disclosure covers the preparation and uses of salts of the compounds disclosed herein. Salts of the compounds disclosed herein can be prepared during the final separation and purification of the compounds, or prepared alone by reacting the compounds with suitable acids or bases.
[0207] Treatment
[0208] The compounds disclosed herein have several uses as described herein. In some embodiments, the compounds disclosed herein can be used in methods for stabilizing mutant PAH proteins. These methods include contacting the protein with one or more of the compounds described herein or a pharmaceutically acceptable salt thereof. The compounds disclosed herein can provide better Phe control for patients whose disease is not well controlled by diet alone and reduce the severity of phenylketonuria in patients. Therefore, patients who administer the compounds disclosed herein will have a better quality of life, such as a more normal lifestyle and / or no or fewer dietary restrictions, compared to patients with phenylketonuria who have not administered the compounds disclosed. In some embodiments, patients who administer the compounds disclosed may experience increased executive function, reduced anxiety symptoms, and / or reduced attention deficit hyperactivity disorder symptoms.
[0209] As used herein, the term "mutated PAH gene" refers to the complete DNA sequence of a PAH that differs in one or more respects from the canonically accepted sequence ("basic gene") published in various select databases. As an example, the sequence described in GenBank accession number NG_008690.2 describes a basic gene.
[0210] As used herein, the term "mutated PAH protein" refers to a PAH protein that contains at least one mutation in its amino acid sequence relative to a reference coding amino acid sequence. The reference human PAH protein is described by Genbank accession number NP_000268 and contains 452 amino acids. PAH protein mutations can be identified using methods known in the art. In some embodiments, the mutated PAH protein contains at least one R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation. In other embodiments, the mutated PAH protein contains at least one R408W, Y414C, I65T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation. In other embodiments, the mutated PAH protein contains at least one R408W, R243Q, R408Q, V388M, or L348V mutation. In other embodiments, the mutated PAH protein contains at least one R408W mutation. In other embodiments, the mutated PAH protein contains at least two R408W mutations. In other embodiments, the mutated PAH protein contains at least one R261Q mutation. In other embodiments, the mutated PAH protein contains at least one R243Q mutation. In other embodiments, the mutated PAH protein contains at least one Y414C mutation. In other embodiments, the mutated PAH protein contains at least one L48S mutation. In other embodiments, the mutated PAH protein contains at least one A403V mutation. In other embodiments, the mutated PAH protein contains at least one I65T mutation. In other embodiments, the mutated PAH protein contains at least one R241C mutation. In other embodiments, the mutated PAH protein contains at least one L348V mutation. In other embodiments, the mutated PAH protein contains at least one R408Q mutation. In other embodiments, the mutated PAH protein contains at least one V388M mutation. In other embodiments, the mutated PAH protein contains at least one F39L mutation. In other embodiments, the mutated PAH protein contains at least one A300S mutation. In other embodiments, the mutated PAH protein contains at least one L48S mutation.
[0211] In other embodiments, this disclosure provides methods for stabilizing the activity of a mutant phenylalanine hydroxylase (PAH) protein compared to wild-type PAH. Such methods involve contacting the phenylalanine hydroxylase with one or more compounds described herein or a pharmaceutically acceptable salt thereof. As used herein, the term "stabilized" refers to modulating the activity or amount of the PAH enzyme such that it catalyzes the hydroxylation of the aromatic side chain of phenylalanine at a rate more similar to the PAH catalytic rate of a control population having wild-type PAH (i.e., without the mutant PAH gene mutation) compared to baseline. In some aspects, the term "stabilized" refers to modulating the activity of a subject's PAH such that it catalyzes the hydroxylation of the aromatic side chain of phenylalanine at a flux more similar to the PAH catalytic flux of a control subject population without the mutant PAH gene mutation. In some embodiments, "stabilized" PAH activity includes increasing the level of the enzyme PAH compared to baseline. By increasing the accumulation of a stable, active PAH protein, the subject's toxic Phe level can be reduced compared to the subject's baseline dietary Phe level prior to administration of the disclosed compounds or pharmaceutical compositions containing the disclosed compounds.
[0212] In some embodiments, this disclosure provides a method for reducing the blood phenylalanine concentration in a subject with phenylketonuria to a concentration less than or equal to about 600 μM. In other embodiments, the blood Phe concentration is reduced to a concentration less than or equal to about 360 μM. In other embodiments, this disclosure provides a method for reducing the blood Phe concentration compared to an untreated baseline. In some embodiments, the percentage reduction in the subject's blood Phe concentration compared to an untreated baseline includes, but is not limited to, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%. In other embodiments, the subject's blood Phe concentration is reduced by at least about 10% compared to an untreated baseline. In other embodiments, the subject's blood Phe concentration is reduced by at least about 20% compared to an untreated baseline. In other embodiments, the subject's blood Phe concentration is reduced by at least about 30% compared to an untreated baseline. In other embodiments, the subject's blood Phe concentration is reduced by at least about 40% compared to an untreated baseline. In other embodiments, the subject's blood Phe concentration is reduced by at least about 50% compared to an untreated baseline. In other embodiments, the subject's blood Phe concentration is reduced by at least about 60% compared to an untreated baseline. In other embodiments, the subject's blood Phe concentration is reduced by at least about 70% compared to an untreated baseline. In other embodiments, the subject's blood Phe concentration is reduced by at least about 80% compared to an untreated baseline. In other embodiments, the subject's blood Phe concentration is reduced by at least about 90% compared to an untreated baseline. The subject's Phe concentration can be determined by blood tests, and methods for measuring such levels are known in the art. In some embodiments, the reduction in Phe concentration achieved using the compounds of this disclosure is obtained in conjunction with the subject actively managing their dietary Phe intake. In other embodiments, the reduction in Phe concentration is obtained in conjunction with the subject maintaining a Phe-restricted diet.
[0213] In some embodiments, a subject is treated with a compound of this disclosure or a pharmaceutical composition comprising a compound of this disclosure. The compound is administered in an amount sufficient to stabilize PAH protein or reduce blood phenylalanine concentration in the subject, or to achieve both in the subject.
[0214] In a further embodiment, the subject is a human patient, such as a human adult aged 18 years or older requiring treatment. In yet another embodiment, the human patient is a human child under 18 years of age. In yet another embodiment, the human patient is a human child between 12 and 18 years of age. In other embodiments, the human patient is a human child under 12 years of age. In any embodiment, the subject has phenylketonuria (PKU), optionally classic PKU or severe PKU. In some embodiments, the subject has a blood Phe concentration greater than about 600 μM prior to administration of the compound of this disclosure or a pharmaceutical composition comprising the compound of this disclosure. In other embodiments, the subject has a blood Phe concentration greater than about 700 μM prior to administration. In other embodiments, the subject has a blood Phe concentration greater than about 800 μM prior to administration. In other embodiments, the subject has a blood Phe concentration greater than about 900 μM prior to administration. In other embodiments, the subject has a blood Phe concentration greater than about 1000 μM prior to administration. In other embodiments, the subject has a blood Phe concentration greater than about 1100 μM prior to administration. In other implementations, the subject's blood Phe concentration was greater than about 1200 μM prior to administration.
[0215] This method also includes administering an adjunct therapeutic agent to the subject in addition to the compounds disclosed herein. In some embodiments, the adjunct therapeutic agent is selected from drugs known to be effective in stabilizing mutant PAH proteins and / or reducing blood Phe concentrations. The adjunct therapeutic agent differs from the compounds disclosed herein. In some embodiments, the adjunct therapeutic agent is sapropterin or metoprene. In other embodiments, the adjunct therapeutic agent is a nutritional supplement. Suitable nutritional supplements include those containing amino acids and other nutrients. In a further embodiment, the nutritional supplement contains macromolecular neutral amino acids such as leucine, tyrosine, tryptophan, methionine, histidine, isoleucine, valine, and threonine. In other embodiments, the nutritional supplement contains tyrosine. In a further embodiment, the nutritional supplement contains casein glycomacropeptide, i.e., a naturally occurring, Phe-free, pure form of milk peptide. In other embodiments, the adjunct therapeutic agent is an enzyme substrate or enzyme cofactor. In still other embodiments, the enzyme substrate or cofactor is tetrahydrobiopterin. In other embodiments, the adjunct therapeutic agent is a biopterin analogue. In further embodiments, the adjunctive therapeutic agent is a biotherapy, synthetic organism, microbiome, or probiotic. In still other embodiments, the biotherapy, synthetic organism, microbiome, or probiotic contains a genetically modified phenylalanine aminolyase (PAL) gene, such as *E. coli* Nissle PAL. Examples of genetically modified *E. coli* Nissle PAL biotherapy agents include SYNB1934 and SYNB1618. In still other embodiments, the adjunctive therapeutic agent is an inhibitor of an amino acid transporter. In some embodiments, the amino acid transporter is B... 0 AT1 (also known as SLC6A19) is the primary target of treatment, and the adjunctive therapy is an SLC6A19 inhibitor. Examples of SLC6A19 inhibitors include nimesulide, benzalkonium chloride, NSC63912, NSC22789, cinnamamide, CB3, E62, JNT-517, etc.
[0216] The compounds and adjunctive therapeutic agents disclosed herein can be administered simultaneously or sequentially to achieve the desired effect. Furthermore, the compounds and adjunctive therapeutic agents disclosed herein can be administered as a single composition or as two separate compositions.
[0217] The adjunctive therapeutic agent is administered in an amount that provides the desired therapeutic effect. The effective dose range for each adjunctive therapeutic agent is known in the art, and the adjunctive therapeutic agent is administered to the individual in need within such an established range.
[0218] The compounds and adjunctive therapeutic agents disclosed herein may be administered together as a single unit dose or separately as multiple unit doses, wherein the compounds of this disclosure are administered before or after the adjunctive therapeutic agents. One or more doses of the compounds of this disclosure and / or one or more doses of the adjunctive therapeutic agents may be administered.
[0219] The compounds disclosed herein can also be administered sequentially or simultaneously with non-pharmacological techniques. In some embodiments, patients use non-pharmacological techniques to maintain low Phe levels. In other embodiments, the non-pharmacological technique is the administration of a low-Phe diet. Those skilled in the art will be able to determine which diet can maintain appropriate Phe levels. In some embodiments, the aniline diet contains about 200 to about 500 mg / day (patients 10 years of age or younger) of Phe or less than about 600 mg / day (patients older than 10 years of age). In other embodiments, the diet may include restricting or eliminating one or more Phe-rich foods, such as soy, egg whites, shrimp, chicken breast, spirulina, watercress, fish, nuts, crayfish, lobster, tuna, turkey, beans, and low-fat cheese.
[0220] An example of dosage is approximately 0.001 to approximately 100 mg of the compound per kilogram of the subject's body weight per day, administered as a single dose or in divided dose units (e.g., BID, TID, QID). For a person weighing 70 kg, an appropriate dose is approximately 0.05 to approximately 7 g per day.
[0221] In some embodiments, a therapeutically effective amount of one or more compounds described herein is an amount that effectively stabilizes the mutant PAH protein described herein. In other embodiments, a therapeutically effective amount of one or more compounds described herein is an amount that effectively reduces blood phenylalanine concentration.
[0222] Unless otherwise stated, the amounts of compounds described herein are based on free base. That is, these amounts represent the amount of compound applied, excluding, for example, solvents or counterions (e.g., pharmaceutically acceptable salts).
[0223] Pharmaceutical Composition
[0224] This disclosure also provides pharmaceutical compositions comprising compounds and pharmaceutically acceptable carriers or excipients that include the contents of this disclosure.
[0225] The method described in this disclosure can be implemented by administering the compounds of this disclosure as pure compounds or as pharmaceutical compositions. Administration of the pharmaceutical composition or the pure compounds of this disclosure can be performed at any time determined by the attending physician. Generally, the pharmaceutical composition does not contain toxic, carcinogenic, or mutagenic compounds that would cause adverse reactions upon administration.
[0226] Pharmaceutical compositions include those in which the compounds of this disclosure are administered in an effective amount to achieve their intended purpose. The exact formulation, route of administration, and dosage are determined by the individual physician.
[0227] The compounds disclosed herein can be administered via any suitable route, such as oral, sublingual, inhalation, sublingual, rectal, vaginal, intracavitary or intrathecal via lumbar puncture, urethral, nasal, percutaneous, i.e., transdermal or parenteral (including intravenous, intramuscular, subcutaneous, intracoronary, intradermal, intramammary, intraperitoneal, intraarticular, intrathecal, retroocular, intrapulmonary injection and / or surgical implantation at a specific site). Parenteral administration can be achieved using needles and syringes or using high-pressure techniques.
[0228] The aforementioned additional therapeutic agents (one or more of which may be used in combination with the compounds disclosed herein) are prepared and administered in accordance with the description in the art.
[0229] The compounds of this disclosure can be co-administered with a pharmaceutical carrier selected according to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions used according to this disclosure are formulated in a conventional manner using one or more physiologically acceptable carriers, said carriers comprising excipients and / or adjuvants that facilitate the processing of the compounds of this disclosure.
[0230] The administration of the compounds or pharmaceutical compositions disclosed herein can be carried out by any method capable of delivering the compounds to the site of action. These methods include oral administration, intraduodenal administration, parenteral injection (including intravenous, intra-arterial, subcutaneous, intramuscular, intravascular, intraperitoneal, or infusion), local administration (e.g., transdermal application), rectal administration, local delivery via catheter or stent, or inhalation. The compounds can also be administered intra-fatty or intrathecally.
[0231] The amount of compound administered will depend on the subject being treated, the severity of the disease or condition, the rate of administration, the disposal of the compound, and the prescribing physician's judgment. The required dose may be administered as a single dose or in multiple doses at appropriate intervals, such as once, twice, three times, four times, or more sub-dose times daily. In some embodiments, the compounds disclosed herein are effective over a wide dose range. For example, dosage forms containing approximately 0.01 to 2000 mg of the compounds disclosed herein daily are examples of dosage forms that can be used when treating adults. The exact dose will depend on the route of administration, the form of administration of the compound, the subject being treated, the weight of the subject being treated, and the preferences and experience of the attending physician. In some cases, dose levels below the lower limit of the above range may be sufficient, while in others, larger doses may still be used without causing any harmful side effects, for example, by dividing such a larger dose into several smaller doses administered throughout the day.
[0232] In some embodiments, the compounds disclosed herein are administered in a single dose.
[0233] Typically, this administration is delivered via solid oral dosage forms (such as tablets or capsules). However, other appropriate routes may also be used. A single dose of the compound may also be used to treat acute conditions.
[0234] In some embodiments, the compounds disclosed herein can be administered in multiple doses. Administration may be about once, twice, three times, four times, five times, six times, or more per day. In another embodiment, the compounds described herein are administered together with another therapeutic agent, about once per day to about six times per day. Administration of the compounds disclosed herein may continue until needed. In some embodiments, the compounds are administered in a continuous manner for a long period, for example, for treating chronic effects.
[0235] Effective amounts of the compounds disclosed herein may be administered in single or multiple doses via any acceptable route of administration of a therapeutic agent with similar efficacy, including rectal, oral, nasal, and transdermal routes, intra-arterial injection, intravenous, intraperitoneal, parenteral, intramuscular, subcutaneous, oral, topical, or inhalation.
[0236] The pharmaceutical composition may be suitable for oral administration, for example, in the form of tablets, capsules, pills, powders, sustained-release formulations, solutions, or suspensions; suitable for parenteral injection, in the form of sterile solutions, suspensions, or emulsions; suitable for topical administration, in the form of ointments or creams; or suitable for rectal administration, in the form of suppositories. The pharmaceutical composition may be administered in a unit dosage form suitable for a precise single-dose administration. The pharmaceutical composition will include one or more conventional pharmaceutical carriers or excipients and the compound disclosed herein as the active ingredient. Furthermore, it may also include other drugs or pharmaceutical preparations, carriers, adjuvants, etc.
[0237] Exemplary parenteral administration forms include solutions or suspensions of the disclosed compounds in sterile aqueous solutions, such as aqueous propylene glycol or glucose solutions. Such dosage forms may be appropriately buffered if desired.
[0238] Pharmaceutical compositions for oral administration
[0239] In some embodiments, this disclosure provides pharmaceutical compositions for oral administration comprising the compounds of this disclosure and pharmaceutical excipients suitable for oral administration.
[0240] In some embodiments, this disclosure provides a solid pharmaceutical composition for oral administration comprising: (i) an effective amount of the compound of this disclosure; optionally (ii) an effective amount of a second therapeutic agent; and (iii) a pharmaceutical excipient suitable for oral administration. In some embodiments, the composition further comprises: (iv) an effective amount of a third therapeutic agent.
[0241] In some embodiments, the pharmaceutical composition may be a pharmaceutical composition suitable for oral administration. Pharmaceutical compositions containing a compound of the present disclosure suitable for oral administration may be present as discrete dosage forms, such as capsules, pods, or tablets, or liquids or aerosol sprays, each dosage form containing a predetermined amount of the active ingredient as a powder or granules, solution or suspension in an aqueous or non-aqueous liquid, water-in-oil emulsion, or oil-in-water liquid emulsion. Such dosage forms can be prepared by any pharmaceutical method, but all methods include the step of combining the compound of the present disclosure with a carrier, which constitutes one or more essential components. Typically, a composition is prepared by uniformly and tightly mixing the compound of the present disclosure with a liquid carrier or a finely dispersed solid carrier, or both, and then, if desired, shaping the product into the desired form. For example, tablets can be prepared by compression or molding, optionally using one or more excipients. Compressed tablets can be prepared by compressing the active ingredient (e.g., powder or granules) in a suitable machine, optionally mixed with excipients (e.g., but not limited to binders, lubricants, inert diluents, and / or surfactants or dispersants). Molded tablets can be prepared by molding a mixture of powdered compounds wetted with an inert liquid diluent in a suitable machine.
[0242] This disclosure also includes anhydrous pharmaceutical compositions and dosage forms containing active ingredients, as water can promote the degradation of certain compounds. For example, in the pharmaceutical industry, water (e.g., 5%) may be added as a means of simulating long-term storage to determine properties such as shelf life or the stability of the formulation over time. Anhydrous pharmaceutical compositions and dosage forms containing compounds of this disclosure can be prepared using anhydrous or low-moisture components and low-moisture or low-humidity conditions. Pharmaceutical compositions and dosage forms containing lactose-containing compounds of this disclosure can be made anhydrous if significant contact with moisture and / or humidity is anticipated during manufacturing, packaging, and / or storage. Anhydrous pharmaceutical compositions can be prepared and stored to maintain their anhydrous properties. Therefore, anhydrous compositions can be packaged using materials known to prevent exposure to water in order to include them in suitable formulation kits. Examples of suitable packaging include, but are not limited to, sealing foil, plastics, unit-dose containers, blister packs, and strip packs.
[0243] The compounds disclosed herein can be tightly mixed with a drug carrier using conventional pharmaceutical formulation techniques. The carrier can take various forms, depending on the desired formulation for administration. In preparing compositions for oral dosage forms, any commonly used pharmaceutical medium can be used as the carrier; for example, in the case of oral liquid formulations (e.g., suspensions, solutions, and elixirs) or aerosols, water, ethylene glycol, oils, alcohols, flavoring agents, preservatives, coloring agents, etc., can be used; or in the case of oral solid formulations, carriers such as starch, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrants can be used, although lactose is not used in some embodiments. Suitable carriers include powders, capsules, and tablets, as well as solid oral formulations. If desired, tablets can be coated using standard aqueous or non-aqueous techniques.
[0244] Binders suitable for pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch or other starches, gelatin, natural and synthetic gums such as gum arabic, sodium alginate, alginic acid, other alginates, tragacanth powder, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, calcium carboxymethyl cellulose, sodium carboxymethyl cellulose), polyvinylpyrrolidone, methyl cellulose, pregelatinized starch, hydroxypropyl methyl cellulose, colloidal silica, microcrystalline cellulose and mixtures thereof.
[0245] Examples of fillers suitable for the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, glucose binders, kaolin, mannitol, silica, sorbitol, starch, pregelatinized starch, and mixtures thereof.
[0246] Disintegrants may be used in the compositions of this disclosure to provide tablets that disintegrate upon exposure to an aqueous environment. Excessive disintegrant may result in tablets that disintegrate in the bottle. Insufficient disintegrant may be insufficient to cause disintegration, thus potentially altering the rate and extent of release of the active ingredient in the dosage form. Therefore, a sufficient amount of disintegrant may be used to form dosage forms of the compounds disclosed herein, neither too little nor too much, without adversely affecting the release of the active ingredient. The amount of disintegrant may vary depending on the type of formulation and route of administration, and can be readily discerned by those skilled in the art. About 0.5 to about 15% by weight of disintegrant, or about 1 to about 5% by weight, may be used in the pharmaceutical composition. Disintegrants that can be used to form the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, agar, alginate, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, croscarmellose, polykrylamide potassium, sodium starch glycolate, potato or cassava starch, other starches, pregelatinized starches, other starches, clays, other alginates, other celluloses, gums, or mixtures thereof.
[0247] Lubricants that can be used to form the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, calcium stearate, magnesium stearate, sodium stearoyl fumarate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oils (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laurate, agar, or mixtures thereof. Other lubricants include, for example, syloid silica gel, coagulated aerosols of synthetic silica, or mixtures thereof. Lubricants may optionally be added in an amount less than about 2% by weight of the pharmaceutical composition.
[0248] When aqueous suspensions and / or elixirs are required for oral administration, the active ingredients therein may be combined with various sweeteners or flavorings, colorants or dyes, and (if necessary) emulsifiers and / or suspending agents, as well as diluents such as water, ethanol, propylene glycol, glycerin, and various combinations thereof.
[0249] Tablets may be uncoated or coated using known techniques to delay disintegration and absorption in the gastrointestinal tract, thereby providing a longer duration of action. For example, delay-release materials such as glyceryl monostearate or glyceryl distearate may be used. Oral formulations may also be available in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent (e.g., calcium carbonate, calcium phosphate, or kaolin), or in the form of soft gelatin capsules in which the active ingredient is mixed with an aqueous or oily medium (e.g., peanut oil, liquid paraffin, or olive oil).
[0250] Surfactants that can be used to form the pharmaceutical compositions and dosage forms of the present invention include, but are not limited to, hydrophilic surfactants, lipophilic surfactants, and mixtures thereof. That is, mixtures of hydrophilic surfactants, mixtures of lipophilic surfactants, or mixtures of at least one hydrophilic surfactant and at least one lipophilic surfactant may be used.
[0251] Suitable hydrophilic surfactants typically have an HLB value of at least 10, while suitable lipophilic surfactants typically have an HLB value of less than about 10. The empirical parameter used to characterize the relative hydrophilicity and hydrophobicity of nonionic amphiphilic compounds is the hydrophilic-lipophilic balance (“HLB” value). Surfactants with lower HLB values are more lipophilic or hydrophobic and have greater solubility in oils, while surfactants with higher HLB values are more hydrophilic and have greater solubility in aqueous solutions.
[0252] Hydrophilic surfactants are generally considered to be compounds with HLB values greater than about 10, as well as anionic, cationic, or zwitterionic compounds (the HLB scale is generally not applicable to them). Similarly, lipophilic (i.e., hydrophobic) surfactants are compounds with HLB values equal to or less than about 10. However, the HLB value of a surfactant is only a rough guideline commonly used to allow the formation of industrial, pharmaceutical, and cosmetic emulsions.
[0253] Hydrophilic surfactants can be ionic or nonionic. Suitable ionic surfactants include, but are not limited to, alkylammonium salts; caryopsisates; fatty acid derivatives of amino acids, oligopeptides, and polypeptides; glycerol ester derivatives of amino acids, oligopeptides, and polypeptides; lecithin and hydrogenated lecithin; lysophosphatidylcholine and hydrogenated lysophosphatidylcholine; phospholipids and their derivatives; lysophosphatidylcholine and its derivatives; carnitine fatty acid ester salts; alkyl sulfates; fatty acid salts; sodium docusate; acylactylates; mono- and di-acetylated tartrate esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citrate esters of mono- and di-glycerides; and mixtures thereof.
[0254] In the foregoing group, ionic surfactants include, for example, lecithin, lysophosphatidylcholine, phospholipids, lysophosphatidylcholine and their derivatives; carnitine fatty acid ester salts; alkyl sulfates; fatty acid salts; sodium docusate; acyl acrylates; mono- and di-acetylated tartrate esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citrate esters of mono- and di-glycerides; and mixtures thereof.
[0255] Ionic surfactants can be ionized forms of the following compounds: lecithin, lysophosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidic acid, lysophosphatidylserine, PEG-phosphatidylethanolamine, PVP-phosphatidylethanolamine, fatty acid lactates, stearoyl-2-lactate, stearoyl lactate, succinylated monoglycerides, mono / diglycerides of mono / diglycerides in tartrate form, mono / diglycerides in citrate form, choylsarcosine, hexanoate, caprylate, caprate, laurate, myristate, palmitate, oleate, castor oil ester, linoleate, linolenic acid ester, stearate, lauryl sulfate, tetradecyl sulfate. Sulfate), sodium docusate, lauroylcarnitine, palmitoylcarnitine, myristoylcarnitine, and mixtures thereof and their salts.
[0256] Hydrophilic nonionic surfactants may include, but are not limited to, alkyl glucosides; alkyl maltodextrins; alkyl glucosulosin; lauryl macrogolglyceride; polyoxyalkylene alkyl ethers such as polyethylene glycol alkyl ethers; polyoxyalkylene alkylphenols such as polyethylene glycol alkylphenols; polyoxyalkylene alkylphenol fatty acid esters such as polyethylene glycol fatty acid monoesters and polyethylene glycol fatty acid diesters; polyethylene glycol glycerol fatty acid esters; polyglycerol fatty acid esters; polyoxyalkylene dehydrated sorbitol fatty acid esters such as polyethylene glycol dehydrated sorbitol fatty acid esters; hydrophilic transesterification products of polyols with at least one member of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids, and sterols; polyoxyethylene sterols, their derivatives, and analogs; polyoxyethylated vitamins and their derivatives; polyoxyethylene-polyoxypropylene block copolymers; and mixtures thereof; polyethylene glycol dehydrated sorbitol fatty acid esters; and hydrophilic transesterification products of polyols with at least one member of triglycerides, vegetable oils, and hydrogenated vegetable oils. The polyol may be glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, or sugars.
[0257] Other hydrophilic nonionic surfactants include, but are not limited to, PEG-10 laurate, PEG-12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG-12 oleate, PEG-15 oleate, PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG-15 stearate, PEG-32 distearate, PEG-40 stearate, PEG-100 stearate, PEG-20 dilaurate, PEG-25 glyceryl trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl oleate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-40 palm kernel oil, and PEG-50 hydrogenated castor oil. PEG-40 castor oil, PEG-35 castor oil, PEG-60 castor oil, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-60 corn oil, PEG-6 glyceryl caprylic / caprylic acid, PEG-8 glyceryl caprylic / caprylic acid, polyglycerol-10 laurate, PEG-30 cholesterol, PEG-25 phytosterols, PEG-30 soybean sterols, PEG-20 trioleate, PEG-40 sorbitol oleate, PEG-80 sorbitol oleate Rhizotriol laurate, sorbitol polyoxyethylene (20) laurate, sorbitol polyoxyethylene (20) oleate, lauryl POE-9 ether, lauryl POE-23 ether, oleyl POE-10 ether, oleyl POE-20 ether, stearyl POE-20 ether, tocopherol PEG-1000 succinate, PEG-24 cholesterol, oleic acid polyglycerol-10 ester, Tween 40, Tween 60, sucrose monostearate, sucrose monolaurate, sucrose monopalmitate, PEG 10-100 nonylphenol series, PEG 15-100 octylphenol series, and poloxamer.
[0258] Suitable lipophilic surfactants include, for example, fatty alcohols; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lower alcohol fatty acid esters; propylene glycol fatty acid esters; sorbitol fatty acid esters; sorbitol polyethylene glycol ether fatty acid esters; sterols and sterol derivatives; polyoxyethylated sterols and sterol derivatives; polyethylene glycol alkyl ethers; sugar esters; sugar ethers; lactic acid derivatives of mono- and di-glycerides; hydrophobic transesterification products of polyols with at least one member of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids, and sterols; oil-soluble vitamin / vitamin derivatives; and mixtures thereof. Among these, preferred lipophilic surfactants include glycerol fatty acid esters, propylene glycol fatty acid esters, and mixtures thereof, or hydrophobic transesterification products of polyols with at least one member of vegetable oils, hydrogenated vegetable oils, and triglycerides.
[0259] In one embodiment, the composition may contain a solubilizer to ensure good solubilization and / or dissolution of the compounds of the present invention and to minimize precipitation of the compounds of the present invention. This can be important for compositions intended for non-oral use, such as compositions intended for injection. Solubilizers may also be added to improve the solubility of hydrophilic drugs and / or other components (e.g., surfactants), or to maintain the composition as a stable or homogeneous solution or suspension.
[0260] Examples of suitable solubilizers include, but are not limited to, the following: alcohols and polyols, such as ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediol and its isomers, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol (PEG), polypropylene glycol, polyvinyl alcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives; ethers of polyethylene glycol with an average molecular weight of about 200 to about 6000, such as tetrahydrofuran-2-methanol PEG ether (polyoxyethylene(2)tetrahydrofurfuryl ether) or methoxyPEG; polyethylene glycol 660 12-Hydroxystearic acid esters; amides and other nitrogen-containing compounds such as 2-pyrrolidone, 2-piperidinone, ε-caprolactam, N-alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidinone, N-alkylcaprolactam, dimethylacetamide and polyvinylpyrrolidone; esters such as ethyl propionate, tributyl citrate, acetyl triethyl citrate, acetyl tributyl citrate, triethyl citrate, ethyl oleate, ethyl octanoate, ethyl butyrate, glyceryl triacetate, propylene glycol monoacetate, propylene glycol diacetate, ε-caprolactone and its isomers, δ-valerolactone and its isomers, β-butyrolactone and its isomers; and other solubilizers known in the art, such as dimethylacetamide, dimethylisosorbitol, N-methylpyrrolidone, monooctanoin, diethylene glycol monoethyl ether and water.
[0261] Mixtures of solubilizers may also be used. Examples include, but are not limited to, triethyl glycerol triacetate, triethyl citrate, ethyl oleate, ethyl octanoate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrin, ethanol, polyoxyethylene (2)tetrahydrofurfuryl ether, transcutol, propylene glycol, and dimethyl isosorbide. Particularly preferred solubilizers include sorbitol, glycerol, triethyl glycerol triacetate, ethanol, PEG with an average molecular weight of about 100 to about 8000 g / mol, polyoxyethylene (2)tetrahydrofurfuryl ether, and propylene glycol.
[0262] There is no particular limitation on the amount of solubilizer that can be included. The given amount of solubilizer may be limited to a bioacceptable amount, which can be readily determined by those skilled in the art. In some cases, it may be advantageous to include an amount of solubilizer far exceeding the bioacceptable amount, for example, to maximize drug concentration, by removing excess solubilizer using conventional techniques such as distillation or evaporation before administering the composition to the subject. Thus, if present, the weight percentage of solubilizer may be less than about 10%, less than about 25%, less than about 50%, about 100%, or up to less than about 200% by weight, based on the combined weight of the drug and other excipients. If desired, very small amounts of solubilizer may also be used, such as less than about 5%, less than about 2%, less than about 1%, or even less. Typically, the amount of solubilizer that may be present is less than about 1% to about 100%, more typically less than about 5% and at least about 25% by weight.
[0263] The composition may also contain one or more pharmaceutically acceptable additives and excipients. These additives and excipients include, but are not limited to, anti-sticking agents, defoamers, buffers, polymers, antioxidants, preservatives, chelating agents, viscosity modifiers, tonicifiers, flavoring agents, coloring agents, flavor enhancers, opacifiers, suspending agents, binders, fillers, plasticizers, lubricants, and mixtures thereof.
[0264] Pharmaceutical composition for injection
[0265] In some embodiments, the present invention provides injectable pharmaceutical compositions comprising the compounds of the present invention and injectable pharmaceutical excipients. The components and dosages in said compositions are as described in this application.
[0266] The compositions disclosed herein can be administered by injection, including aqueous or oily suspensions or emulsions. Such compositions may contain sesame oil, corn oil, cottonseed oil, peanut oil, elixirs containing mannitol or glucose, sterile water, and similar drug carriers.
[0267] Saline solutions are also suitable for injection. Ethanol, glycerol, propylene glycol, liquid polyethylene glycol (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils can also be used. Appropriate flowability can be maintained, for example, by using coatings such as lecithin to maintain the desired particle size in the case of dispersions, and by using surfactants. Prevention of microbial action can be achieved with various antibacterial and antifungal agents (e.g., p-hydroxybenzoic acid, chlorobutanol, phenol, sorbic acid, and thimerosal).
[0268] Sterile injectable solutions are prepared by combining the required amount of the compound of the invention with various other components listed above in a suitable solvent, followed by filtration and sterilization. Typically, dispersions are prepared by incorporating various sterile active ingredients into a sterile medium containing a base dispersion medium and the desired other components listed above. In the case of sterile powders used to prepare sterile injectable solutions, certain desirable methods include vacuum drying and freeze-drying techniques, which yield powders of the active ingredient and any other desired components from a previously sterile filtered solution.
[0269] Other pharmaceutical compositions
[0270] The pharmaceutical composition can also be prepared from the composition described in this application and one or more pharmaceutically acceptable excipients suitable for topical, sublingual, sublingual, rectal, intraosseous, intraocular, intranasal, epidural, or spinal administration. The preparation of this pharmaceutical composition is well known in the art. See, e.g., Anderson, Philip O.; Knoben, James E.; Troutman, William G, eds., Handbook of Clinical Drug Data, Tenth Edition, McGraw-Hill, 2002; Pratt and Taylor, eds., Principles of Drug Action, Third Edition, Churchill Livingston, New York, 1990; Katzung, ed., Basic and Clinical Pharmacology, Ninth Edition, McGraw Hill, 2004; Goodman and Gilman, eds., The Pharmacological Basis of Therapeutics, Tenth Edition, McGraw Hill, 2001; Remington's Pharmaceutical Sciences, 20th Ed., Lippincott Williams & Wilkins., 2000; Martindale, The Extra Pharmacopoeia, 32nd Edition (The Pharmaceutical Press, London, 1999; the full contents of all these references are incorporated into this paper by way of citation.
[0271] Synthesis of the compounds disclosed herein
[0272] The compounds disclosed herein can be prepared by the general schemes, procedures, and methods described in the examples listed herein, as well as related methods known in the art. For example, compounds of formula I can be prepared by the general methods shown in general schemes 1-11.
[0273] General Scheme 1: Preparation of Compound I
[0274]
[0275] Compound I is obtained via the reaction shown in General Scheme 1. First, the amine of Formula 1.1 or 1.2 is reacted with the aldehyde of Formula 1.3 under Pictet-Spengler reaction conditions to give the core amine of Formula 1.4. If an imine byproduct is formed during the Pictet-Spengler reaction, the imine byproduct can be converted to the core amine of Formula 1.4 by reacting it with sodium borohydride in an alcoholic solvent (e.g., methanol or ethanol). Various L and R groups are then assembled using nucleophilic substitution reactions (method A1), Buchwald or other similar cross-coupling reactions (method A2), reductive amination reactions (method B), or amide coupling reactions (methods C, D, E, and F). 2 Group. According to method A1, under basic conditions, such as DIPEA, nucleophilic substitution is used to convert R of formula 1.5 into a radical. 2 Aryl or heteroaryl halide (where X is Br, Cl, or F) is coupled to the core amine of formula 1.4 to give the compound of formula 1.6. According to method A2, under Buchwald coupling or cross-coupling conditions known in the art, for example using a palladium catalyst (e.g., CPos-Pd-G3, Pd(OAc)2, Pd(dppf)Cl2) and a base (e.g., Cs2CO3), R of formula 1.5 is coupled... 2 An aryl or heteroaryl halide (where X is Br, Cl, or I) is coupled to the core amine of formula 1.4 to give a compound of formula 1.6. According to method B, under reductive amination conditions, a hydride (e.g., sodium triacetoxyborohydride) is used to couple R of formula 1.7... 2 Aryl or heteroaryl aldehydes are coupled to the core amine of formula 1.4 to give compounds of formula 1.8. According to method C, using acid coupling conditions known in the art, such as one of the following reagents (HOBt, EDCI, HATU, T3P) and a base (e.g., DIPEA (Hunig base), pyridine, or TEA), R of formula 1.9 is coupled... 2 A carboxylic acid or its basic salt (i.e., Li, K, or Na) is coupled to the core amine of formula 1.4 to give a compound of formula 1.11, wherein L 2 C is a key, and can be arbitrarily replaced. 1-6 Alkylene, optionally substituted C 2-6 alkenyl, or optionally substituted C 1-6 Alkyl halide. Or, according to method D, R of formula 1.10 2 Acyl chlorides are coupled to the core amine of formula 1.4 under basic conditions to give compounds of formula 1.11, wherein L 2 C is a key, and can be arbitrarily replaced. 1-6 Alkylene, optionally substituted C 2-6 alkenyl, or optionally substituted C 1-6 Alkyl halide. According to method E, R of formula 1.12 is... 2Acyl chlorides are coupled to the core amine of formula 1.4 under basic conditions to give compounds of formula 1.14, wherein L 3 C is a key or an optional replacement 1-6 Alkylene. According to method F, R of formula 1.13 is prepared under alkaline conditions. 2 The amine is coupled with the core amine of formula 1.4 and a carbonyl diimidazole to give the compound of formula 1.14, wherein L 3 C is a key or an optional replacement 1-6 Alkylene.
[0276] General Scheme 2: Preparation of the deuterated core amine intermediate of formula 2.2
[0277]
[0278] R was prepared according to general scheme 2. 5 The compound of formula I is D. An amine of formula 1.1 or 1.2 reacts with an aldehyde of formula 1.3 under Pictet-Spengler reaction conditions to give a compound of formula 2.1 or a mixture of compound 2.1 and an imine byproduct of formula 2.1a. Then, a compound of formula 2.1 or a mixture of compounds 2.1 and 2.1a reacts with sodium borodeuteride in deuterated methanol to give a deuterated core amine of formula 2.2. The deuterated core amine intermediate of formula 2.2 can then be further reacted with various L and R by methods A, B, C, D, E, and F described in General Scheme 1. 2 Group coupling yields compound I, wherein R 5 The answer is D.
[0279] General Scheme 3: Preparation of Oxazolyl R 2 acid intermediate
[0280]
[0281] Prepared according to general scheme 3 in R 6 and / or R 7 The position contains a substituted oxazolyl group R 2Carboxylic acid intermediate. The carboxylic acid of formula 3.1 is reacted with oxalyl chloride and catalytic N,N-dimethylformamide to give the acyl chloride of formula 3.2. The acyl chloride of formula 3.2 is then reacted with the enamine of formula 3.3 to give the enamide of formula 3.4. The enamide of formula 3.4 is then subjected to a high-valent iodine-mediated cyclization following a reaction with [bis(trifluoroacetoxy)iodo]benzene and boron trifluoride diethyl ether to give the oxazole of formula 3.5. The oxazole ester of formula 3.5 is hydrolyzed in THF / water with a base (e.g., LiOH, KOH, or NaOH) to give the compound of formula 3.6. Alternatively, after hydrolysis, the product can be separated at an alkaline pH to obtain a basic salt (i.e., Li, K, or Na) of the carboxylic acid of formula 3.6. The carboxylic acid or its basic salt can then be used in the coupling reaction described in Method C of General Scheme 1 without further purification.
[0282] General Scheme 4: Preparation of Oxazolyl R 2 acid intermediate
[0283]
[0284] Prepared according to general scheme 4 in R 6 and / or R 7 The position contains a substituted oxazolyl group R 2 Carboxylic acid intermediate. Halogenation of the β-keto ester of formula 4.1 with a chlorinating agent (e.g., SOCl2) or a brominating agent (e.g., NBS) yields the compound of formula 4.2 (where X...). 1 (where X is Br or Cl). Reaction of the compound of formula 4.2 with urea yields the amine oxazole compound of formula 4.3. Furthermore, reaction of the compound of formula 4.2 with the amide of formula 4.5 yields the oxazole compound of formula 4.6. Placement of the amine in the compound of formula 4.3 under Sandmeyer reaction conditions yields the compound of formula 4.4 (where X is Cl, Br, or F) and the compound of formula 4.10. Alternatively, the compound of formula 4.8 can be deprotonated with a base (e.g., LiHMDS) and then subjected to a nucleophilic substitution reaction with a reagent of formula 4.9 (where Y is a suitable leaving group, such as Br, Cl, methanesulfonate, or toluenesulfonate) to yield the compound of formula 4.10. Hydrolysis of the esters of compounds 4.6 and 4.10 in THF / water with a base (e.g., LiOH, KOH, or NaOH) yields the compounds of formulas 4.7 and 4.11. Alternatively, after the hydrolysis reaction, the products can be separated at an alkaline pH to obtain basic salts (i.e., Li, K, or Na) of the carboxylic acids of formulas 4.7 and 4.11. The carboxylic acids or their basic salts can then be used for the coupling reaction described in method C of general scheme 1 without further purification.
[0285] General Scheme 5: Synthesis of thiazolyl and oxazolyl R 2 acid intermediate
[0286]
[0287] Prepared according to general scheme 5 in R 6 and / or R 7 The position contains substituted oxazolyl and thiazolyl R groups 2 Carboxylic acid intermediates. According to method A, the halide of formula 5.1 is reacted with a heteroaryl or aryl group of formula 5.2 in a Suzuki coupling (where Y is a boric acid or ester) or Stille coupling (where Y is SnR3) to give the compound of formula 5.3. According to method B, the compound of formula 5.4 is reacted with a heteroaryl or aryl halide of formula 5.5 in a cross-coupling reaction using a metal catalyst (e.g., a Buchwald catalyst or an Ullman catalyst) to give the compound of formula 5.3. According to method C, the halide of formula 5.1 can also undergo a substitution reaction with an amine or heterocyclic amine of formula 5.7 (e.g., piperidine, morpholine, piperazine, aziridine, and pyrrolidine) and a base (e.g., TEA) to give the compound of formula 5.8. The esters of compounds of formulas 5.3 and 5.8 are hydrolyzed in THF / water with a base (e.g., LiOH, KOH, or NaOH) to give compounds of formulas 5.6 and 5.9. Alternatively, after the hydrolysis reaction, the basic salts (i.e., Li, K, or Na) of the carboxylic acids of formulas 5.6 and 5.9 can be obtained by separating the products at an alkaline pH. The carboxylic acids or their basic salts can then be used for the coupling reaction described in method C of general scheme 1 without further purification.
[0288] General Scheme 6: Synthesis of thiazolyl and oxazolyl R 2 acid intermediate
[0289]
[0290] According to general scheme 6, prepare oxazolyl and thiazolyl R groups containing hydroxyalkyl and haloalkyl substitutions. 2Carboxylic acid intermediates. According to method A, the halide of formula 6.1 is reacted with tributyl(1-ethoxyvinyl)stanane in Stille coupling, followed by hydrolysis with acid / water (e.g., TFA) to give the compound of formula 6.3. The alkyl group (“R”) is then added to the ketone in the compound of formula 6.3 using RMgBr or RLi or by reducing the ketone with NaBR to give the compound of formula 6.4. According to method B, the compound of formula 6.4 can also be obtained by Grignard addition reaction of the compound of formula 6.1 with a ketone of formula 6.2 (where R is an alkyl group) or cyclobutanone and RMgCl (e.g., iPrMgCl). The hydroxyl substituent in the compound of formula 6.4 is converted to a fluorinated substituent using a fluorinating agent (e.g., BAST) to give the compound of formula 6.6. The esters of compounds of formula 6.4 and 6.6 are hydrolyzed in THF / water with a base (e.g., LiOH, KOH, or NaOH) to give compounds of formulas 6.5 and 6.7. Alternatively, after the hydrolysis reaction, the products can be separated at an alkaline pH to obtain basic salts (i.e., Li, K, or Na) of the carboxylic acids of formulas 6.5 and 6.7. The carboxylic acids or their basic salts can then be used for the coupling reaction described in Method C of General Scheme 1 without further purification.
[0291] General Scheme 7: Synthesis of pyrazolo[1,5-a]pyridyl R 2 acid intermediate
[0292]
[0293] The substituted pyrazolo[1,5-a]pyridyl R was prepared according to general scheme 7. 2 Carboxylic acid intermediate. In method A, a metal catalyst (e.g., Buchwald catalyst or Ullman catalyst) is used to react the halide of formula 7.1 (where X...) with... 1 (where X is Br or Cl) reacts with an amine or heterocyclic amine of formula 7.2 (e.g., piperidine, morpholine, piperazine, azacyclic butane, and pyrrolidine) in a CN cross-coupling reaction to give a compound of formula 7.3. In method B, a halide of formula 7.1 (where X is Br or Cl) can also be reacted with an amine or heterocyclic amine of formula 7.2 (e.g., piperidine, morpholine, piperazine, azacyclic butane, and pyrrolidine) in a CN cross-coupling reaction to give a compound of formula 7.3. 1 The compound of formula 7.6 is reacted with a heteroaryl or aryl compound of formula 7.5 via Suzuki coupling (where Y is a boric acid or ester) or Stille coupling (where Y is SnR3) to give the compound of formula 7.6. According to method C, the halide of formula 7.1 (where X is Br or Cl) is reacted with a heteroaryl or aryl compound of formula 7.5 via Suzuki coupling (where Y is a boric acid or ester) or Stille coupling (where Y is SnR3) to give the compound of formula 7.6. 1The alkene in compound 7.8 is then oxidatively cleaved to an aldehyde in a Suzuki coupling reaction (where X is Cl, Br, or F) to give compound 7.9. According to method D, the aldehyde in compound 7.9 is reduced to an alcohol in an alcohol solvent (e.g., methanol or ethanol) using a hydride (e.g., NaBH4) to give compound 7.13. The alcohol in compound 7.13 is alkylated with sodium hydride and an alkyl (“R”) halide of formula 7.14 (where X is Cl, Br, or F) to give compound 7.15. According to method E, compound 7.9 is reacted with an amine of formula 7.10 under reductive amination conditions to give compound 7.11. The esters of compounds of formulas 7.3, 7.6, 7.11, and 7.15 are hydrolyzed in THF / water with an alkali (e.g., LiOH, KOH, or NaOH) to give compounds of formulas 7.4, 7.7, 7.12, and 7.16. Alternatively, after the hydrolysis reaction, the products can be separated at an alkaline pH to give basic salts (i.e., Li, K, or Na) of the carboxylic acids of formulas 7.4, 7.7, 7.12, and 7.16. The carboxylic acids or their basic salts can then be used in the coupling reaction described in Method C of General Scheme 1 without further purification.
[0294] General Scheme 8: Synthesis of pyrazolo[1,5-a]pyridyl R 2 acid intermediate
[0295]
[0296] Disubstituted pyrazolo[1,5-a]pyridinyl R 2 The carboxylic acid intermediate was prepared according to General Scheme 8. The starting reagent 3-bromo-4-chloropyridine was reacted with (E)-N-((tris(methyltrimethylsulfonyl)oxy)acetylimine ethyl ester to give N-aminopyridinium salt 8.1. The N-aminopyridinium salt 8.1 underwent a cycloaddition reaction with ethyl propargylate and a base such as K₂CO₃ to give 6-bromo-5-chloropyrazolo[1,5-a]pyridine-3-carboxylate ethyl ester 8.2. Compound 8.2 was subjected to a CN-cross-coupling reaction with an amine or heterocyclic amine of formula 8.4 (e.g., piperidine, morpholine, piperazine, azacyclobutane, and pyrrolidine) using a metal catalyst (e.g., Buchwald or Ullman catalyst) to give compounds of formula 8.5. The esters of compounds 8.2 and 8.5 were hydrolyzed in THF / water with a base (e.g., LiOH, KOH, or NaOH) to give compounds of formulas 8.3 and 8.6. Alternatively, after the hydrolysis reaction, the product can be separated at an alkaline pH to obtain the basic salts (i.e., Li, K, or Na) of the carboxylic acids of formulas 8.3 and 8.6. The carboxylic acid or its basic salt can then be used in the coupling reaction described in Method C of General Scheme 1 without further purification.
[0297] General Scheme 9: Synthesis of 1,3,4-oxadiazolyl R 2 acid intermediate
[0298]
[0299] According to general scheme 9, heteroaryl and aryl-substituted oxadiazolyl R were prepared. 2 Carboxylic acid intermediate. In method A, the heteroaryl and aryl ester of formula 9.1 are reacted with hydrazine hydrate to give hydrazine of formula 9.2. The compound of formula 9.2 is then reacted with ethyl 2-chloro-2-oxoacetate to give the compound of formula 9.3, which is subsequently intramolecularly cyclized with p-toluenesulfonyl chloride and a base (e.g., TEA) to give 1,3,4-oxadiazole of formula 9.4. Alternatively, the compound of formula 9.4 can be prepared using method B. In method B, ethyl 2-hydrazino-2-oxoacetate is reacted with 1,1'-thiocarbonyldiimidazole to form 1,3,4-oxadiazole, which is then alkylated with methyl iodide and a base (e.g., TEA) to give ethyl 5-(methylthio)-1,3,4-oxadiazole-2-carboxylate. Ethyl 5-(methylthio)-1,3,4-oxadiazole-2-carboxylate is reacted with a heteroaryl or arylboronic acid or ester of formula 9.5 in a desulfurized CC cross-coupling reaction (also known as Liebeskind-Srogl cross-coupling) to give the compound of formula 9.4. The ester of compound 9.4 is hydrolyzed in THF / water with an alkali (e.g., LiOH, KOH, or NaOH) to give the compound of formula 9.6. Alternatively, after the hydrolysis reaction, the product can be separated at an alkaline pH to obtain a basic salt (i.e., Li, K, or Na) of the carboxylic acid of formula 9.6. The carboxylic acid or its basic salt can then be used for the coupling reaction described in method C of general scheme 1 without further purification.
[0300] General Scheme 10: Synthesis of 1,3,4-oxadiazolyl R 2 acid intermediate
[0301]
[0302] The substituted 1,3,4-oxadiazolyl R was prepared according to general scheme 10. 2Carboxylic acid intermediate. The starting reagent ethyl 5-amino-1,3,4-oxadiazole-2-carboxylate is treated under Sandmeyer reaction conditions to give ethyl 5-bromo-1,3,4-oxadiazole-2-carboxylate (compound 10.1). The bromine in compound 10.1 reacts with an amine or heterocyclic amine of formula 10.2 (e.g., piperidine, morpholine, piperazine, aziridine, and pyrrolidine) and a base (e.g., TEA) to give compound 10.3. The ester of compound 10.3 is hydrolyzed in THF / water with a base (e.g., LiOH, KOH, or NaOH) to give compound 10.4. Alternatively, after hydrolysis, the product can be separated at an alkaline pH to obtain a basic salt (i.e., Li, K, or Na) of the carboxylic acid of formula 10.4. The carboxylic acid or its basic salt can then be used in the coupling reaction described in Method C of General Scheme 1 without further purification.
[0303] General Scheme 11: Preparation of deuterated core amine intermediates of formulas 11.6 and 11.7
[0304]
[0305] R is prepared according to general scheme 11. 5A The compound of formula I is D. The amine of formula 2.1 prepared according to general scheme 2 is protected with a BOC protecting group or other suitable nitrogen protecting group to give the compound of formula 11.1. The amine of formula 11.1 is then protected with a dimethylaminosulfonyl protecting group to give a mixture of compounds of formulas 11.2 and 11.3, which are separated during purification. The compound of formula 11.2 is then deprotonated with butyllithium, followed by the addition of D₂O, to introduce deuterium into R. 5A The positions were determined to yield compounds of formulas 11.4 and 11.5. Deprotection of the nitrogen protecting group with an acid yielded the deuterated core amine intermediate of formula 11.6. The deuterated core amine intermediate of formula 11.6 can be further reacted with various L and R groups according to methods A, B, C, D, E, and F in General Scheme 1. 2 Group coupling yields a compound of formula I, wherein R 5A It is D.
[0306] The present disclosure will be more fully understood by referring to the following embodiments. The embodiments provided herein are illustrative and should not be construed as limiting the scope of the present disclosure. Example
[0307] In some implementations, this disclosure provides specific examples of Formula I and its pharmaceutically acceptable salts and / or isotopes, as shown in Table 1 below.
[0308]
[0309]
[0310]
[0311]
[0312]
[0313]
[0314]
[0315]
[0316]
[0317]
[0318]
[0319]
[0320]
[0321]
[0322]
[0323]
[0324]
[0325]
[0326]
[0327]
[0328]
[0329]
[0330]
[0331]
[0332]
[0333]
[0334]
[0335]
[0336]
[0337]
[0338]
[0339]
[0340]
[0341]
[0342]
[0343]
[0344]
[0345]
[0346]
[0347]
[0348]
[0349]
[0350]
[0351]
[0352]
[0353]
[0354]
[0355]
[0356]
[0357]
[0358]
[0359]
[0360]
[0361]
[0362]
[0363]
[0364]
[0365]
[0366]
[0367]
[0368]
[0369]
[0370]
[0371]
[0372]
[0373]
[0374]
[0375]
[0376]
[0377]
[0378]
[0379]
[0380]
[0381]
[0382]
[0383]
[0384]
[0385]
[0386]
[0387]
[0388]
[0389]
[0390]
[0391]
[0392]
[0393]
[0394]
[0395]
[0396]
[0397]
[0398]
[0399]
[0400]
[0401]
[0402]
[0403]
[0404]
[0405]
[0406]
[0407]
[0408]
[0409]
[0410]
[0411]
[0412]
[0413]
[0414]
[0415]
[0416]
[0417]
[0418]
[0419]
[0420]
[0421]
[0422]
[0423]
[0424]
[0425]
[0426]
[0427]
[0428]
[0429]
[0430]
[0431]
[0432]
[0433]
[0434]
[0435]
[0436]
[0437]
[0438]
[0439]
[0440]
[0441]
[0442]
[0443]
[0444]
[0445]
[0446]
[0447]
[0448]
[0449]
[0450]
[0451]
[0452]
[0453]
[0454]
[0455]
[0456]
[0457]
[0458]
[0459]
[0460]
[0461]
[0462]
[0463]
[0464]
[0465]
[0466]
[0467]
[0468]
[0469]
[0470]
[0471]
[0472]
[0473]
[0474]
[0475]
[0476]
[0477]
[0478]
[0479]
[0480]
[0481]
[0482]
[0483]
[0484]
[0485]
[0486]
[0487]
[0488]
[0489]
[0490]
[0491]
[0492]
[0493]
[0494]
[0495]
[0496]
[0497]
[0498]
[0499]
[0500]
[0501]
[0502]
[0503]
[0504]
[0505]
[0506]
[0507]
[0508]
[0509]
[0510]
[0511]
[0512]
[0513]
[0514]
[0515]
[0516] In other embodiments, the compound of formula I is one or more of the compounds in Table 1, which are S-enantiomers or pharmaceutically acceptable salts thereof.
[0517] In other embodiments, the compound of formula I is one or more of the following: Examples 605, 626, 640, 670, 688, 708, 710, 726, 728, 733, 748, 760, 762, 764, 791, 836, 840, 906, 922, 938, 942, 944, 946, 948, 950, 952, 954, 957, 958, 960, 962, 964, 966, 969, 971, 972, 9 75, 976, 979, 980, 982, 984, 988, 1381, 1438, 1461, 1506, 1531, 1548, 1589, 1607, 1613, 1628, 1652, 1657, 1728, 1737, 1757, 1807, 1809, 1823, 1843, 1849, 1850, 1943, 1953, 1986, 2218, 2221 and 2223, or pharmaceutically acceptable salts thereof. In other embodiments, the compound of formula I is one or more of the following: Examples 640, 670, 688, 708, 710, 726, 728, 733, 748, 760, 762, 764, 836, 840, 906, 922, 938, 942, 944, 946, 948, 950, 952, 954, 957, 960, 96 2, 969, 971, 972, 975, 976, 979, 980, 984, 988, 1438, 1461, 1506, 1548, 1628, 1652, 1657, 1728, 1737, 1757, 1809, 1849, 1850, 1953, 1986, 2218 and 2221, or pharmaceutically acceptable salts thereof. In other embodiments, the compound of formula I is one or more of the following: Examples 640, 670, 688, 708, 710, 726, 728, 733, 748, 760, 762, 764, 836, 840, 906, 922, 938, 942, 944, 946, 948, 950, 952, 954, 957, 960, 962, 969, 971, 972, 975, 976, 979, 980, 984, 988, 1438, 1461, 1506, 1548, 1628, 1652, 1657, 1728, 1986, and 2218, or a pharmaceutically acceptable salt thereof.
[0518] List of abbreviations and terms:
[0519]
[0520]
[0521] Solvents and reagents:
[0522]
[0523]
[0524]
[0525]
[0526] General Experiment
[0527] In the following examples, reagents and solvents were purchased from commercial sources (e.g., Alfa, Acros, AstaTech, CombiBlocks, Enamine, Sigma Aldrich, TCI, PharmaBock, Bide Pharmatech Ltd., AccelaChemBio, Aladdin, Shanghai Haohong Pharmaceutical Co., Ltd., Amkchem, Beijing Ouhe Technology Co., Ltd., Haoyuan Chemexpress Co., Ltd., Hualun, Coolpharm, Scochem, Titan, and WuXi LabNetwork) and were used without further purification unless otherwise specified. Rapid chromatography was performed on a CombiFlash Rf 150 (ISCO) using a column with 200-300 mesh silica gel particles. HPLC was performed on an Agilent 1100 liquid chromatograph (Agilent, USA) and a Shimadzu LC 20 / 20A (Shimadzu, Japan). Supercritical fluid chromatography was performed on a Waters Prep SFC. Performed on a 150AP / 80Q / 200 / 350 system (Waters, USA). Analytical and preparative thin-layer chromatography (TLC) plates were HSGF 254 (0.15–0.2 mm thickness, Shanghai Anbang Co., Ltd., China). Nuclear magnetic resonance (NMR) spectra were obtained on a Bruker AV-400 NMR or Bruker AVIII 500 MHz NMR (Bruker, Switzerland). Chemical shifts are reported in parts per million (ppm, δ) from tetramethylsilane. Mass spectra were obtained by electrospray ionization (ESI) on a Waters LCT TOF mass spectrometer (Waters, USA). LC-MS was performed on an Agilent Prime-6125B / Agilent LC1260-MS6150 / Agilent LC1260-MS6125B / Agilent The microwave reactions were performed on an LC1200-MS6110 (Agilent Technologies, USA) and a Shimadzu LC20-MS2020. The microwave reactions were run on an Initiator 2.5 microwave synthesizer (Biotage, Sweden).
[0528] Intermediate (1-(1H-imidazol-5-yl)cyclopropyl)methylamine hydrochloride
[0529]
[0530] Step 1: Preparation of 2-(3-triphenylmethylimidazol-4-yl)acetonitrile (B2)
[0531] B2 was prepared from 2-(1H-imidazol-5-yl)acetonitrile (B1) according to the literature procedure. See, for example, WO2008 / 003766 (page 19).
[0532] Step 2: Preparation of 1-(3-triphenylmethylimidazol-4-yl)cyclopropaneformonitrile (B3)
[0533] LDA (2M, 42.9 mL, 3 eq) was added dropwise to a solution of 2-(3-triphenylmethylimidazol-4-yl)acetonitrile (B2) (10 g, 28.6 mmol) in THF (200 mL) at -78 °C. After the addition was complete, the reaction mixture was stirred at -20 °C to -10 °C for 1 h. The reaction mixture was then cooled to -78 °C, and 1,2-dibromoethane (10.75 g, 57.2 mmol, 4.32 mL, 2 eq) was added dropwise at -78 °C. After the addition was complete, the reaction mixture was slowly warmed to room temperature and stirred for another 2 h. The reaction progress was monitored using TLC (PE:EtOAc = 1:1). The reaction mixture was quenched with saturated NH4Cl solution (200 mL) and stirred at room temperature for 0.5 hr. The aqueous fraction was extracted with EtOAc (100 mL x 3), and the combined organic layers were dried over Na2SO4, filtered, and concentrated to dryness. The residue (combined with two other reactions using 10 g of B2) was purified by rapid silica gel chromatography. 120g Silica Flash column, elution buffer 0–40% EtOAc / PE, gradient @ 40 mL / min) to obtain B3 (23.4 g, 72% yield). 1 H NMR (400MHz, DMSO-d6) δ7.30-7.52 (m, 10H), 7.09 (dd, 6H), 6.84 (d, 1H), 1.51-1.66 (m, 2H), 1.29-1.46 (m, 2H).
[0534] Step 3: Preparation of 1-(3-triphenylmethylimidazol-4-yl)cyclopropyl]methylamine (B4)
[0535] A mixture of 1-(3-triphenylmethylimidazol-4-yl)cyclopropaneformonitrile (B3) (19 g, 50.6 mmol), Raney-Ni (4.60 g, 53.7 mmol, 1.06 eq), and NH3·H2O (591 mg, 5.06 mmol, 650 μL, 30% purity, 0.1 eq) in MeOH (200 mL) was degassed and purged three times with H2. The reaction mixture was then stirred at 45 °C under H2 (45 psi) for 16 h. The reaction progress was tracked using TLC (DCM:MeOH = 10:1). The reaction mixture was filtered, and additional Raney-Ni (4.60 g, 53.7 mmol, 1.06 eq) was added. The reaction mixture was then stirred again at 45 °C under H2 (45 psi) for 24 h. The reaction mixture was filtered through a diatomaceous earth pad, and the filtrate was concentrated to dryness to give B4 (18 g), which was used without further purification. 1 H NMR (400MHz, DMSO-d6) δ7.33-7.44(m, 9H), 7.18-7.25(m, 1H), 7.04-7.13(m, 6H), 6.64-6.71(m, 1H), 3.17(br s, 2H), 2.58-2.74 (m, 2H), 0.60-0.82 (m, 4H).
[0536] Step 4: Preparation of [1-(1H-imidazol-5-yl)cyclopropyl]methylamine hydrochloride (B5)
[0537] HCl / MeOH (4 M, 100 mL, 8.4 eq) was added to a solution of [1-(3-triphenylmethylimidazol-4-yl)cyclopropyl]methylamine (B4) (18 g, 47.4 mmol) in MeOH (100 mL). The reaction mixture was stirred at 60 °C for 16 h. The reaction progress was monitored by LC-MS. The reaction mixture was concentrated to dryness, and the residue was ground with EtOAc (40 mL) and stirred for 15 min. The precipitate was collected by filtration and then dried under vacuum to give B5 (8.5 g, 2 HCl salt). 1 H NMR (400MHz, DMSO-d6) δ 14.73 (brs, 1H), 9.04 (s, 1H), 8.27 (br s, 2H), 7.51 (s, 1H), 2.98-3.22 (m, 2H), 0.90-1.23 (m, 4H).
[0538] Intermediate 2-(1H-imidazol-5-yl)-2-methylpropyl-1-amine hydrochloride
[0539]
[0540] Step 1: Preparation of (2-methyl-2-(3-triphenylmethylimidazol-4-yl)propionitrile (B6)
[0541] LiHMDS (1M, 96.2 mL, 2.8 eq) was added dropwise to a solution of 2-(3-triphenylmethylimidazol-4-yl)acetonitrile (B2) (12 g, 34.3 mmol) in THF (400 mL) at -78 °C. The reaction mixture was stirred at -78 °C for 15 min, and then MeI (14.62 g, 103 mmol, 6.41 mL, 3 eq) was added. The reaction mixture was stirred at -78 °C for 1 h, and then warmed to room temperature and held for 18 h. The reaction progress was tracked using TLC (PE:EtOAc = 1:1). The reaction mixture was cooled to 0 °C and quenched by adding saturated NH4Cl solution (15 mL), followed by adding H2O (60 mL). The aqueous fraction was extracted with EtOAc (60 mL x 3). The combined organic layers were washed with brine (60 mL), dried over Na2SO4, and concentrated to dryness. The residue (combined with the residue from another reaction using 2g of B2) was purified by rapid silica gel chromatography. 80g Silica Flash column, elution buffer 0-80% EtOAc / PE, gradient @ 60 mL / min) to obtain B6 (14 g, 92% yield). 1 H NMR (400MHz, CDCl3) δ7.41 (d, 1H), 7.32-7.39 (m, 9H), 7.08-7.16 (m, 6H), 6.81 (d, 1H), 1.69 (s, 6H).
[0542] Step 2: Preparation of (2-methyl-2-(3-triphenylmethylimidazol-4-yl)propyl-1-amine (B7)
[0543] Raney-Ni (2 g, 23.3 mmol, 0.63 eq) was added to a solution of 2-methyl-2-(3-triphenylmethylimidazol-4-yl)propionitrile (B6) (14 g, 37.1 mmol) in MeOH (350 mL) under N2. The reaction mixture was degassed under vacuum and washed several times with H2. The reaction mixture was stirred at 40 °C for 36 h under H2 (50 psi). The reaction progress was tracked using TLC (PE:EtOAc = 1:1). The reaction mixture was filtered through a diatomaceous earth pad and the filtrate was concentrated to dryness to give B7 (12 g, 85% yield). 1HNMR (400MHz, CDCl3) δ7.38 (s, 1H), 7.29-7.36 (m, 9H), 7.10-7.18 (m, 6H), 6.55 (s, 1H), 3.49 (br s, 1H), 2.74 (s, 2H), 1.20 (s, 6H); LCMS: m / z382.2[M+H] + .
[0544] Step 3: Preparation of (2-(1H-imidazol-5-yl)-2-methyl-prop-1-amine (B8)
[0545] HCl / MeOH (4 M, 150 mL, 16.4 eq) was added to a solution of 2-methyl-2-(3-triphenylmethylimidazol-4-yl)propyl-1-amine (B7) (14 g, 36.7 mmol) in MeOH (150 mL), and the reaction mixture was stirred at 50 °C for 18 h. The reaction progress was tracked using TLC (EtOAc). The reaction mixture was concentrated to dryness, and 200 mL of EtOAc was added. The mixture was stirred at 60 °C for 1 hr. The precipitate was collected by filtration and washed with EtOAc, then dried under vacuum to give B8 (7.0 g, 90% yield, 2HCl salt). 1 H NMR (400MHz, CD3OD) δ 8.96 (s, 1H), 7.52 (s, 1H), 3.20-3.27 (m, 2H), 1.49 (s, 6H).
[0546] Intermediate 2-(1H-imidazol-5-yl)propyl-1-amine hydrochloride
[0547]
[0548] Step 1: Preparation of 2-(3-triphenylmethylimidazol-4-yl)propionitrile (B9)
[0549] LiHMDS (1M, 51.5mL, 1.2eq) was added dropwise to a solution of 2-(3-triphenylmethylimidazol-4-yl)acetonitrile (B2) (15g, 42.9mmol) in THF (120mL) at -78°C. After the addition, the reaction mixture was stirred for 0.5h, and then MeI (10.97g, 77.3mmol, 4.81mL, 1.8eq) was added dropwise at -78°C. The reaction mixture was stirred at -78°C for 2h. The reaction progress was tracked using TLC (PE:EtOAc = 2:1). The reaction mixture was quenched by adding saturated NH4Cl solution (120mL) and stirred for 15min. The aqueous fraction was extracted with EtOAc (400mL), and the organic layer was washed with water (100mL) and brine (60mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue (combined with the residue from another reaction using 15 g of B2) was purified by silica gel column chromatography (PE:EtOAc = 20:1 to 2:1) to give B9 (33.5 g, 75% yield). 1 H NMR (400MHz, DMSO-d6) δ7.38-7.45 (m, 10H), 7.06-7.13 (m, 6H), 6.82-6.92 (m, 1H), 4.12-4.23 (m, 1H), 1.48 (d, 3H).
[0550] Step 2: Preparation of 2-(3-triphenylmethylimidazol-4-yl)propyl-1-amine (B10)
[0551] A mixture of 2-(3-triphenylmethylimidazol-4-yl)propionitrile (B9) (16.5 g, 45.4 mmol), Raney-Ni (4.08 g, 47.7 mmol, 1.05 eq), and NH3·H2O (910 mg, 7.79 mmol, 1 mL, 30% purity) in MeOH (300 mL) was degassed under vacuum and washed three times with H2. The reaction mixture was stirred at 45 °C under H2 (45 psi) atmosphere for 16 h. The reaction progress was tracked using TLC (PE:EtOAc = 2:1). The reaction mixture was filtered through a diatomaceous earth pad and the filtrate was concentrated to dryness to give B10 (33 g), which was used without further purification. 1 H NMR (400MHz, CD3OD) δ7.36-7.44 (m, 10H), 7.13-7.20 (m, 6H), 6.72 (br s, 1H), 2.57-2.92 (m, 3H), 1.21 (br d, 3H).
[0552] Step 3: Preparation of 2-(1H-imidazol-5-yl)propyl-1-amine (B11)
[0553] HCl / MeOH (4M, 100mL) was added to a solution of 2-(3-triphenylmethylimidazol-4-yl)propyl-1-amine (B10) (23g, 62.6mmol) in MeOH (100mL). The mixture was stirred at room temperature for 12 hours. The reaction progress was tracked using TLC (EtOAc). The reaction mixture (combined with the reaction mixture of another reaction using 23g of B10) was concentrated to dryness. H2O (40mL) was added to the residue, and the aqueous layer was washed with EtOAc (50mL). The aqueous layer was lyophilized to give B11 (21g, 2HCl). 1 HNMR (400MHz, CD3OD) δ 8.96 (d, 1H), 7.56 (s, 1H), 3.43-3.51 (m, 1H), 3.17-3.32 (m, 2H), 1.29-1.53 (m, 3H).
[0554] Intermediates 2-[(2R)-2-(1H-imidazol-5-yl)propyl]isoindoline-1,3-dione and 2-[(2S)-2-(1H-imidazol-5-yl)propyl]isoindoline-1,3-dione
[0555]
[0556] Step 1: Preparation of 2-[2-(1H-imidazol-5-yl)propyl]isoindoline-1,3-dione (B13)
[0557] Et3N (15.32 g, 151 mmol, 21.1 mL, 3 eq) was added to a solution of 2-(1H-imidazol-5-yl)propyl-1-amine (B11) (10 g, 50.5 mmol, 2 HCl) and phthalic anhydride (7.85 g, 53.0 mmol, 1.05 eq) in i-PrOH (400 mL). The reaction mixture was stirred at 100 °C under a nitrogen atmosphere for 18 h. After cooling, the reaction mixture was concentrated to dryness. Water (200 mL) was then added, and the mixture was stirred at room temperature for 10 mins. The precipitate was collected by filtration, washed with water (100 mL), and dried under vacuum to give B13 (13 g), which was used without further purification. 1 H NMR (400MHz, DMSO-d6) δ7.71-7.89 (m, 4H), 7.49 (s, 1H), 6.79 (s, 1H), 3.70-3.76 (m, 1H), 3.60-3.65 (m, 1H), 3.15-3.23 (m, 1H), 1.16 (d, 3H).
[0558] Step 2: SFC separation
[0559] Compound 2-[2-(1H-imidazol-5-yl)propyl]isoindoline-1,3-dione (13 g) was separated by SFC (column: DAICL CHIRALPAK AD (250 mm * 50 mm, 10 μm); mobile phase: [0.1% NH3H2O ETOH]; B%: 40%-40%, min) to give enantiomer 1 (4.8 g, 37% yield, Rt = 3.953 min) and enantiomer 2 (5.2 g, 40% yield, Rt = 4.652 min).
[0560] Enantiomer 1: 2-[(2R)-2-(1H-imidazol-5-yl)propyl]isoindoline-1,3-dione (B13A). 1 HNMR (400MHz, CD3OD) δ7.73-7.89 (m, 4H), 7.56 (d, 1H), 6.82 (s, 1H), 3.84-3. 93 (m, 1H), 3.70-3.82 (m, 1H), 3.36-3.39 (m, 1H), 1.31 (d, 3H); SFC: 98.4%ee.
[0561] Enantiomer 2: 2-[(2S)-2-(1H-imidazol-5-yl)propyl]isoindoline-1,3-dione (B13B). 1 HNMR (400MHz, CD3OD) δ7.77-7.88 (m, 4H), 7.55 (d, 1H), 6.82 (s, 1H), 3.84-3. 97 (m, 1H), 3.72-3.82 (m, 1H), 3.36-3.42 (m, 1H), 1.31 (d, 3H); SFC: 99.1%ee.
[0562] Intermediate pyrazolo[1,5-a]pyridine-2-carboxaldehyde
[0563]
[0564] Step 1: Preparation of N-methoxy-N-methyl-pyrazolo[1,5-a]pyridine-2-carboxamide (C2)
[0565] To a solution of pyrazolo[1,5-a]pyridine-2-carboxylic acid (C1) (12.5 g, 77.1 mmol) and N-methoxymethylamine (9.42 g, 96.6 mmol, 1.25 eq, HCl) in DMF (200 mL), EDCI (22.17 g, 116 mmol, 1.5 eq), DIPEA (29.89 g, 231 mmol, 40.3 mL, 3 eq) and HOBt (15.63 g, 116 mmol, 1.5 eq) were added. The reaction mixture was stirred at room temperature for 12 hours. The reaction progress was monitored by TLC (PE:EtOAc = 1:1). The reaction mixture was combined with the reaction mixture from another reaction using 12.5 g of C1 and concentrated to dryness. The residue was dissolved in DCM (200 mL), and the organic layer was washed with saturated Na2CO3 solution (100 mL) and brine (100 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography (PE:EtOAc = 20:1 to 1:1) to give C2 (30.5 g, 96% yield). 1 H NMR (400MHz, CDCl3) δ 8.47-8.54 (m, 1H), 7.59 (d, 1H), 7.16 (ddd, 1H), 7.02 (s, 1H), 6.86 (td, 1H), 3.81 (s, 3H), 3.51 (s, 3H).
[0566] Step 2: Preparation of pyrazolo[1,5-a]pyridine-2-carboxaldehyde (C3)
[0567] DIBAL-H (1M, 146.2mL, 2eq) was added dropwise to a solution of N-methoxy-N-methyl-pyrazolo[1,5-a]pyridine-2-carboxamide (C2) (15g, 73.1mmol) in THF (150mL), and the reaction mixture was stirred at -78°C under N2 for 2 hours. The reaction progress was tracked using TLC (PE:EtOAc = 1:1). The reaction mixture was combined with the reaction mixture of another reaction using 15g of C2 and quenched by slow addition of saturated NH4Cl solution (200mL) and stirring for 15 min. 1M HCl solution was added until a clear solution was observed. The aqueous fraction was extracted with EtOAc (250mL x 3), and the combined organic layers were washed with water (100mL) and brine (100mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography (PE:EtOAc = 20:1 to 1:1) to give C3 (14.2 g). 1H NMR (400MHz, DMSO-d6) δ 10.14 (s, 1H), 8.81 (dd, 1H), 7.84 (d, 1H), 7.34 (t, 1H), 7.10-7.15 (m, 2H).
[0568] The intermediate 3-methylpyrazolo[1,5-a]pyridine-2-carboxaldehyde was prepared according to the general steps described in C3 above, starting from 3-methylpyrazolo[1,5-a]pyridine-2-carboxylic acid.
[0569] The intermediate 3-bromopyrazolo[1,5-a]pyridine-2-carboxaldehyde was prepared according to the general steps described in C3 above, starting from 3-bromopyrazolo[1,5-a]pyridine-2-carboxylic acid.
[0570] The intermediate 4-chloropyrazolo[1,5-a]pyridine-2-carboxaldehyde was prepared according to the general steps described in C3 above, starting from 4-chloropyrazolo[1,5-a]pyridine-2-carboxylic acid.
[0571] The intermediate 6-bromopyrazolo[1,5-a]pyridine-2-carboxaldehyde was prepared according to the general steps described in C3 above, starting from 6-bromopyrazolo[1,5-a]pyridine-2-carboxylic acid.
[0572] The intermediate 6-chloropyrazolo[1,5-a]pyridine-2-carboxaldehyde was prepared according to the general steps described in C3 above, starting from 6-chloropyrazolo[1,5-a]pyridine-2-carboxylic acid.
[0573] The intermediate 7-methylpyrazolo[1,5-a]pyridine-2-carboxaldehyde was prepared according to the general steps described in C3 above, starting from 7-methylpyrazolo[1,5-a]pyridine-2-carboxylic acid.
[0574] Intermediate 4-Fluoropyrazolo[1,5-a]pyridine-2-carboxaldehyde
[0575]
[0576] Step 1: Preparation of 3-(3-fluoro-2-pyridyl)prop-2-yn-1-yl acetate (C5)
[0577] A mixture of 2-bromo-3-fluoropyridine (C4) (30 g, 170 mmol), propyne-2-yn-1-ethyl acetate (23.41 g, 239 mmol, 1.4 eq), Pd(PPh3)2Cl2 (5.98 g, 8.52 mmol, 0.05 eq), CuI (1.62 g, 8.52 mmol, 0.05 eq), and TEA (51.75 g, 511 mmol, 71.2 mL, 3 eq) in dioxane (300 mL) was degassed and purged three times with N2. The reaction mixture was then stirred at 50 °C under N2 atmosphere for 6 hours. The reaction progress was monitored by TLC (PE:EtOAc = 5:1). The reaction mixture was concentrated to dryness. EtOAc (600 mL) was added to the residue, and the organic fraction was washed with water (300 mL) and brine (300 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by rapid silica gel chromatography. 120g Silica Flash column, elution buffer 0–20% EtOAc / PE, gradient @ 120 mL / min) to obtain C5 (23.4 g, 71% yield). 1 HNMR (400MHz, CDCl3) δ 8.43 (d, 1H), 7.46 (td, 1H), 7.32 (dt, 1H), 4.99 (s, 2H), 2.16 (s, 3H).
[0578] Step 2: Preparation of 3-(3-fluoro-2-pyridyl)prop-2-yn-1-ol (C6)
[0579] LiOH·H2O (5.34 g, 127 mmol, 1.05 eq) was added to a solution of 3-(3-fluoro-2-pyridyl)prop-2-ynyl acetate (C5) (23.4 g, 121 mmol) in THF (300 mL) and H2O (150 mL) at 0 °C. The reaction mixture was stirred at room temperature for 2 h. The reaction progress was monitored by TLC (PE:EtOAc = 1:1). EtOAc (600 mL) was added to the reaction mixture, and the organic layer was washed with H2O (400 mL) and brine (400 mL), dried over Na2SO4, filtered, and concentrated to dryness to give C6 (17.5 g), which was used without further purification. 1 H NMR (400MHz, DMSO-d6) δ 8.34-8.53 (m, 1H), 7.72-7.88 (m, 1H), 7.50 (dt, 1H), 5.54 (t, 1H), 4.38 (d, 2H).
[0580] Step 3: Preparation of 1-amino-3-fluoro-2-(3-hydroxyprop-1-yn-1-yl)pyridine-1-onium 2,4,6-trimethylbenzenesulfonate (C7)
[0581] Ethyl (1E)-N-(2,4,6-trimethylphenyl)sulfonyloxyethanimidate (33.70 g, 118 mmol, 1.05 eq) was added to a mixture of H₂O (35 mL, 1.94 mol, 17.3 eq) and TFA (308.0 g, 2.70 mol, 200 mL, 24.0 eq) at 0 °C, and the reaction mixture was stirred at 0 °C for 2 h. The reaction was quenched with ice-water (40 mL). The precipitate was filtered and washed with water (20 mL x 2). The precipitate was then dissolved in DCM (200 mL), dried over Na₂SO₄, and filtered. 3-(3-fluoro-2-pyridyl)prop-2-yn-1-ol (C6) (17 g, 112 mmol, 1 eq) was added to the filtrate at 0 °C. The reaction mixture was warmed to room temperature and maintained for 16 h. The reaction progress was monitored by TLC (PE:EtOAc = 1:1). TBME (400 mL) was slowly added to the reaction mixture, and the precipitate was collected by filtration. The precipitate was washed with TBME (200 mL x 2) to give C7 (26 g), which was used without further purification. 1 H NMR (400MHz, DMSO-d6) δ 8.66-8.88 (m, 3H), 8.32 (t, 1H), 8.01 (dt, 1H), 6.75 (s, 2H), 4.58 (s, 2H), 3.17 (s, 1H), 2.49 (s, 6H), 2.17 (s, 3H).
[0582] Step 4: Preparation of (4-fluoropyrazolo[1,5-a]pyridin-2-yl)methanol (C8)
[0583] NaOMe (5.4 M, 26.3 mL, 2 eq) was added to a solution of 1-amino-3-fluoro-2-(3-hydroxyprop-1-yn-1-yl)pyridin-1-onium 2,4,6-trimethylbenzenesulfonate (C7) (26 g, 71.0 mmol) in MeOH (250 mL) at 0 °C. The reaction mixture was stirred at room temperature for 1 hr. The reaction progress was tracked by TLC (PE:EtOAc = 1:1). The reaction mixture was quenched by adding ice-cold H2O (200 mL), concentrated to remove most of the MeOH, and extracted with EtOAc (200 mL x 3). The combined organic layers were washed with brine (400 mL), dried over Na2SO4, filtered, and concentrated to dryness to give C8 (7.5 g), which was used without further purification. 1H NMR (400MHz, CDCl3) δ 8.27 (d, 1H), 6.62-6.88 (m, 3H), 4.94 (s, 2H).
[0584] Step 5: Preparation of 4-fluoropyrazolo[1,5-a]pyridine-2-carboxaldehyde (C9)
[0585] IBX (15.17 g, 54.2 mmol, 1.2 eq) was added to a solution of (4-fluoropyrazolo[1,5-a]pyridin-2-yl)methanol (C8) (7.5 g, 45.1 mmol) in MeCN (150 mL). The reaction mixture was stirred at 80 °C for 3 h. The reaction progress was monitored by TLC (PE:EtOAc = 5:1). The reaction mixture was filtered and concentrated to dryness. The residue was purified by rapid silica gel chromatography. 40g Silica Flash column, elution buffer 0–4% EtOAc / PE, gradient @ 40 mL / min) to obtain C9 (4 g, 54% yield). 1 H NMR (400MHz, CDCl3) δ10.22 (s, 1H), 8.33-8.41 (m, 1H), 7.20 (d, 1H), 6.85-6.98 (m, 2H).
[0586] The intermediate 4-methylpyrazolo[1,5-a]pyridine-2-carboxaldehyde was prepared according to the general steps described in C9 above, starting from 2-bromo-3-methylpyridine.
[0587] The intermediate 4-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carboxaldehyde was prepared according to the general steps described in C9 above, starting from 2-bromo-3-(trifluoromethyl)pyridine.
[0588] The intermediate 4-methoxypyrazolo[1,5-a]pyridine-2-carboxaldehyde was prepared according to the general steps described in C9 above, starting from 2-bromo-3-methoxypyridine.
[0589] The intermediate 5-methylpyrazolo[1,5-a]pyridine-2-carboxaldehyde was prepared according to the general steps described in C9 above, starting from 2-bromo-4-methylpyridine.
[0590] The intermediate 5-fluoropyrazolo[1,5-a]pyridine-2-carboxaldehyde was prepared according to the general steps described in C9 above, starting from 2-bromo-4-fluoropyridine.
[0591] The intermediate 5-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carboxaldehyde was prepared according to the general steps described in C9 above, starting from 4-(trifluoromethyl)pyridine.
[0592] The intermediate 6-methylpyrazolo[1,5-a]pyridine-2-carboxaldehyde was prepared according to the general steps described in C9 above, starting from 2-bromo-5-methylpyridine.
[0593] The intermediate 6-fluoropyrazolo[1,5-a]pyridine-2-carboxaldehyde was prepared according to the general steps described in C9 above, starting from 2-bromo-5-fluoropyridine.
[0594] The intermediate 6-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carboxaldehyde was prepared according to the general steps described in C9 above, starting from 2-bromo-5-(trifluoromethyl)pyridine.
[0595] Intermediate 7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carboxaldehyde
[0596]
[0597] Step 1: Preparation of 1-amino-2-(trifluoromethyl)pyridine-1-onium 2,4,6-trimethylbenzenesulfonate (C11)
[0598] Ethyl (1E)-N-(2,4,6-trimethylphenyl)sulfonyloxyiminoethyl acetate (21.34 g, 74.8 mmol, 1.1 eq) was added to a mixture of TFA (215.60 g, 1.89 mol, 140 mL, 27.8 eq) and H₂O (20.00 g, 1.11 mol, 20.0 mL, 16.3 eq) at 0 °C, and the reaction mixture was stirred at 0 °C for 2 h. The reaction was quenched by adding ice-water (100 mL), and the precipitate was filtered and washed with water (50 mL x 2). The precipitate was then dissolved in DCM (140 mL), dried over Na₂SO₄, and filtered. 2-(trifluoromethyl)pyridine (C10) (10 g, 68.0 mmol, 7.87 mL) was added to the filtrate at 0 °C. The reaction mixture was warmed to room temperature and stirred for 16 h. TBME (100 mL) was slowly added to the reaction mixture, and the precipitate was collected and washed with TBME (40 mL x 3), and then dried under vacuum to give C11 (8.5 g, 35% yield), which was used without further purification. 1 HNMR (400MHz, DMSO-d6) δ9.06 (d, 1H), 8.40-8.60 (m, 2H), 8.20-8.26 (m, 1H), 8.12 (s, 2H), 6.60 (s, 2H), 2.34 (s, 6H), 2.02 (s, 3H).
[0599] Step 2: Preparation of dimethyl 7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2,3-dicarboxylate (C12)
[0600] Dimethyl butyrate (6.66 g, 46.9 mmol, 2 eq) was added to a mixture of 1-amino-2-(trifluoromethyl)pyridin-1-onthium 2,4,6-trimethylbenzenesulfonate (C11) (8.5 g, 23.5 mmol) and K2CO3 (6.49 g, 46.9 mmol, 2 eq) in DMF (100 mL). The reaction mixture was warmed to room temperature and stirred for 16 hours. The reaction progress was tracked by TLC (PE:EtOAc = 1:1). Water (200 mL) was added, and the solution was stirred for 30 minutes. The resulting precipitate was collected by vacuum filtration, washed with water, and dried. The residue was purified by rapid silica gel chromatography. 80g SilicaFlash column, eluent 0–40% EtOAc:PE@60 mL / min) to obtain C12 (2.85 g, 40% yield). 1 H NMR (400MHz, DMSO-d6) δ 8.40 (d, 1H), 7.74-7.96 (m, 2H), 3.85-3.96 (m, 6H).
[0601] Step 3: Preparation of 2-(methoxycarbonyl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-3-carboxylic acid (C13)
[0602] A solution of 7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2,3-dicarboxylate (C12) (2.85 g, 9.43 mmol) in THF (20 mL) was added to a solution of LiOH·H2O (1.58 g, 37.7 mmol, 4 eq) in H2O (20 mL), and the reaction mixture was stirred at room temperature for 16 h. The reaction progress was monitored using TLC (PE:EtOAc = 1:1). The reaction mixture was concentrated under vacuum to remove most of the THF, and the aqueous phase was adjusted to pH ~2 with 4 M HCl. The precipitate was collected by filtration and then dried under vacuum to give C13 (2.25 g), which was used without further purification. 1 H NMR (400MHz, DMSO-d6) δ 8.43 (d, 1H), 7.85 (d, 1H), 7.71-7.76 (m, 1H).
[0603] Step 4: Preparation of 7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carboxylic acid (C14)
[0604] A mixture of 2-(methoxycarbonyl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-3-carboxylic acid (C13) (2.25 g, 8.21 mmol) in H2SO4 (41.40 g, 422 mmol, 22.5 mL, 51.4 eq) and H2O (11.25 g, 624 mmol, 11.3 mL, 76.1 eq) was stirred at 90 °C for 16 h. The reaction progress was monitored using LC-MS. The reaction mixture was cooled to room temperature and water (60 mL) was added. The precipitate was collected by filtration and then dried under vacuum to give C14 (1.7 g), which was used without further purification. 1 H NMR (400MHz, DMSO-d6) δ 8.14 (d, 1H), 7.71 (d, 1H), 7.41-7.49 (m, 1H), 7.32 (s, 1H).
[0605] Step 5: Preparation of N-methoxy-N-methyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carboxamide (C15)
[0606] HOBt (7.05 g, 52.1 mmol, 1.5 eq), EDCI (10.00 g, 52.1 mmol, 1.5 eq), and DIPEA (13.48 g, 104 mmol, 18.2 mL, 3 eq) were added to a solution of 7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carboxylic acid (C14) (8.00 g, 34.8 mmol) and N-methoxymethylamine (10.17 g, 104 mmol, 18.2 mL, 3 eq) in DMF (80 mL). The mixture was stirred at room temperature for 16 hours. The reaction progress was tracked using TLC (DCM:MeOH = 10:1). DCM (150 mL) was added, and the organic fraction was washed with saturated Na2CO3 solution (100 mL × 2) and brine (100 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by rapid silica gel chromatography. 80g Silica Flash column, eluent 0–10% MeOH:DCM@60 mL / min) to obtain C15 (6 g, 60% yield). 1 H NMR (400MHz, DMSO-d6) δ8.11 (d, 1H), 7.67 (d, 1H), 7.37-7.49 (m, 1H), 7.21 (s, 1H), 3.77 (s, 3H), 2.50-2.52 (m, 3H); LCMS: m / z274.1[M+H] + .
[0607] Step 6: Preparation of 7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carboxaldehyde (C16)
[0608] DIBAL-H (1M, 65.9mL, 3eq) was added dropwise to a solution of N-methoxy-N-methyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carboxamide (C15) (6g, 22.0mmol) in THF (60mL), and the reaction mixture was stirred at -78°C under N2 for 2 hours. The reaction progress was tracked by TLC (PE:EtOAc = 5:1). The reaction mixture was quenched by adding saturated NH4Cl solution (150mL), followed by adding 4M HCl solution (80mL). The aqueous fraction was extracted with EtOAc (100mL x 2), and the combined organic layers were washed with water (80mL) and brine (80mL). The organic layers were dried over Na2SO4, filtered, and evaporated to dryness. The residue was purified by rapid silica gel chromatography. 40g Silica Flash column, eluent 0–30% EtOAc:PE@40 mL / min) to obtain C16 (3.95 g, 68% yield). 1 H NMR (400MHz, DMSO-d6) δ 10.20 (s, 1H), 8.20 (d, 1H), 7.79 (d, 1H), 7.49 (dd, 1H), 7.40 (s, 1H).
[0609] The intermediate 7-chloropyrazolo[1,5-a]pyridine-2-carboxaldehyde was prepared according to the general steps described in C16 above, starting with 2-chloropyridine.
[0610] The intermediate 5-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carboxaldehyde was prepared according to the general steps described in C16 above, starting from 4-(trifluoromethyl)pyridine.
[0611] Intermediate 7-Fluoropyrazolo[1,5-a]pyridine-2-carboxaldehyde
[0612]
[0613] Step 1: Preparation of ethyl 7-fluopyrazolo[1,5-a]pyridine-2-carboxylate (C18)
[0614] CsF (1.69 g, 11.2 mmol, 411 μL, 3 eq) was added to a solution of 7-bromopyrazolo[1,5-a]pyridine-2-carboxylate (C17) (1 g, 3.72 mmol) in DMA (8 mL), and the reaction mixture was stirred in a microwave oven at 150 °C for 1 hr. The reaction progress was monitored using LCMS. DCM (60 mL) was added to the reaction mixture, and the organic fraction was washed with water (30 mL) and brine (30 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO2, PE / EtOAc = 1 / 0 to 4 / 1) to give C18 (450 mg, 29% yield). 1 H NMR (400MHz, CDCl3) δ7.48 (d, 1H), 7.18-7.26 (m, 2H), 6.64 (ddd, 1H), 4.52 (q, 2H), 1.48 (t, 3H); LCMS: m / z 208.8[M+H] + .
[0615] Step 2: Preparation of (7-fluoropyrazolo[1,5-a]pyridin-2-yl)methanol (C19)
[0616] LiBH4 (260 mg, 11.9 mmol, 5.5 eq) was added to a solution of ethyl 7-fluopyrazolo[1,5-a]pyridine-2-carboxylate (C18) (450 mg, 2.16 mmol) in THF (4 mL) and EtOH (2 mL) at 0 °C. The reaction mixture was stirred at room temperature for 2 h. The reaction progress was monitored using LCMS. The reaction mixture was quenched by adding saturated NH4Cl solution (10 mL), and the aqueous fraction was extracted with EtOAc (30 mL). The organic layer was washed with water (20 mL) and brine (20 mL), dried over Na2SO4, filtered, and concentrated to dryness to give C19 (360 mg), which was used without further purification. LCMS: m / z 167.0 [M+H] + .
[0617] Step 3: Preparation of 7-fluoropyrazolo[1,5-a]pyridine-2-carboxaldehyde (C20)
[0618] IBX (971 mg, 3.47 mmol, 1.6 eq) was added to a solution of (7-fluoropyrazolo[1,5-a]pyridin-2-yl)methanol (C19) (360 mg, 2.17 mmol) in MeCN (5 mL), and the reaction mixture was stirred at 80 °C for 1 hr. The reaction progress was monitored using LCMS. The reaction mixture was filtered and concentrated to dryness to give C20 (355 mg), which was used without further purification. 1HNMR (400MHz, CDCl3) δ 10.26-10.46 (m, 1H), 7.52 (dd, 1H), 7.22-7.28 (m, 1H), 7.16 (d, 1H), 6.69 (ddd, 1H); LCMS: m / z 165.0 [M+H] + .
[0619] Intermediate 4-(difluoromethyl)oxazol-5-carboxylic acid, according to general scheme 4
[0620]
[0621] Step 1: Preparation of ethyl 2-bromo-4,4-difluoro-3-oxo-butyrate (E1)
[0622] TsOH (4.15 g, 24.1 mmol, 0.2 eq) and NBS (22.50 g, 126 mmol, 1.05 eq) were added fractionally to a solution of ethyl 4,4-difluoro-3-oxo-butyrate (20 g, 120 mmol) in DCM (240 mL) at 0 °C. After the addition was complete, the reaction mixture was stirred at room temperature for 1 hr. The reaction progress was monitored by TLC (PE:EtOAc = 5:1). DCM (100 mL) was added, and the organic fraction was washed with saturated Na₂CO₃ solution (100 mL) and brine (150 mL), dried over Na₂SO₄, filtered, and concentrated to dryness to give E1 (34 g), which was used without further purification. 1 H NMR (400MHz, DMSO-d6) δ 5.81-6.16 (m, 1H), 4.34-4.41 (m, 1H), 4.12-4.20 (m, 2H), 1.17-1.23 (m, 3H).
[0623] Step 2: Preparation of ethyl 2-amino-4-(difluoromethyl)oxazol-5-carboxylate (E2)
[0624] A mixture of E1 (37 g, 151 mmol) and urea (45.34 g, 755 mmol, 40.5 mL, 5 eq) in DMF (30 mL) was stirred at 120 °C for 12 h. The reaction progress was monitored by LC-MS. The reaction mixture was cooled to room temperature and poured into 100 mL of water. The reaction mixture was stirred at 0 °C for 15 min, and the precipitate was collected by filtration, washed with water (50 mL), and dried under vacuum to give E2 (15.5 g, 63% yield, for steps 1 and 2). LC-MS: m / z 207.2 (M+H) + ; 1H NMR (400MHz, DMSO-d6) δ7.86 (s, 2H), 6.84-7.44 (m, 1H), 4.27 (q, 2H), 1.28 (t, 3H).
[0625] Step 3: Preparation of ethyl 4-(difluoromethyl)oxazol-5-carboxylate (E3)
[0626] t-BuONO (30.01 g, 291 mmol, 34.6 mL, 3 eq) was added dropwise to a solution of ethyl 2-amino-4-(difluoromethyl)oxazol-5-carboxylate (20 g, 97.0 mmol) in THF (300 mL) at 0 °C, and the reaction mixture was stirred at room temperature for 12 h. DCM (300 mL) was added, and the organic fraction was washed with water (200 mL) and brine (200 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO2, PE / EtOAc = 1 / 0 to 10 / 1) to give E3 (12.7 g, 69% yield). 1 HNMR (400MHz, CDCl3) δ8.05 (s, 1H), 6.93-7.27 (m, 1H), 4.44 (q, 2H), 1.40 (t, 3H).
[0627] Step 5: Preparation of 4-(difluoromethyl)oxazol-5-carboxylic acid (E4)
[0628] LiOH·H2O (3.07 g, 73.1 mmol, 1.1 eq) was added to a solution of ethyl 4-(difluoromethyl)oxazol-5-carboxylate (12.7 g, 66.5 mmol) in THF (100 mL) and H2O (20 mL). The reaction mixture was stirred at room temperature for 1 hr, and then concentrated under vacuum to remove THF. Water (80 mL) was added, and the aqueous fraction was extracted with TBME (50 mL). The aqueous layer was then adjusted to pH ~6 by adding 0.5 M HCl. The aqueous layer was concentrated to dryness to give E4 (11 g), which was used without further purification. 1 HNMR (400MHz, DMSO-d6) δ8.30 (s, 1H), 7.34-7.76 (m, 1H).
[0629] The intermediate ethyl 2-bromo-4-(difluoromethyl)oxazol-5-carboxylate, according to general scheme 4
[0630]
[0631] Preparation of ethyl 2-bromo-4-(difluoromethyl)oxazol-5-carboxylate (E5)
[0632] CuBr2 (40.63 g, 182 mmol, 8.5 mL, 1.5 eq) was added to a solution of ethyl 2-amino-4-(difluoromethyl)oxazol-5-carboxylate (E2) (25 g, 121 mmol) in MeCN (200 mL) at 0 °C. The mixture turned dark green and was further stirred at room temperature for 15 min. t-BuONO (18.76 g, 182 mmol, 21.6 mL, 1.5 eq) was added at 0 °C. The reaction was stirred at room temperature for 2 h, then heated to 50 °C and stirred for 12 h. The reaction progress was tracked using TLC (EtOAc:PE = 5:1). The reaction mixture was filtered. DCM (200 mL) was added to the filtrate, and the organic layer was washed with water (100 mL) and brine (100 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by rapid silica gel chromatography. 120g Silica Flash column, eluent 0–20% EtOAc / PE gradient @ 100 mL / min, to obtain E5 (19 g, 58% yield). 1 H NMR (400MHz, CDCl3) δ7.02 (t, 1H), 4.39 (q, 2H), 1.35 (t, 3H).
[0633] Intermediate 4-(difluoromethyl)-2-(1-hydroxy-1-methyl-ethyl)oxazol-5-carboxylic acid, according to general scheme 6, method A
[0634]
[0635] Step 1: Preparation of ethyl 2-acetyl-4-(difluoromethyl)oxazol-5-carboxylate (E6)
[0636] Pd(PPh3)2Cl2 (2.60 g, 3.70 mmol, 0.1 eq) and tributyl(1-ethoxyvinyl)stanane (17.39 g, 48.1 mmol, 16.3 mL, 1.3 eq) were added to a solution of ethyl 2-bromo-4-(difluoromethyl)oxazol-5-carboxylate (E5) (10 g, 37.0 mmol) in toluene (150 mL). The mixture was stirred at 85 °C under a nitrogen atmosphere for 12 h. The reaction progress was monitored by TLC (PE:EtOAc). EtOAc (100 mL) was added to the reaction mixture, and the organic fraction was washed with saturated KF solution (150 mL) and brine (100 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was dissolved in THF (60 mL) and treated with HCl (4 M, 60 mL), and then stirred at 40 °C for 12 h. The reaction progress was monitored by TLC (petroleum ether:EtOAc = 10:1). EtOAc (100 mL) was added to the reaction mixture, and the organic fraction was washed with water (50 mL) and brine (50 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by rapid silica gel chromatography. 40g Silica Flash column, eluent 0–20% EtOAc / PE gradient @ 40 mL / min, to obtain E6 (7.1 g, 82% yield). 1 HNMR (400MHz, CDCl3) δ7.00-7.36 (m, 1H), 4.48 (q, 2H), 2.66-2.86 (m, 3H), 1.43 (t, 3H).
[0637] Step 2: Preparation of ethyl 4-(difluoromethyl)-2-(1-hydroxy-1-methyl-ethyl)oxazol-5-carboxylate (E7)
[0638] MeMgBr (3M, 7.15mL, 2eq) was added to a solution of E6 (2.5g, 10.7mmol) in THF (120mL) at -78°C. The mixture was stirred at -78°C for 1 hour. The reaction progress was monitored by TLC (PE:EtOAc = 2:1). The reaction mixture was quenched by adding saturated NH4Cl solution (50mL), followed by the addition of water (100mL). The aqueous fraction was extracted with EtOAc (100mL x 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by rapid silica gel chromatography. 40g Silica Flash column, eluent 0–12% EtOAc / PE gradient @ 40 mL / min, to obtain E7 (3.2 g, 60% yield). 1¹H NMR (400 MHz, CDCl₃) δ 6.94–7.29 (m, 1H), 4.46 (q, 2H), 2.86 (s, 1H), 1.72 (s, 6H), 1.44 (t, 3H). The starting material E₆ (300 mg) was also recovered.
[0639] Step 3: Preparation of 4-(difluoromethyl)-2-(1-hydroxy-1-methyl-ethyl)oxazol-5-carboxylic acid (E8)
[0640] LiOH·H2O (690 mg, 16.4 mmol, 1.05 eq) was added to a solution of E7 (3.9 g, 15.7 mmol) in THF (40 mL) and H2O (40 mL). The mixture was stirred at room temperature for 1 hour. The reaction progress was monitored by TLC (PE:EtOAc = 5:1). The reaction mixture was concentrated to remove THF. The aqueous mixture was then adjusted to pH ~3 by adding 1 M HCl and then lyophilized under vacuum to obtain E8 (4 g), which was used without further purification. 1 H NMR (400MHz, DMSO-d6) δ7.35-7.71 (m, 1H), 5.68 (br s, 1H), 1.50 (s, 6H).
[0641] Intermediate 2-(1-hydroxycyclobutyl)-4-(trifluoromethyl)oxazol-5-carboxylic acid
[0642]
[0643] Step 1: Preparation of ethyl 4-(trifluoromethyl)oxazol-5-carboxylate (E10)
[0644] t-BuONO (1.84 g, 17.9 mmol, 2.12 mL, 2 eq) was added to a solution of ethyl 2-amino-4-(trifluoromethyl)oxazol-5-carboxylate (2.00 g, 8.92 mmol) in THF (60 mL). The reaction mixture was stirred at 55 °C for 24 h. EtOAc (120 mL) was added to the reaction mixture, and the organic fraction was washed with water (100 mL) and brine (100 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO2, PE / EtOAc = 1 / 0 to 8 / 1) to give E10 (1.2 g, 64% yield). 1 H NMR (400MHz, CDCl3) δ7.96 (s, 1H), 4.39 (q, 2H), 1.34 (t, 3H).
[0645] Step 2: Preparation of ethyl 2-(1-hydroxycyclobutyl)-4-(trifluoromethyl)oxazol-5-carboxylate (E11)
[0646] LiHMDS (1M, 8.61 mL, 1.5 eq) was added to a solution of ethyl 4-(trifluoromethyl)oxazol-5-carboxylate (1.2 g, 5.74 mmol) in THF (30 mL) at -78 °C, and the reaction mixture was stirred at -78 °C for 0.5 h. A solution of cyclobutanone (1.21 g, 17.2 mmol, 1.29 mL, 3 eq) in THF (5 mL) was added to the reaction mixture, and the mixture was stirred at -78 °C under a N2 atmosphere for 2 h. The reaction mixture was quenched by adding saturated NH4Cl solution (30 mL), and the aqueous fraction was extracted with EtOAc (100 mL). The organic layer was washed with water (70 mL) and brine (70 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO2, PE / EtOAc = 1 / 0 to 10 / 1) to give E11 (600 mg, 37% yield). 1 H NMR (400MHz, CDCl3) δ4.29 (q, 2H), 2.78-2.94 (m, 1H), 2.52-2.65 (m, 2H), 2.24-2.38 (m, 2H), 1.78-1.98 (m, 3H), 1.26 (t, 3H).
[0647] Step 3: Preparation of 2-(1-hydroxycyclobutyl)-4-(trifluoromethyl)oxazol-5-carboxylic acid (E12)
[0648] LiOH·H₂O (99.2 mg, 2.36 mmol, 1.1 eq) was added to a solution of ethyl 2-(1-hydroxycyclobutyl)-4-(trifluoromethyl)oxazol-5-carboxylate (600 mg, 2.15 mmol) in H₂O (2 mL) and THF (10 mL) at 0 °C. The reaction mixture was stirred at room temperature for 2 h and concentrated under vacuum to remove THF. Water (10 mL) was added, and the aqueous fraction was extracted with TBME (30 mL). The aqueous layer was then adjusted to pH ~6 by adding 0.5 M HCl and concentrated to dryness to give E12 (540 mg), which was used without further purification. 1 H NMR (400MHz, CD3OD) δ2.54-2.67(m, 2H), 2.19-2.34(m, 2H), 1.81-1.95(m, 1H), 1.66-1.80(m, 1H).
[0649] The intermediate ethyl 4-bromo-2-(2-hydroxypropyl-2-yl)oxazol-5-carboxylate, according to general scheme 6
[0650]
[0651] Step 1: Preparation of ethyl 4-bromooxazol-5-carboxylate (E14)
[0652] Ethyl oxazol-5-carboxylate (E13) (500 mg, 3.54 mmol) was added to THF (2.50 mL) and DMF (2.50 mL) at approximately 10 °C. The reaction mixture was cooled to -80 °C and LiHMDS (1 M, 4.61 mL, 1.30 eq) was added dropwise at approximately -80 °C. The reaction mixture was stirred at approximately -80 °C for 0.5 hr. Then Br2 (736 mg, 4.61 mmol, 1.3 eq) was added dropwise at approximately -80 °C. The reaction mixture was stirred at approximately -80 °C for 0.5 h. The reaction progress was monitored by LC-MS. The reaction mixture was combined with 19 other reactions using 500 mg E13. The combined reaction mixture was poured into saturated citric acid at approximately -10 °C. The aqueous fraction was extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO2, PE / EtOAc = 1 / 0 to 0 / 1) to give E14 (3.00 g, 19% yield). 1 H NMR (400MHz, DMSO-d6) δ8.70 (s, 1H), 4.29-4.34 (m, 2H), 1.29 (t, 3H); LC-MS: m / z219.9&221.9 (M+H) + .
[0653] Step 2: Preparation of ethyl 4-bromo-2-iodoxazole-5-carboxylate (E15)
[0654] Ethyl 4-bromooxazol-5-carboxylate (E14) (3.15 g, 14.3 mmol, 1.00 eq) was added to THF (15.0 mL) at room temperature. LiHMDS (1 M, 17.2 mL, 1.20 eq) was added dropwise at approximately -80 °C. Then, a solution of I2 (5.45 g, 21.5 mmol, 1.50 eq) in THF (15.0 mL) was added dropwise at approximately -80 °C. The reaction mixture was stirred at approximately -80 °C for 1 hour. The reaction progress was monitored using TLC (PE / EtOAc). The reaction mixture was poured into saturated citric acid (30 mL) at approximately -10 °C. The aqueous phase was extracted with ethyl acetate (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO2, PE / EtOAc = 1 / 0 to 0 / 1) to give E15 (1.10 g, 22% yield). 1H NMR (400MHz, DMSO-d6) δ: 4.29-4.35 (m, 2H), 1.30 (t, 3H). LC-MS: m / z 345.8&347.9(M+H) + .
[0655] Step 3: Preparation of ethyl 4-bromo-2-(2-hydroxypropyl-2-yl)oxazol-5-carboxylate (E16)
[0656] Ethyl 4-bromo-2-iodooxazol-5-carboxylate (E15) (1.10 g, 3.18 mmol) was added to THF (10 mL) at approximately 10 °C under N2. The reaction mixture was degassed under vacuum and washed three times with N2. The mixture was cooled to -80 °C, and iPr-MgCl·LiCl (1.3 M, 2.45 mL, 1 eq) was added dropwise at approximately -80 °C. The reaction mixture was stirred at approximately -80 °C for 0.5 h, followed by the addition of acetone (222 mg, 3.82 mmol, 1.20 eq) at approximately -80 °C. The mixture was stirred at approximately -80 °C for 0.5 h. The reaction progress was monitored by TLC (PE / EtOAc = 5 / 1). The reaction mixture was poured into a saturated citric acid solution (5 mL) at approximately -10 °C. The aqueous fraction was extracted with ethyl acetate (5 mL x 3). The combined organic layers were washed with brine (5 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO2, PE / EtOAc = 1 / 0 to 0 / 1) and further purified by prep-HPLC (column: Phenomenex luna C18 80x40mm x 3um; mobile phase: [water (0.04% HCl)-ACN]; B%: 18%-45%, 7 min) to give E16 (140 mg, 16% yield). 1 H NMR (400MHz, DMSO-d6) δ: 5.93 (s, 1H), 4.30–4.37 (m, 2H), 1.50 (s, 6H), 1.32 (t, 3H). LC-MS: m / z 277.9&279.9(M+H) + .
[0657] The intermediate ethyl 4-chloro-2-(2-hydroxypropyl-2-yl)oxazol-5-carboxylate, according to general scheme 6
[0658]
[0659] Step 1: Preparation of ethyl 4-chlorooxazol-5-carboxylate (E17)
[0660] Ethyl oxazolium-5-carboxylate (E13) (10.0 g, 70.9 mmol) was added to DMF (50 mL) at approximately 10 °C. The reaction mixture was cooled to -80 °C, and LiHMDS (1 M, 92.1 mL, 1.3 eq) was added dropwise at approximately -80 °C. The reaction mixture was stirred at approximately -80 °C for 0.5 h, and then a solution of NCS (12.3 g, 92.1 mmol, 1.3 eq) in THF (50 mL) was added dropwise at approximately -80 °C. The mixture was stirred at approximately -80 °C for 0.5 h. The reaction progress was monitored by TLC (PE / EtOAc = 5 / 1). The reaction mixture was combined with seven other reaction combinations for post-treatment, each using 10 g of E13. The combined reaction mixtures were poured into a saturated citric acid solution (100 mL) at approximately -10 °C. The aqueous fraction was extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO2, PE / EtOAc = 1 / 0 to 0 / 1) to give E17 (18.0 g, 18% yield). 1 H NMR (400MHz, CDCl3) δ7.94 (s, 1H), 4.44 (q, 2H), 1.42 (t, 3H); LC-MS: m / z 176.0 (M+H) + .
[0661] Step 2: Preparation of ethyl 4-chloro-2-iodoxazole-5-carboxylate (E18)
[0662] Three reactions were carried out in parallel. Ethyl 4-chlorooxazol-5-carboxylate (E17) (6.00 g, 34.2 mmol) was dissolved in THF (30 mL) at room temperature. LiHMDS (1 M, 41.0 mL, 1.2 eq) was added dropwise at approximately -80 °C, followed by the addition of I2 (13.0 g, 51.3 mmol, 1.5 eq) in THF (30 mL) at approximately -80 °C. The reaction mixture was stirred at approximately -80 °C for 1 hour. The reaction progress was monitored by TLC (PE / EtOAc = 5 / 1). The three parallel reactions were combined for post-treatment. The combined reaction mixture was poured into a saturated citric acid solution (100 mL) at approximately -5 °C. The aqueous fraction was extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO2, PE / EtOAc = 1 / 0 to 0 / 1) to give E18 (10.0 g, 32% yield). 1 H NMR (400MHz, DMSO-d6) δ4.20–4.27 (m, 2H), 1.21 (t, 3H); LC-MS: m / z 301.9 (M+H)+ .
[0663] Step 3: Preparation of ethyl 4-chloro-2-(2-hydroxypropyl-2-yl)oxazol-5-carboxylate (E19)
[0664] The two reactions were carried out in parallel. Compound E18 (5.00 g, 16.6 mmol) was added to THF (50 mL) at about 10 °C under N2. The suspension was degassed under vacuum and washed three times with N2. The mixture was cooled to -80 °C, and iPr-MgCl·LiCl (1.3 M, 12.8 mL, 1 eq) was added dropwise at about -80 °C. The mixture was stirred at about -80 °C for 0.5 h, and then acetone (1.16 g, 19.9 mmol, 1.2 eq) was added dropwise at about -80 °C. The mixture was stirred at about -80 °C for 0.5 h. The reaction progress was monitored by TLC (PE / EtOAc = 5 / 1). The two parallel reactions were combined for post-treatment. The combined reaction mixture was poured into a saturated citric acid solution (50 mL) at about -10 °C. The aqueous fraction was extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with brine (50 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE / EtOAc = 1 / 0 to 0 / 1) and further purified by prep-HPLC (column: Phenomenex luna C18 (250 x 70 mm, 15 μm); mobile phase: [water (0.05% HCl) - ACN]; B%: 20%–50%, 23 min) to give E19 (1.80 g, 23% yield). 1 H NMR (400MHz, DMSO-d6) δ: 5.92 (s, 1H), 4.32–4.37 (m, 2H), 1.51 (s, 6H), 1.31 (t, 3H); LC-MS: m / z234.0 (M+H) + .
[0665] Intermediate 4-(difluoromethyl)-2-(2-cyanopropyl-2-yl)oxazol-5-carboxylic acid
[0666]
[0667] Step 1: Preparation of 2-cyano-2-methyl-propionyl chloride (E20)
[0668] Oxaloyl chloride (2.69 g, 21.2 mmol, 1.86 mL, 1.2 eq) was added dropwise to a solution of 2-cyano-2-methyl-propionic acid (2 g, 17.7 mmol) and DMF (129 mg, 1.77 mmol, 136 μL, 0.1 eq) in DCM (20 mL) at 0 °C, and the reaction mixture was stirred at room temperature for 1 hr. The reaction mixture was concentrated to dryness to give E20 (2.5 g), which was used without further purification.
[0669] Step 2: Preparation of (Z)-3-[(2-cyano-2-methyl-propionyl)amino]-4,4-difluoro-but-2-enoic acid ethyl ester (E21)
[0670] A solution of 2-cyano-2-methylpropionyl chloride (E20) (2.39 g, 18.2 mmol, 1.5 eq) in dioxane (20 mL) was added to a solution of (Z)-3-amino-4,4-difluoro-but-2-enoic acid ethyl ester (2 g, 12.1 mmol) in dioxane (20 mL) at room temperature. The reaction mixture was stirred at 110 °C for 12 h. The reaction progress was monitored by TLC (PE / ethyl acetate = 5 / 1). The reaction mixture was concentrated to dryness, and the residue was purified by rapid silica gel chromatography. 40g Silica Flash column, eluent 0–7% EtOAc / PE gradient @ 40 mL / min, to obtain E21 (2.4 g, 76% yield). 1 H NMR (400MHz, DMSO-d6) δ 10.90 (s, 1H), 6.95-7.27 (m, 1H), 5.81 (s, 1H), 4.12-4.29 (m, 2H), 1.51-1.69 (m, 6H), 1.20 (t, 3H); LCMS: m / z 259.1[M+H] + .
[0671] Step 3: Preparation of ethyl 2-(1-cyano-1-methyl-ethyl)-4-(difluoromethyl)oxazol-5-carboxylate (E22)
[0672] BF3·Et2O (2.62 g, 18.4 mmol, 2.28 mL, 2 eq) and PIDA (4.16 g, 12.9 mmol, 1.4 eq) were added to a solution of (Z)-3-[(2-cyano-2-methyl-propionyl)amino]-4,4-difluoro-but-2-enoic acid ethyl ester (E21) (2.4 g, 9.22 mmol) in DCE (20 mL) at room temperature. The mixture was stirred at 90 °C for 18 hours. The reaction progress was monitored by TLC (PE / EtOAc). The reaction mixture was concentrated to dryness. DCM (100 mL) was added to the residue, and the organic layer was washed with saturated Na2CO3 solution (10 mL) and brine (50 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by rapid silica gel chromatography. 12g Silica Flash column, eluent 0–7% EtOAc / PE gradient @ 30 mL / min, to obtain E22 (0.25 g, 11% yield). 1 H NMR (400MHz, DMSO-d6) δ7.03-7.55 (m, 1H), 4.35 (q, 2H), 1.77 (s, 6H), 1.29 (t, 3H).
[0673] Step 4: Preparation of 2-(1-cyano-1-methyl-ethyl)-4-(difluoromethyl)oxazol-5-carboxylic acid (E23)
[0674] LiOH·H2O (48.8 mg, 1.16 mmol, 1.2 eq) was added to a solution of ethyl 2-(1-cyano-1-methyl-ethyl)-4-(difluoromethyl)oxazol-5-carboxylate (E22) (0.25 g, 968 μmol) in THF (3 mL) and H2O (1 mL). The mixture was stirred at room temperature for 18 h. The completion of the reaction was checked by TLC (PE:EtOAc = 5:1). The reaction mixture was concentrated under reduced pressure to remove THF. The aqueous fraction was adjusted to pH ~7 with 2 M HCl and then lyophilized under vacuum to give E23 (0.22 g, 99% yield). 1 H NMR (400MHz, DMSO-d6) δ7.23-7.74 (m, 1H), 1.73 (s, 6H).
[0675] Intermediate 4-(difluoromethyl)-2-(pyrimidin-2-yl)oxazol-5-carboxylic acid, according to general scheme 5, method B
[0676]
[0677] Step 1: Preparation of ethyl 4-(difluoromethyl)-2-pyrimidin-2-yl-oxazol-5-carboxylate (E24)
[0678] 2-Chloroprene (599 mg, 5.23 mmol) was added to a solution of ethyl 4-(difluoromethyl)oxazol-5-carboxylate (E4) (1 g, 5.23 mmol), Pd2(dba)3 (240 mg, 262 μmol, 0.05 eq), (5-diphenylphosphyl-9,9-dimethyl-xanthon-4-yl)-diphenylphosphine (151 mg, 262 μmol, 0.05 eq), and Cs2CO3 (3.41 g, 10.5 mmol, 2 eq) in 1,2-dimethoxyethane (3 mL) under a nitrogen atmosphere. The reaction mixture was stirred at 90 °C for 12 hours. DCM (50 mL) was added to the reaction mixture, and the organic fraction was washed with water (40 mL) and brine (40 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO2, PE / EtOAc = 1 / 0 to 1 / 1) to give E24 (400 mg, 25% yield). 1 HNMR (400MHz, CDCl3) δ9.02 (br d, 2H), 7.52 (t, 1H), 7.38 (s, 1H), 7.24 (s, 1H), 7.11 (s, 1H), 4.54 (q, 2H), 1.48 (t, 3H).
[0679] Step 2: Preparation of 4-(difluoromethyl)-2-pyrimidin-2-yl-oxazol-5-carboxylic acid (E25)
[0680] LiOH·H2O (77.2 mg, 1.84 mmol, 1.1 eq) was added to a solution of ethyl 4-(difluoromethyl)-2-pyrimidin-2-yl-oxazol-5-carboxylate (E24) (450 mg, 1.67 mmol) in THF (2 mL) and H2O (2 mL). The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated to remove THF and H2O (10 mL) was added. The aqueous layer was extracted with TBME (30 mL). The aqueous layer was then adjusted to pH ~6 with 0.5 M HCl and extracted three times with DCM / MeOH (30 / 3 mL). The combined DCM / MeOH organic layers were dried over Na2SO4, filtered, and concentrated to dryness to give E25 (350 mg), which was used without further purification. 1 H NMR (400MHz, DMSO-d6) δ9.06 (d, 2H), 7.75 (t, 1H), 7.20-7.57 (m, 1H).
[0681] Intermediate 2-(1-hydroxy-1-methyl-ethyl)-4-methyl-oxazol-5-carboxylic acid, according to general schemes 4 and 6, method A
[0682]
[0683] Step 1: Preparation of ethyl 2-amino-4-methyl-oxazol-5-carboxylate (E26)
[0684] A mixture of ethyl 2-chloro-3-oxo-butyrate (55 g, 334 mmol, 46.2 mL) and urea (100.34 g, 1.67 mol, 89.6 mL, 5 eq) in DMF (100 mL) was stirred at 120 °C for 12 h. The reaction progress was monitored by TLC (PE:EtOAc = 5:1). The reaction mixture was cooled to room temperature, poured into H2O (400 mL), and stirred at 0 °C for 30 min. The solid was collected by filtration, washed with water (30 mL), and then dried under vacuum to give E26 (22.2 g, 39% yield). 1 H NMR (400MHz, CD3OD) δ4.29 (q, 2H), 2.32 (s, 3H), 1.35 (t, 3H).
[0685] Step 2: Preparation of ethyl 2-bromo-4-methyl-oxazol-5-carboxylate (E27)
[0686] CuBr2 (21.85 g, 97.9 mmol, 4.58 mL, 1.5 eq) was added to a solution of E26 (11.1 g, 65.2 mmol) in MeCN (120 mL) at 0 °C. The mixture turned dark green and was further stirred at room temperature for 15 min. t-BuONO (10.09 g, 97.9 mmol, 11.6 mL, 1.5 eq) was added. The reaction was stirred at room temperature for 2 h, then heated at 50 °C for 4 h. The reaction progress was monitored using TLC (petroleum ether:EtOAc = 3:1). The reaction mixture was concentrated to dryness. The residue was purified by rapid silica gel chromatography. 120g Silica Flash column, eluent 0–5% EtOAc / PE gradient @ 100 mL / min, to obtain E27 (8.5 g, 56% yield). 1 H NMR (400MHz, CDCl3) δ4.25-4.35 (m, 2H), 2.45 (s, 3H), 1.32 (t, 3H).
[0687] Step 3: Preparation of ethyl 2-acetyl-4-methyloxazol-5-carboxylate (E28)
[0688] A mixture of E27 (9.5 g, 40.6 mmol), tributyl(1-ethoxyvinyl)stanane (17.59 g, 48.7 mmol, 16.4 mL, 1.2 eq), and Pd(PPh3)2Cl2 (2.85 g, 4.06 mmol, 0.1 eq) in toluene (200 mL) was stirred at 90 °C under a nitrogen atmosphere for 12 hours. The reaction progress was monitored by TLC (petroleum ether:EtOAc = 5:1). EtOAc (300 mL) was added, followed by saturated KF solution (500 mL). The resulting mixture was stirred at room temperature for 40 minutes, filtered, and the filtrate was separated. The organic layer was washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was dissolved in THF (300 mL), and 4N HCl (300 mL) was added. The mixture was stirred at room temperature for 12 hours. The desired substance was detected by LCMS. The reaction mixture was extracted with DCM (100 mL x 3). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by rapid silica gel chromatography. 24g Silica Flash column, eluent 0–10% EtOAc / PE gradient @ 35 mL / min, to obtain E28 (6.8 g, 85% yield). 1 H NMR (400MHz, CDCl3) δ4.35 (q, 2H), 2.62 (s, 3H), 2.48 (s, 3H), 1.34 (t, 3H); LCMS: m / z 198.1 (M+H) + .
[0689] Step 4: Preparation of ethyl 2-(2-hydroxypropyl-2-yl)-4-methyloxazol-5-carboxylate (E29)
[0690] MeMgBr (3M, 12.7mL, 3eq) was added dropwise to a solution of E28 (2.5g, 12.7mmol) in THF (25mL) at -78°C under N2. The reaction was stirred at -78°C for 1.5hr. The reaction progress was monitored by TLC (petroleum ether:EtOAc = 5:1, via UV). The reaction was slowly quenched by the addition of saturated NH4Cl solution (30mL), and the organic fraction was then extracted with EtOAc (30mL x 3). The combined organic phases were washed with brine (30mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO2, petroleum ether / EtOAc = 1 / 0 to 1 / 1) to give E29 (1.7g, 63% yield). 1H NMR (400MHz, CDCl3) δ4.39 (q, 2H), 2.47 (s, 3H), 1.67 (s, 6H), 1.40 (t, 3H).
[0691] Alternatively, E29 can be prepared by reacting 2-hydroxy-2-methylpropionamide with ethyl 2-chloro-3-oxo-butyrate at 150°C for 6 hours in a net reaction.
[0692] Step 5: Preparation of ethyl 2-(2-hydroxypropyl-2-yl)-4-methyloxazol-5-carboxylate (E30)
[0693] LiOH·H2O (803 mg, 19.1 mmol, 1.2 eq) was added to a solution of E29 (3.4 g, 16.0 mmol) in THF (30 mL) and H2O (15 mL). The reaction mixture was stirred at room temperature for 1.5 hr. The reaction progress was tracked using LCMS. The reaction mixture was adjusted to pH 7 with HCl (1 M) and concentrated to dryness to give E30 (4 g), which was used without further purification. 1 H NMR (400MHz, DMSO-d6) δ5.67 (s, 1H), 2.30 (s, 2H), 1.44 (s, 6H); LCMS: m / z 186.1 (M+H) + .
[0694] Intermediate 4-cyclopropyl-2-(2-hydroxypropyl-2-yl)oxazol-5-carboxylic acid, according to general scheme 4
[0695]
[0696] Step 1: Preparation of ethyl 2-bromo-3-cyclopropyl-3-oxo-propionate (E31)
[0697] NBS (9.12 g, 51.2 mmol) and TsOH·H₂O (1.95 g, 10.2 mmol, 0.2 eq) were added to a solution of ethyl 3-cyclopropyl-3-oxo-propionate (8 g, 51.2 mmol) in DCM (100 mL). The reaction mixture was stirred at room temperature for 2 h. The reaction progress was tracked using TLC (PE:EtOAc = 10:1). The reaction mixture was concentrated to dryness. EtOAc (120 mL) was added to the residue, and the mixture was filtered. The filtrate was washed with saturated NaHCO₃ solution (2 × 100 mL) and water (100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE / EtOAc = 1:0 to 10:1) to give E31 (12 g, 100% yield). 1H NMR (400MHz, DMSO-d6) δ5.71 (s, 1H), 4.18 (q, 2H), 2.14-2.28 (m, 1H), 1.18 (t, 3H), 1.01-1.08 (m, 2H), 0.89-0.96 (m, 2H); LCMS: m / z 235.0[M+H] + .
[0698] Step 2: Preparation of ethyl 4-cyclopropyl-2-(1-hydroxy-1-methyl-ethyl)oxazol-5-carboxylate (E32)
[0699] 2-hydroxy-2-methylpropionamide (2.19 g, 21.3 mmol, 5 eq) was added to a solution of ethyl 2-bromo-3-cyclopropyl-3-oxopropionate (E31) (1 g, 4.25 mmol) in DMF (2 mL). The mixture was stirred at 110 °C for 40 h. The reaction progress was monitored using LC-MS. The reaction mixture was adjusted to pH ~8 at 0 °C by adding saturated aqueous NaHCO3 solution. H2O (50 mL) was added, and the aqueous fraction was extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO2, PE / EtOAc = 1:0 to 2:1) to give E32 (0.15 g, 14% yield). 1 HNMR (400MHz, DMSO-d6) δ5.70 (s, 1H), 4.29 (q, 2H), 2.40-2.45 (m, 1H), 1.43 (s, 6H), 1.27 (t, 3H), 0.94-1.04 (m, 2H), 0.79-0.92 (m, 2H); LCMS: m / z 240.0[M+H] + .
[0700] Step 3: Preparation of 4-cyclopropyl-2-(1-hydroxy-1-methyl-ethyl)oxazol-5-carboxylic acid (E33)
[0701] LiOH·H₂O (114 mg, 2.71 mmol, 1.1 eq) was added to a solution of ethyl 4-cyclopropyl-2-(1-hydroxy-1-methyl-ethyl)oxazol-5-carboxylate (E32) (590 mg, 2.47 mmol) in THF (4 mL) and H₂O (4 mL). The reaction mixture was stirred at room temperature for 16 h. The reaction progress was monitored using LC-MS. The reaction mixture was concentrated to remove THF. The aqueous fraction was adjusted to pH ~7 by adding HCl (1 M) and then lyophilized to give E33 (550 mg, 90% yield). 1H NMR (400MHz, DMSO-d6) δ2.70-2.84 (m, 1H), 1.39 (s, 6H), 0.62-0.81 (m, 4H); LCMS: m / z 212.0[M+H] + .
[0702] Intermediate 4-cyanoxazol-5-carboxylic acid
[0703]
[0704] Step 1: Preparation of ethyl 4-cyanoxazole-5-carboxylate (E34)
[0705] Zn(CN)₂ (3.74 g, 31.8 mmol, 2.02 mL, 0.7 eq) and t-BuXPhos-Pd-G₃ (1.81 g, 2.27 mmol, 0.05 eq) were added to a solution of ethyl 4-bromooxazol-5-carboxylate (E14) (10 g, 45.5 mmol) in THF (30 mL) and H₂O (150 mL). The reaction mixture was degassed under vacuum and washed three times with N₂, then stirred at 40 °C under N₂ for 16 h. The reaction progress was tracked using TLC (PE:EtOAc = 5:1). EtOAc (300 mL) was added to the reaction mixture, and the organic layer was washed with H₂O (50 mL) and brine (50 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO2, PE / EtOAc = 100 / 1 to 10 / 1) to give E34 (7.5 g, 99% yield). 1 H NMR (400MHz, DMSO-d6) δ 8.89 (s, 1H), 4.37 (q, 2H), 1.30 (t, 3H).
[0706] Step 2: Preparation of (4-cyanoxazol-5-carbonyl)oxylithium (E35)
[0707] LiOH·H2O (1.33 g, 31.6 mmol, 1.05 eq) was added to a solution of E34 (5 g, 30.1 mmol) in THF (40 mL) and H2O (80 mL). The mixture was stirred at room temperature for 2 hours. The reaction progress was tracked using TLC (PE:EtOAc = 5:1). The reaction mixture was concentrated under vacuum to remove most of the THF, and then lyophilized under vacuum to give E35 (4.5 g), which was used without further purification. 1 H NMR (400MHz, DMSO-d6) δ 8.47 (s, 1H).
[0708] The intermediate [5-[1-(2,2,2-trifluoroethyl)pyrazol-4-yl]-1,3,4-oxadiazole-2-carbonyl]oxylithium, according to general scheme 9
[0709]
[0710] Step 1: Preparation of ethyl 5-methylthio-1,3,4-oxadiazole-2-carboxylate (E36)
[0711] A mixture of 16 g (121 mmol) of 2-hydrazino-2-oxo-ethyl acetate and 25.90 g (145 mmol, 1.2 eq) of di(1H-imidazol-1-yl)methylthione in 300 mL of THF was stirred at room temperature for 12 h, then heated to 75 °C and held for 4 h. After cooling to room temperature, 50.21 g (363 mmol, 3 eq) of K₂CO₃ and 85.95 g (606 mmol, 37.7 mL, 5 eq) of CH₃I were added. The resulting mixture was stirred at room temperature for 2 h. The reaction progress was monitored using TLC (PE:EtOAc = 1:1). The reaction mixture was combined with another reaction using 8.5 g of 2-hydrazino-2-oxo-ethyl acetate and quenched by the addition of 100 mL of H₂O. DCM (500 mL) was added, and the organic layer was separated and washed with brine (2 x 100 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by rapid silica gel chromatography (eluent: 0–25% PE:EtOAc@40 mL / min) to give E36 (25 g). 1 HNMR (400MHz, CDCl3) δ4.43 (q, 2H), 2.72 (s, 3H), 1.38 (t, 3H).
[0712] Step 2: Preparation of ethyl 5-[1-(2,2,2-trifluoroethyl)pyrazol-4-yl]-1,3,4-oxadiazole-2-carboxylate (E37)
[0713] A mixture of E36 (233 mg, 1.24 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1-(2,2,2-trifluoroethyl)pyrazole (410 mg, 1.49 mmol, 1.2 eq), Na2CO3 (394 mg, 3.71 mmol, 3 eq), thiophene-2-carbonyloxycopper (472 mg, 2.48 mmol, 2 eq), and Pd(dppf)Cl2 (181 mg, 248 μmol, 0.2 eq) in dioxane (9 mL) was degassed and purged three times with N2. The reaction mixture was then stirred at 75 °C under N2 for 16 h. The reaction progress was tracked using TLC (PE:EtOAc = 2:1). EtOAc (100 mL) was added to the reaction mixture, and the organic layer was washed with water (30 mL) and brine (30 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO2, PE / EtOAc = 1 / 0 to 2 / 1) to give E37 (140 mg, 39% yield). 1 H NMR (400MHz, CD3OD) δ8.61 (s, 1H), 8.22 (s, 1H), 5.12 (q, 2H), 4.51 (q, 2H), 1.44 (t, 3H); LCMS: m / z 291.1 (M+H) + .
[0714] Step 3: Preparation of [5-[1-(2,2,2-trifluoroethyl)pyrazol-4-yl]-1,3,4-oxadiazole-2-carbonyl]oxylithium (E38)
[0715] A solution of LiOH·H₂O (22.3 mg, 531 μmol, 1.1 eq) in H₂O (3 mL) was added to a solution of E37 (140 mg, 482 μmol) in THF (1.5 mL). The reaction mixture was stirred at room temperature for 2 hours. The reaction progress was tracked using TLC (DCM:MeOH). The reaction mixture was concentrated under vacuum to remove most of the THF, and then lyophilized under vacuum to obtain E38 (115 mg), which was used without further purification. 1 H NMR (400MHz, DMSO-d6) δ 8.58 (s, 1H), 8.14 (s, 1H), 5.27 (q, 2H).
[0716] Alternatively, ethyl 5-[1-(2,2,2-trifluoroethyl)pyrazol-4-yl]-1,3,4-oxadiazole-2-carboxylate (E37) can be prepared according to the following scheme.
[0717]
[0718] Step A: Preparation of ethyl 1-(2,2,2-trifluoroethyl)pyrazole-4-carboxylate (E39)
[0719] 2,2,2-trifluoroethyl trifluoromethanesulfonic acid (21.53 g, 92.8 mmol, 1.3 eq) was added dropwise to a solution of ethyl 1H-pyrazole-4-carboxylate (10 g, 71.4 mmol) and K₂CO₃ (19.72 g, 142 mmol, 2 eq) in DMF (45 mL), and the resulting mixture was stirred at 50 °C for 6 h. The reaction progress was monitored using TLC (PE:EtOAc = 1:1). EtOAc (300 mL) was added to the reaction mixture, and the organic layer was washed with H₂O (100 mL) and brine (2 x 100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by rapid silica gel chromatography. 40g Silica Flash column, elution buffer 0-12% PE / EtOAc@60mL / min) to obtain E39 (16g). 1 HNMR (400MHz, CDCl3) δ 8.01 (d, 2H), 4.73 (q, 2H), 4.32 (q, 2H), 1.36 (t, 3H).
[0720] Step B: Preparation of 1-(2,2,2-trifluoroethyl)pyrazole-4-carbazide (E40)
[0721] NH₂NH₂·H₂O (7.73 g, 151 mmol, 7.5 mL, 98% purity, 2.1 eq) was added to a solution of E39 (16 g, 72.0 mmol) in THF (100 mL), and the reaction mixture was stirred at 80 °C for 15 h. The reaction progress was monitored using TLC (PE:EtOAc = 1:1). The reaction mixture was concentrated to dryness. The residue was ground with TBME (50 mL) and stirred for 15 min. The precipitate was collected by filtration and then dried under vacuum to give E40 (13 g). 1 H NMR (400MHz, CD3OD) δ 8.19 (s, 1H), 7.93 (s, 1H), 4.98 (q, 2H).
[0722] Step C: Preparation of N-[[1-(2,2,2-trifluoroethyl)pyrazole-4-carbonyl]amino]carbamate (E41)
[0723] 2-Chloro-2-oxo-ethyl acetate (2.36 g, 17.3 mmol, 1.9 mL, 1.2 eq) was added dropwise to a solution of E40 (3 g, 14.4 mmol) in THF (70 mL) at 0 °C, and the reaction mixture was stirred at room temperature for 3 h. The precipitate was collected by filtration and washed with TBME (30 mL), and then dried under vacuum to give E41 (1.5 g, 37% yield). 1 H NMR (400MHz, CDCl3) δ9.75 (br s, 1H), 9.06 (br s, 1H), 8.25 (s, 1H), 7.99 (s, 1H), 4.76 (q, 2H), 4.42 (q, 2H), 1.42 (t, 3H).
[0724] Step D: Preparation of ethyl 5-[1-(2,2,2-trifluoroethyl)pyrazol-4-yl]-1,3,4-oxadiazole-2-carboxylate (E37)
[0725] TsCl (491 mg, 6.96 mmol, 1.3 eq) was added fractionally to a solution of E41 (1.5 g, 5.35 mmol) and Et3N (271 mg, 2.68 mmol, 373 μL, 0.5 eq) in DCM (30 mL) at 0 °C, and the resulting mixture was stirred at room temperature for 18 h. The reaction progress was monitored using TLC (PE:EtOAc = 1:1). DCM (100 mL) was added to the reaction mixture, and the organic layer was washed with saturated Na2CO3 solution (60 mL) and brine (60 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by rapid silica gel chromatography. 40g Silica Flash column, eluent 0–16% PE / EtOAc @ 40 mL / min, to obtain E37 (0.65 g, 42% yield). 1 H NMR (400MHz, CDCl3) δ8.16-8.29 (m, 2H), 4.80 (q, 2H), 4.53 (q, 2H), 1.47 (t, 3H).
[0726] Intermediate 5-morpholino-1,3,4-oxadiazole-2-carboxylate, according to general scheme 10
[0727]
[0728] Step 1: Preparation of ethyl 5-bromo-1,3,4-oxadiazole-2-carboxylate (E42)
[0729] CuBr2 (10.66 g, 47.7 mmol, 2.2 mL, 1.5 eq) was added to a solution of ethyl 5-amino-1,3,4-oxadiazole-2-carboxylate (5 g, 31.8 mmol) in MeCN (60 mL) at 0 °C. The reaction mixture turned dark green and was stirred for 15 min at room temperature. t-BuONO (4.92 g, 47.7 mmol, 5.7 mL, 1.5 eq) was added at 0 °C, and the reaction mixture was stirred at room temperature for 2 h, then heated at 50 °C for 12 h. The reaction progress was monitored by TLC (PE / EtOAc = 1 / 1). The reaction mixture was filtered and concentrated to dryness. The residue was purified by rapid silica gel chromatography. 40g Silica Flash column, eluent 0–50% EtOAc / PE gradient @ 40 mL / min, to obtain E42 (4.5 g, 64% yield). 1 H NMR (400MHz, CDCl3) δ4.52 (q, 2H), 1.45 (t, 3H).
[0730] Step 2: Preparation of ethyl 5-morpholino-1,3,4-oxadiazole-2-carboxylate (E43)
[0731] DIPEA (1.17 g, 9.05 mmol, 1.6 mL, 2 eq) was added to a solution of ethyl 5-bromo-1,3,4-oxadiazol-2-carboxylate (E42) (1 g, 4.52 mmol) and morpholine (473 mg, 5.43 mmol, 478 μL, 1.2 eq) in THF (40 mL) at 0 °C. The mixture was stirred at room temperature for 1 hour. The reaction progress was monitored by TLC (PE / EtOAc = 1 / 1). EtOAc (100 mL) was added to the reaction mixture, and the organic fraction was washed with water (30 mL) and brine (30 mL x 2), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by rapid silica gel chromatography. 12g SilicaFlash column, eluent 0–30% EtOAc / PE gradient @ 35 mL / min, to obtain E43 (800 mg, 78% yield). 1 HNMR (400MHz, DMSO-d6) δ4.37 (q, 2H), 3.68-3.74 (m, 4H), 3.48-3.52 (m, 4H), 1.31 (t, 3H).
[0732] Step 3: Preparation of (5-morpholino-1,3,4-oxadiazole-2-carbonyl)oxylithium (E44)
[0733] LiOH·H₂O (162 mg, 3.87 mmol, 1.1 eq) was added to a solution of ethyl 5-morpholino-1,3,4-oxadiazol-2-carboxylate (E43) (800 mg, 3.52 mmol) in THF (8 mL) and H₂O (12 mL). The reaction mixture was stirred at room temperature for 12 hours. The reaction progress was monitored by TLC (PE / EtOAc = 1 / 1). The reaction mixture was concentrated to dryness to give E44 (600 mg), which was used without further purification. 1 H NMR (400MHz, DMSO-d6) δ3.62-3.74 (m, 4H), 3.36 (br d, 4H).
[0734] Intermediate [5-(5-fluoro-2-pyridyl)-1,3,4-oxadiazole-2-carbonyl]oxylithium, according to General Scheme 9, Method A
[0735]
[0736] Step 1: Preparation of methyl 5-fluoropyridine-2-carboxylate (E45)
[0737] A solution of 5-fluoropyridine-2-carboxynitrile (15 g, 123 mmol) in HCl / MeOH (4 M, 180 mL, 5.9 eq) was stirred at 60 °C for 12 hours. The reaction mixture was concentrated under vacuum, and the residue was dissolved in EtOAc (150 mL) and washed with saturated NaHCO3 solution (50 mL) and brine (20 mL). The organic layer was dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by rapid silica gel chromatography. 80g Silica Flash column, eluent 0–25% EtOAc / PE gradient @ 60 mL / min, to obtain E45 (15.24 g, 80% yield). 1 H NMR (400MHz, CDCl3) δ 8.58 (d, 1H), 8.20 (dd, 1H), 7.53 (ddd, 1H), 4.00 (s, 3H).
[0738] Step 2: Preparation of 5-fluoropyridine-2-carbonylhydrazide (E46)
[0739] A mixture of methyl 5-fluoropyridine-2-carboxylate (E45) (16 g, 103 mmol) and NH2NH2.H2O (11.06 g, 217 mmol, 10.7 mL, 98% purity, 2.1 eq) in EtOH (70 mL) was degassed and purged three times with N2. The reaction mixture was then stirred at room temperature under N2 atmosphere for 3 hours. The reaction mixture was concentrated to dryness to give E46 (15 g, 94% yield).1 H NMR (400MHz, DMSO-d6) δ9.89 (br s, 1H), 8.61 (d, 1H), 8.07 (dd, 1H), 7.88 (td, 1H), 4.57 (br s, 2H).
[0740] Step 3: Preparation of ethyl 2-[2-(5-fluoropyridine-2-carbonyl)hydrazino]-2-oxo-ethyl acetate (E47)
[0741] 2-Chloro-2-oxo-ethyl acetate (15.45 g, 113 mmol, 12.7 mL, 1.3 eq) was added over 10 minutes to a mixture of 5-fluoropyridine-2-carbonylhydrazine (E46) (13.5 g, 87.0 mmol) and TEA (17.61 g, 174 mmol, 24.2 mL, 2 eq) in DCM (500 mL). The reaction mixture was stirred at room temperature for 2 hours. H2O (100 mL) was added to the reaction mixture, and the aqueous fraction was extracted with DCM (300 mL x 3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by rapid silica gel chromatography. 80g SilicaFlash column, eluent 0–2.5% EtOAc / PE gradient @ 60 mL / min, to obtain E47 (16 g, 53% yield). 1 H NMR (400MHz, CDCl3) δ10.03-10.15 (m, 1H), 9.65 (br d, 1H), 8.35-8.42 (m, 1H), 8.11-8.18 (m, 1H), 7.51 (td, 2H), 4.35 (q, 1H), 1.34 (t, 3H); LCMS: m / z 256.2[M+H] + .
[0742] Step 4: Preparation of ethyl 5-(5-fluoro-2-pyridyl)-1,3,4-oxadiazole-2-carboxylate (E48)
[0743] TEA (8.25 g, 81.5 mmol, 11.3 mL, 1.3 eq) and TosCl (5.98 g, 31.4 mmol, 0.5 eq) were added in three fractions to a solution of 2-[2-(5-fluoropyridin-2-carbonyl)hydrazino]-2-oxo-ethyl acetate (E47) (16 g, 62.7 mmol) in DCM (350 mL). The mixture was stirred at room temperature for 3 hours. A saturated NaHCO3 solution (200 mL) was added, and the aqueous fraction was extracted with DCM (400 mL x 3). The combined organic layers were washed with brine (200 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by rapid silica gel chromatography. 120g Silica Flash column (eluent: 0–2.5% MeOH / DCM @ 85 mL / min) was used to obtain E48 (8.2 g, 49% yield). 1 H NMR (400MHz, CDCl3) δ8.71 (d, 1H), 8.39 (dd, 1H), 7.66 (ddd, 1H), 4.59 (q, 2H), 1.51 (t, 3H); LCMS: m / z238.2[M+H] + .
[0744] Step 5: Preparation of [5-(5-fluoro-2-pyridyl)-1,3,4-oxadiazole-2-carbonyl]oxylithium (E49)
[0745] LiOH·H2O (2.23 g, 53.1 mmol, 1.05 eq) was added to a solution of ethyl 5-(5-fluoro-2-pyridyl)-1,3,4-oxadiazole-2-carboxylate (E48) (12 g, 50.6 mmol) in THF (140 mL) and H2O (180 mL). The mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under vacuum to remove most of the THF, and the aqueous fraction was lyophilized under vacuum to give E49 (11.5 g), which was used without further purification. 1 H NMR (400MHz, DMSO-d6) δ 8.79 (d, 1H), 8.24 (dd, 1H), 7.99 (td, 1H).
[0746] Intermediate 5-(difluoromethyl)-1-(2,2,2-trifluoroethyl)pyrazole-4-carboxylic acid
[0747]
[0748] Step 1: Preparation of ethyl 5-(difluoromethyl)-1-(2,2,2-trifluoroethyl)pyrazole-4-carboxylate (E50)
[0749] 2,2,2-trifluoroethylhydrazine (670 mg, 5.88 mmol, 1.3 eq) was added dropwise to a solution of ethyl (Z)-2-(ethoxymethylene)-4,4-difluoro-3-oxobutyrate (1 g, 4.52 mmol) in THF (8 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h, and then stirred at room temperature for 16 h. The reaction progress was monitored using LC-MS. The reaction mixture was concentrated to dryness, and the residue was purified by rapid silica gel chromatography (elution: 0–5% EtOAc / PE gradient) to give E50 (850 mg, 69% yield). 1 H NMR (400MHz, CDCl3) δ8.02 (s, 1H), 7.38-7.75 (m, 1H), 4.95 (q, 2H), 4.37 (q, 2H), 1.40 (t, 3H); LCMS: m / z 273.1[M+H] + .
[0750] Step 2: Preparation of 5-(difluoromethyl)-1-(2,2,2-trifluoroethyl)pyrazole-4-carboxylic acid (E51)
[0751] LiOH·H2O (224 mg, 5.35 mmol, 1.6 eq) was added to a solution of ethyl 5-(difluoromethyl)-1-(2,2,2-trifluoroethyl)pyrazole-4-carboxylate (E50) (910 mg, 3.34 mmol) in THF (5 mL) and H2O (5 mL). The mixture was stirred at room temperature for 2 hours. The reaction progress was monitored by TLC (PE:EtOAc = 2:1). The reaction mixture was concentrated to remove THF. The aqueous fraction was adjusted to pH ~6 by adding HCl (1 M). The resulting precipitate was collected by filtration and then dried under vacuum to give E51 (816 mg, 100% yield). 1 H NMR (400MHz, DMSO-d6) δ 8.08 (s, 1H), 7.45-7.78 (m, 1H), 5.30 (q, 2H).
[0752] intermediate ethyl 2-(2-pyridyl)pyrazole-3-carboxylate
[0753]
[0754] Step 1: Preparation of (E)-4-(dimethylamino)-2-oxo-but-3-enoic acid ethyl ester (E52)
[0755] Ethyl 2-oxopropionate (2 g, 17.2 mmol, 1.9 mL) and 1,1-dimethoxy-N,N-dimethyl-methylamine (2.09 g, 17.6 mmol, 2.3 mL, 1.02 eq) were stirred at room temperature for 12 hours. The reaction progress was monitored by TLC (PE:EtOAc = 10:1). The reaction mixture was concentrated to dryness to give E52 (2.4 g), which was used without further purification.
[0756] Step 2: Preparation of ethyl 2-(2-pyridyl)pyrazole-3-carboxylate (E53)
[0757] A mixture of (E)-4-(dimethylamino)-2-oxo-but-3-enoic acid ethyl ester (E52) (2.4 g, 14.0 mmol) and 2-pyridylhydrazine (1.53 g, 14.0 mmol) in HOAc (100 mL) was stirred at 110 °C for 12 h. The reaction progress was monitored by TLC (PE:EtOAc = 10:1). The reaction mixture was adjusted to pH ~9 by adding saturated Na2CO3 solution. The aqueous fraction was extracted with EtOAc (300 mL). The organic layer was dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO2, PE / EtOAc = 100 / 1 to 50 / 1) to give E53 (1.03 g, 34% yield). 1 H NMR (400MHz, DMSO-d6) δ8.48 (dt, 1H), 8.05 (td, 1H), 7.83-7.96 (m, 1H), 7.76 (d, 1H), 7.49(ddd, 1H), 6.96-7.05(m, 1H), 4.21(q, 2H), 1.05-1.23(m, 3H); LCMS: m / z 218.1[M+H] + .
[0758] Also obtained was ethyl 1-(2-pyridyl)pyrazole-3-carboxylate (E53a) (190 mg, 6% yield). 1 ¹H NMR (400 MHz, DMSO-d⁶) δ 8.70–8.81 (m, ¹H), 8.54 (dd, ¹H), 7.92–8.13 (m, 2H), 7.47 (ddd, ¹H), 7.02 (d, ¹H), 4.35 (q, 2H), 1.34 (t, 3H). Regional chemistry of E53 and E53a was confirmed by HSQC and HMBC NMR analysis.
[0759] Step 3: Preparation of 2-(2-pyridyl)pyrazole-3-carboxylic acid (E54)
[0760] LiOH·H2O (386 mg, 9.21 mmol, 2 eq) was added to a solution of ethyl 2-(2-pyridyl)pyrazole-3-carboxylate (E53) (1 g, 4.60 mmol) in THF (10 mL) and H2O (10 mL), and the reaction mixture was stirred at room temperature for 12 h. The reaction progress was monitored by TLC (PE / EtOAc = 1 / 1). The reaction mixture was concentrated under reduced pressure to remove THF. The aqueous fraction was adjusted to pH ~7 by adding 2 M HCl and lyophilized under vacuum to give (E54) (1.2 g), which was used without further purification. 1 HNMR (400MHz, DMSO-d6) δ 8.36-8.44 (m, 1H), 7.88 (td, 1H), 7.44-7.53 (m, 2H), 7.35 (ddd, 1H), 6.44 (d, 1H).
[0761] Intermediate [5-(difluoromethyl)-2-methyl-1,2,4-triazol-3-carbonyl]oxylithium
[0762]
[0763] Step 1: Preparation of (Z)-2-(1-amino-2-ethoxy-2-oxoethylidene)hydrazine-1-carboxylic acid tert-butyl ester (E55)
[0764] (Z)-2-(1-amino-2-ethoxy-2-oxoethylene)hydrazine-1-carboxylic acid tert-butyl ester was prepared from ethyl 2-amino-2-thioethylcarboxylate according to the steps described in Bioorg. Med. Chem., 26(2016) 3223-3225. The reaction was heated to reflux.
[0765] Step 2: Preparation of ethyl 3-(difluoromethyl)-1H-1,2,4-triazole-5-carboxylate (E56)
[0766] The reagent 2,2-difluoroacetyl chloride was prepared by adding dropwise at 0 °C to a solution of 2,2-difluoroacetic acid (13 g, 135 mmol, 8.5 mL) and DMF (989 mg, 13.5 mmol, 1.0 mL, 0.1 eq) in DCM (80 mL). The reaction mixture was stirred at room temperature for 1 hour, and the solution was used without further purification.
[0767] To a solution of (Z)-2-(1-amino-2-ethoxy-2-oxoethylidene)hydrazine-1-carboxylic acid tert-butyl ester (E55) (13 g, 56.2 mmol) in pyridine (90 mL), 2,2-difluoroacetyl chloride (15.47 g, 135 mmol, 2.4 eq) was added. The reaction mixture was heated to 120 °C and stirred for 12 h. The reaction progress was monitored using LC-MS. The reaction mixture was concentrated to dryness. DCM (200 mL) was added to the residue, and the organic fraction was washed with 1 M HCl (30 mL) and brine (60 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography (PE:EtOAc = 20:1 to 2:1) to give E56 (8.87 g, 83% yield). 1 H NMR (400MHz, DMSO-d6) δ7.01-7.32 (m, 1H), 4.36 (q, 2H), 1.30 (t, 3H); LCMS: m / z 192.0[M+H] + .
[0768] Step 3: Preparation of ethyl 5-(difluoromethyl)-2-methyl-1,2,4-triazole-3-carboxylate (E57)
[0769] MeI (22.28 g, 157 mmol, 9.8 mL, 3 eq) and K₂CO₃ (21.69 g, 157 mmol, 3 eq) were added to a solution of ethyl 3-(difluoromethyl)-1H-1,2,4-triazol-5-carboxylate (E56) (10 g, 52.3 mmol) in DMF (80 mL). The mixture was stirred at room temperature for 12 h. The reaction progress was monitored by TLC (PE:EtOAc = 1:1). The reaction mixture was filtered, and the precipitate was washed with EtOAc (150 mL). The filtrate was washed with water (30 mL) and brine (30 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography (PE:EtOAc = 20:1 to 1:1) to give E57 (4.46 g, 42% yield). 1 H NMR (400MHz, DMSO-d6) δ 6.99-7.34 (m, 1H), 4.39 (q, 2H), 4.11-4.22 (m, 3H), 1.35 (t, 3H).
[0770] Step 4: Preparation of [5-(difluoromethyl)-2-methyl-1,2,4-triazol-3-carbonyl]oxylithium (E58)
[0771] LiOH·H2O (505 mg, 12.0 mmol, 1.05 eq) was added to a solution of ethyl 5-(difluoromethyl)-2-methyl-1,2,4-triazol-3-carboxylate (E57) (2.35 g, 11.5 mmol) in THF (40 mL) and H2O (10 mL). The reaction mixture was stirred at room temperature for 1 hour. The reaction progress was monitored by TLC (PE:EtOAc = 2:1). The reaction mixture was concentrated under vacuum to remove THF. H2O (20 mL) was added, and the aqueous fraction was extracted with TBME (20 mL) and then lyophilized under vacuum to give E58 (2.15 g), which was used without further purification. 1 H NMR (400MHz, DMSO-d6) δ6.75-7.21 (m, 1H), 4.09 (s, 3H).
[0772] Intermediate ethyl 3-(1-hydroxy-1-methyl-ethyl)-1,2,4-oxadiazole-5-carboxylate
[0773]
[0774] Step 1: Preparation of N',2-dihydroxy-2-methylpropanediamine (E59)
[0775] Hydroxyamino hydrochloride (3.49 g, 50.3 mmol, 2 eq) and Na₂CO₃ (5.33 g, 50.3 mmol, 2 eq) were added to a solution of 2-hydroxy-2-methylpropionitrile (2.14 g, 25.2 mmol, 2.3 mL) in EtOH (20 mL), and the reaction was stirred at 70 °C for 16 h. The reaction mixture was concentrated to dryness. EtOAc (200 mL) was added to the residue, and the organic fraction was washed twice with water (50 mL) and brine (50 mL), dried over Na₂SO₄, filtered, and concentrated to dryness to give E59 (1 g), which was used without further purification. 1 H NMR (400MHz, DMSO-d6) δ 10.11 (s, 1H), 8.86 (s, 1H), 5.03 (br s, 1H), 1.70 (s, 3H), 1.66 (s, 3H).
[0776] Step 2: Preparation of ethyl 3-(1-hydroxy-1-methyl-ethyl)-1,2,4-oxadiazole-5-carboxylate (E60)
[0777] A solution of N',2-dihydroxy-2-methylpropanediidine (E59) (520 mg, 4.40 mmol) and pyridine (696 mg, 8.80 mmol, 711 μL, 2 eq) in toluene (15 mL) was added at 0 °C to ethyl 2-chloro-2-oxo-ethyl (601 mg, 4.40 mmol, 493 μL). The reaction mixture was stirred at room temperature for 1 h, then at 100 °C for 15 h. The reaction progress was monitored using LC-MS. The reaction mixture was concentrated to dryness. The residue was purified by column chromatography (SiO2, PE / EtOAc = 1 / 0 to 2 / 1) and further purified by prep-HPLC (column: Boston Uni C18 40*150*5 μm; mobile phase: [water (0.225% FA)-ACN]; B%: 16%-46%, 7.7 min) to give E60 (250 mg, 28% yield). 1 H NMR (400MHz, CDCl3) δ4.52 (q, 2H), 2.65 (br s, 1H), 1.67 (s, 6H), 1.45 (t, 3H); LCMS: m / z 201.1[M+H] + .
[0778] Step 3: Preparation of ethyl 3-(1-hydroxy-1-methyl-ethyl)-1,2,4-oxadiazole-5-carboxylate (E61)
[0779] LiOH·H2O (41.9 mg, 999 μmol) was added to a solution of ethyl 3-(1-hydroxy-1-methyl-ethyl)-1,2,4-oxadiazole-5-carboxylate (E60) (200 mg, 999 μmol) in THF (5 mL) and H2O (5 mL), and the reaction mixture was stirred at room temperature for 1 hour. The solvent was removed under vacuum, and the aqueous fraction was lyophilized under vacuum to give E61 (170 mg), which was used without further purification.
[0780] Intermediates E62, E63, E64, E65, E66 and E67
[0781]
[0782] Step A: Preparation of methyl 6-(2-hydroxypropyl-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylate (E62) and methyl 6-bromo-7-(2-hydroxypropyl-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylate (E63).
[0783] i-PrMgCl-LiCl (1.3 M, 6.03 mL, 2 eq) was added to a solution of methyl 6-bromopyrazolo[1,5-a]pyridine-3-carboxylate (1 g, 3.92 mmol) in THF (10 mL) at -78 °C. The reaction mixture was stirred at -78 °C for 15 min, and then acetone (1.37 g, 23.5 mmol, 1.7 mL, 6 eq) was added dropwise to the reaction mixture. The reaction mixture was stirred at -78 °C for 1 hr. The reaction progress was monitored using LC-MS. The reaction mixture was added dropwise to 10 mL of aqueous NH4Cl solution. Water (30 mL) was added, and the aqueous fraction was extracted with EtOAc (25 mL x 2). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO2, PE / EtOAc = 1 / 0 to 20:1) to give E62 (320 mg, 34% yield) and E63 (300 mg, 23% yield).
[0784] E62: 1 H NMR (400MHz, CD3OD) δ 8.40-8.54 (m, 1H), 8.14 (dd, 1H), 7.57 (dd, 1H), 7.27 (dd, 1H), 3.88-4.03 (m, 3H), 1.77-1.92 (m, 6H); LCMS: m / z 235.2[M+H] + .
[0785] E63: 1 H NMR (400MHz, CD3OD) δ8.46 (s, 1H), 8.02 (d, 1H), 7.76 (d, 1H), 3.93 (s, 3H), 1.95 (s, 6H); LCMS: m / z 313.0 [M+H] + .
[0786] Step B: Preparation of 6-(2-hydroxypropyl-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylic acid (E64)
[0787] LiOH·H₂O (116 mg, 2.77 mmol, 1.3 eq) was added to a solution of methyl 6-(1-hydroxy-1-methyl-ethyl)pyrazolo[1,5-a]pyridine-3-carboxylate (E62) (500 mg, 2.13 mmol) in MeOH (3 mL) and H₂O (1 mL). The reaction mixture was stirred at 40 °C for 12 h. The reaction progress was monitored using LCMS. The reaction mixture was concentrated under vacuum to remove MeOH, and water (50 mL) was added. The aqueous fraction was extracted with TBME (30 mL), and the aqueous layer was then adjusted to pH ~6 by adding 0.5 M HCl. The resulting suspension was extracted three times with DCM / MeOH (100 / 10 mL). The combined DCM / MeOH organic layers were dried over Na₂SO₄, filtered, and concentrated to dryness to give E64 (420 mg, 89% yield). LCMS: m / z 221.1 [M+H] + .
[0788] Step C: Preparation of 6-bromo-7-(2-hydroxypropyl-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylic acid (E65)
[0789] LiOH·H₂O (17.69 mg, 422 μmol, 1.1 eq) was added to a solution of methyl 6-bromo-7-(2-hydroxypropyl-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylate (E63) (120 mg, 383 μmol) in MeOH (2 mL) and H₂O (1 mL), and the mixture was stirred at 40 °C for 12 hr. The reaction progress was monitored using LCMS. The reaction mixture was concentrated under vacuum to remove MeOH, and water (10 mL) was added. The aqueous fraction was extracted with TBME (30 mL) and then adjusted to pH ~6 by adding 0.5 M HCl. The resulting suspension was extracted three times with DCM / MeOH (30 / 3 mL). The combined DCM / MeOH organic layers were dried over Na₂SO₄, filtered, and concentrated to dryness to give E65 (100 mg, 87% yield). 1 HNMR (400MHz, CD3OD) δ8.44 (s, 1H), 8.07 (d, 1H), 7.74 (d, 1H), 1.96 (s, 6H); LCMS: m / z 301.1[M+H] + .
[0790] Step D: Preparation of methyl 7-(2-hydroxypropyl-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylate (E66)
[0791] Pd / C (100 mg, 10% purity) was added to a solution of methyl 6-bromo-7-(2-hydroxypropyl-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylate (E63) (450 mg, 1.44 mmol) in MeOH (10 mL) under N2. The resulting mixture was degassed under vacuum and washed three times with H2, then stirred at room temperature under H2 (15 psi) for 1 hr. The reaction progress was monitored using LCMS. The reaction mixture was filtered through a diatomaceous earth pad, and the filtrate was concentrated under vacuum to give E66 (350 mg), which was used without further purification. LCMS: m / z 234.9 [M+H] + .
[0792] Step E: Preparation of 7-(2-hydroxypropyl-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylic acid (E67)
[0793] To a solution of methyl 7-(2-hydroxypropyl-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylate (E66) (350 mg, 1.49 mmol) in MeOH (5 mL) and H₂O (1 mL), NaOH (89.64 mg, 2.24 mmol, 1.5 eq) was added, and the mixture was stirred at 40 °C for 12 h. The reaction progress was monitored using LCMS. The reaction mixture was concentrated under vacuum to remove MeOH, and water (10 mL) was added. The aqueous fraction was extracted with TBME (30 mL) and then adjusted to pH ~6 by adding 0.5 M HCl. The resulting suspension was extracted three times with DCM / MeOH (30 / 3 mL). The combined DCM / MeOH organic layers were dried over Na₂SO₄, filtered, and concentrated to dryness to give E67 (320 mg), which was used without further purification. LCMS: m / z 220.9 [M+H] + .
[0794] Intermediate E72, according to general scheme 7, methods C and D
[0795]
[0796] Step A: Preparation of methyl 6-vinylpyrazolo[1,5-a]pyridine-3-carboxylate (E68)
[0797] A mixture of 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxabortane (8.15 g, 52.9 mmol, 8.98 mL), methyl 6-bromopyrazolo[1,5-a]pyridine-3-carboxylate (9 g, 35.3 mmol), K3PO4 (22.47 g, 106 mmol), and Pd(dppf)Cl2 (1.29 g, 1.76 mmol) in dioxane (80 mL) and H2O (40 mL) was stirred at 80 °C under N2 for 12 hours. The reaction progress was monitored using LC-MS. The reaction mixture was combined with another 1 g batch and DCM (200 mL) was added. The organic layer was washed with brine (2 x 80 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO2, PE / EtOAc = 1 / 0 to 4 / 1) to give E68 (6.4 g, 80.2% yield). 1 H NMR (400MHz, CDCl3) δ8.37 (s, 1H), 8.30 (s, 1H), 8.03 (d, 1H), 7.52 (dd, 1H), 6.61 (dd, 1H), 5.76 (d, 1H), 5.34 (d, 1H), 3.84 (s, 3H); LCMS: m / z 203.1[M+H] + .
[0798] Step B: Preparation of methyl 6-formylpyrazolo[1,5-a]pyridine-3-carboxylate (E69)
[0799] K₂O₄·2H₂O (583 mg, 1.58 mmol) and NaIO₄ (16.92 g, 79.1 mmol, 4.38 mL) were added to a solution of methyl 6-vinylpyrazolo[1,5-a]pyridine-3-carboxylate (E68) (6.4 g, 31.7 mmol) in THF (80 mL) and H₂O (80 mL) at 0 °C. The reaction mixture was then stirred at room temperature for 12 h. The reaction progress was monitored using LCMS. DCM (200 mL) was added to the reaction mixture, and the organic layer was washed with brine (2 x 80 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, DCM / EtOAc = 1 / 0 to 6 / 1) to give E69 (5.9 g, 91.3% yield). 1 H NMR (400MHz, CDCl3) δ9.94 (s, 1H), 8.90-8.98 (m, 1H), 8.48 (s, 1H), 8.18 (d, 1H), 7.80 (dd, 1H), 3.88 (s, 3H); LCMS: m / z 204.9[M+H] + .
[0800] Step C: Preparation of methyl 6-(hydroxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylate (E70)
[0801] NaBH4 (1.78 g, 47.0 mmol) was added to a solution of methyl 6-formylpyrazolo[1,5-a]pyridine-3-carboxylate (E69) (2.4 g, 11.8 mmol) in THF (30 mL) and MeOH (30 mL) at 0 °C, and the reaction mixture was stirred at room temperature for 1 hr. The reaction progress was monitored using LCMS. The reaction mixture was quenched by adding saturated aqueous NH4Cl solution (50 mL), and the aqueous fraction was extracted with EtOAc (100 mL). The organic layer was washed with water (50 mL) and brine (40 mL), dried over Na2SO4, filtered, and concentrated to dryness to give E70 (2.3 g, 94.9% yield). 1 H NMR (400MHz, CDCl3) δ8.54 (s, 1H), 8.38 (s, 1H), 8.11 (d, 1H), 7.41 (dd, 1H), 4.78 (s, 2H), 3.93 (s, 3H); LCMS: m / z 207.0 [M+H] + .
[0802] Step D: Preparation of methyl 6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylate (E71)
[0803] NaH (512 mg, 12.8 mmol, 60% purity) was added to a solution of methyl 6-(hydroxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylate (E70) (2.2 g, 10.7 mmol) in THF (50 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 15 min, and then MeI (1.82 g, 12.8 mmol, 797 μL) was added to the reaction mixture. The reaction mixture was stirred at room temperature for 1 h, and the reaction progress was monitored using LCMS. The reaction mixture was quenched by adding saturated aqueous NH4Cl solution (40 mL), and the aqueous fraction was extracted with DCM (2 x 60 mL). The combined organic layers were washed with water (30 mL) and brine (30 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO2, PE / EtOAc = 1 / 0 to 5 / 1) to give E71 (1.8 g, 76.6% yield). 1 H NMR (400MHz, CDCl3) δ 8.52 (s, 1H), 8.41 (s, 1H), 8.16 (d, 1H), 7.42 (dd, 1H), 4.53 (s, 2H), 3.94 (s, 3H), 3.46 (s, 3H); LCMS: m / z 221.1[M+H] + .
[0804] Step E: Preparation of 6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylic acid (E72)
[0805] NaOH (719 mg, 18.0 mmol) was added to a solution of methyl 6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylate (E71) (1.8 g, 8.17 mmol) in MeOH (40 mL) and H₂O (40 mL), and the reaction mixture was stirred at 40 °C for 12 h. The reaction progress was monitored using LCMS. The reaction mixture was concentrated to remove MeOH, and then H₂O (10 mL) was added. The pH of the aqueous mixture was adjusted to ~6 by adding 0.5 M HCl, and the aqueous mixture was filtered. The precipitate was dried under vacuum to give E72 (1.6 g, 94.9% yield). 1 H NMR (400MHz, CDCl3) δ8.57 (s, 1H), 8.45-8.51 (m, 1H), 8.21 (d, 1H), 7.48 (dd, 1H), 4.55 (s, 2H), 3.48 (s, 3H); LCMS: m / z 206.7[M+H] + .
[0806] Intermediate E78, according to general scheme 9, method A
[0807]
[0808] Step A: Preparation of 2,6-difluorobenzoylhydrazide (E73)
[0809] NH₂NH₂·H₂O (18.18 g, 363 mmol, 17.7 mL) was added to a solution of methyl 2,6-difluorobenzoate (25 g, 145 mmol) in MeOH (250 mL), and the reaction mixture was stirred at 60 °C for 12 h. The reaction progress was monitored by TLC. Further NH₂NH₂·H₂O (7.27 g, 145 mmol, 7.05 mL) was added, and the reaction mixture was stirred at 60 °C for another 3 h. The reaction mixture was concentrated under vacuum to give E73 (25 g), which was used without further purification. 1 H NMR (400MHz, CDCl3) δ7.37 (s, 1H), 6.93 (t, 2H), 3.45-3.89 (m, 2H).
[0810] Step B: Preparation of methyl 2-[2-(2,6-difluorobenzoyl)hydrazino]-2-oxo-acetate (E74)
[0811] Methyl 2-chloro-2-oxo-acetate (19.57 g, 160 mmol, 14.7 mL) was added to a solution of 2,6-difluorobenzoyl hydrazine (E73) (25 g, 145 mmol) in THF (250 mL) at 0 °C, and the reaction mixture was stirred at 0 °C for 1 hr. The reaction progress was monitored by TLC. The reaction mixture was filtered. The precipitate was washed with MTBE (800 mL) and then dried under vacuum to give E74 (37 g). 1 H NMR (400MHz, DMSO-d6) δ7.59 (ddd, 2H), 7.21 (t, 1H), 3.83 (s, 2H).
[0812] Step C: Preparation of methyl 5-(2,6-difluorophenyl)-1,3,4-oxadiazole-2-carboxylate (E75)
[0813] Et3N (23.52 g, 232 mmol, 32.4 mL) and TosCl (14.40 g, 75.5 mmol) were added fractionally to a solution of methyl 2-[2-(2,6-difluorobenzoyl)hydrazino]-2-oxo-acetate (E74) (15 g, 58.1 mmol) in DCM (250 mL) at 0 °C. The reaction mixture was warmed to room temperature and stirred at room temperature for 12 h. The reaction progress was monitored by TLC. DCM (100 mL) was added to the reaction mixture, and the organic layer was washed with saturated aqueous solution of NaHCO3 (100 mL) and water (100 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO2, PE / EtOAc = 1 / 0 to 1 / 1) to give E75 (4.3 g, 30.8% yield). 1 H NMR (400MHz, CDCl3) δ7.61 (tt, 1H), 7.14 (t, 2H), 4.10 (s, 3H).
[0814] Step D: Preparation of 5-(2,6-difluorophenyl)-1,3,4-oxadiazole-2-carboxylic acid (E76)
[0815] LiOH·H₂O (52.4 mg, 1.25 mmol) was added to a solution of methyl 5-(2,6-difluorophenyl)-1,3,4-oxadiazole-2-carboxylate (E75) (300 mg, 1.25 mmol) in H₂O (2 mL) and THF (4 mL). The reaction mixture was stirred at room temperature for 1 hour. The reaction progress was monitored using LCMS. The reaction mixture was concentrated under vacuum to obtain E76 (300 mg), which was used without further purification. LCMS: m / z 226.8 [M+H] +
[0816] Step E: Preparation of 2-(2,6-difluorophenyl)-1,3,4-oxadiazole (E77)
[0817] HCl (1 M, 35.4 mL) was added to a solution of 5-(2,6-difluorophenyl)-1,3,4-oxadiazol-2-carboxylic acid (E76) (4 g, 17.7 mmol) in H2O (20 mL), and the reaction mixture was stirred at room temperature for 1 hr. The reaction progress was monitored using LCMS and TLC. DCM (60 mL) was added to the reaction mixture, and the organic layer was washed with water (20 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO2, PE / EtOAc = 1 / 0 to 1 / 1) to give E77 (1.5 g, 46.6% yield). 1 H NMR (400MHz, CDCl3) δ8.63 (s, 1H), 7.57 (tt, 1H), 7.12 (t, 2H); LCMS: m / z 182.8[M+H] + .
[0818] Step F: Preparation of 2-bromo-5-(2,6-difluorophenyl)-1,3,4-oxadiazole (E78)
[0819] LiHMDS (1M, 16.5mL) was added dropwise to a solution of 2-(2,6-difluorophenyl)-1,3,4-oxadiazole (E77) (1.5g, 8.24mmol) in THF (50mL) at -78°C. The reaction mixture was stirred at -78°C for 30 min, and then Br2 (2.63g, 16.5mmol, 849μL) was added dropwise to the reaction mixture at -78°C. The reaction mixture was stirred at -78°C for 2 h. The reaction progress was monitored by TLC. A saturated aqueous solution of NH4Cl (100mL) was added to the reaction mixture, and the aqueous fraction was extracted with DCM (3 x 50mL). The combined organic layers were washed with brine (40mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO2, PE / EtOAc = 1 / 0 to 3 / 1) to give E78 (1.6g, 54.2% yield). 1 H NMR (400MHz, DMSO-d6) δ7.79 (tt, 1H), 7.41 (t, 2H); LCMS: m / z 341.2[M+H] + .
[0820] According to General Scheme 1, Method C was used to prepare Examples 640 and 641.
[0821]
[0822] Step 1: Preparation of 4-(pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
[0823] A mixture of pyrazolo[1,5-a]pyridin-2-carboxaldehyde (C3) (9.2 g, 63.0 mmol), 2-(1H-imidazol-5-yl)ethylamine (15.06 g, 81.8 mmol, 1.3 eq, 2HCl salt) and K2CO3 (17.40 g, 126 mmol, 2 eq) in EtOH (300 mL) was stirred at 80 °C under N2 for 16 h. The reaction progress was monitored using LCMS. The reaction mixture was combined with another reaction mixture using 5 g of C3 and filtered, and the filtrate was concentrated to dryness. The residue was purified by silica gel column chromatography (DCM:MeOH = 20:1 to 10:1) to give 4-pyrazolo[1,5-a]pyridin-2-yl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine (11.4 g). 1 H NMR (400MHz, CD3OD) δ8.48 (d, 1H), 7.54-7.62 (m, 2H), 7.09-7.29 (m, 1H), 6.82-6.90 (m, 1H) , 6.44(s, 1H), 5.28(s, 1H), 3.28(dt, 1H), 3.04-3.12(m, 1H), 2.73-2.80(m, 2H); LC-MS: m / z 240.2(M+H) + .
[0824] Step 2: Preparation of 5-(4-pyrazolo[1,5-a]pyridin-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-carbonyl)oxazol-4-carboxynitrile
[0825] To a solution of 4-pyrazolo[1,5-a]pyridin-2-yl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine (4 g, 16.7 mmol) and (4-cyanoxazol-5-carbonyl)oxylithium (E35) (3.37 g, 23.4 mmol, 1.4 eq) in DMF (90 mL), HATU (7.63 g, 20.1 mmol, 1.2 eq) and pyridine (3.97 g, 50.2 mmol, 4.1 mL, 3 eq) were added. The reaction mixture was stirred at room temperature for 2 h. The reaction progress was monitored using LC-MS, and the reaction mixture was stirred at room temperature for another 12 h. The reaction progress was monitored using TLC (DCM:MeOH = 10:1). DCM (300 mL) was added, and the organic fraction was washed with saturated NaHCO3 solution (100 mL) and brine (100 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by rapid silica gel chromatography. 40g A Silica Flash column was used as the eluent (0–8.5% MeOH / DCM @ 35 mL / min) to yield 5-(4-pyrazolo[1,5-a]pyridin-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-carbonyl)oxazol-4-carboxylonitrile (2.6 g). 1 H NMR (400MHz, CD3OD) δ8.51 (s, 1H), 8.46 (d, 1H), 7.69 (s, 1H), 7.57-7.65 (m, 1H), 7.17-7.23 (m, 1H), 6.83-6.91 (m, 2H), 6.59-6.72 (m, 1H), 4.40 (br d, 1H), 3.77 (br d, 1H), 3.19 (s, 1H), 2.85 (br s, 1H); LC-MS: m / z 360.2 (M+H) + .
[0826] Step 3: S...
Claims
1. Compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein: m is 1 or 2; R 1 for x is 0 to 5; Each R a are independently halogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy or C 1-6 Haloalkoxy; R 2 C 1-4 Alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; R 3 H or C 1-6 alkyl; R 4 H or C 1-6 alkyl; or R 3 and R 4 , together with the atoms to which they are attached, form C 3-6 Cycloalkyl; R 5 is H or D; R 5A is H or D; L is a bond, a carbonyl group, an optionally substituted C 1-6 Alkylene, optionally substituted C 1-6 Alkylenecarbonyl, optionally substituted C 2-6 Alkenylenecarbonyl, optionally substituted C 1-6 haloalkylenecarbonyl, or optionally substituted -C(O)NR b (C 1-6 alkylene)-, wherein the carbon atom of the carbonyl group is connected to N in formula I; and R b H or C 1-6 alkyl.
2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R 5A is D.
3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R 5A For H.
4. The compound of claim 1, wherein the compound has Formula IA: or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1, wherein the compound has Formula IB: or a pharmaceutically acceptable salt thereof.
6. The compound of claim 1, wherein the compound has Formula IC: or a pharmaceutically acceptable salt thereof.
7. The compound of claim 1, wherein the compound has Formula ID: like or a pharmaceutically acceptable salt thereof.
8. The compound of claim 1, wherein the compound has Formula IE: like or a pharmaceutically acceptable salt thereof.
9. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein L is a bond, -C(O)-, -C(O)CH 2 -、-C(O)CH 2 CH 2 -、-C(O)CH 2 CH 2 CH 2 -、-C(O)CF 2 -、-C(O)CHF-、-C(O)C(CH 3 ) 2 -、-C(O)CH=CH-、 -C(O)NHCH 2 -、-CH 2 -or-CH 2 CH 2 -.
10. The compound according to claim 9 or a pharmaceutically acceptable salt thereof, wherein L is a bond, -C(O)-, -C(O)CH 2 -or-C(O)CF 2 -.
11. The compound of any one of claims 1 to 3 and 9 to 10, or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 Each is hydrogen.
12. The compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein m is 1.
13. The compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein m is 2.
14. The compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein x is 0 or 1.
15. The compound according to any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein R 1 for 16. The compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein R a is a halogen such as F, Br or Cl.
17. The compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein R a C 1-6 Alkyl groups such as methyl, ethyl or isopropyl.
18. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein R a C 1-6 Alkoxy groups such as methoxy or ethoxy.
19. The compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein R a C 1-6 Haloalkyl such as CF 3 or CHF 2 .
20. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein R a C 1-6 Haloalkoxy such as OCF 3 or OCHF 2 .
21. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein R a C 3-6 Cycloalkyl groups include cyclopropyl.
22. The compound of any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof, wherein R 5 is D.
23. The compound of any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof, wherein R 5 For H.
24. The compound of any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein R 2 is an optionally substituted C 3-8 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
25. The compound of claim 24 or a pharmaceutically acceptable salt thereof, wherein R 2 is cyclopentyl, cyclobutyl, cyclopropyl, cyclohexyl, azetidinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazolo[1,5-a]pyridinyl, indazolyl, thiadiazolyl, imidazo[1,5-a]pyridinyl, pyrrolo[1,2-b]pyridazinyl, thienyl, isoxazolyl, isothiazolyl, benzo[d]thiazolyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]isoxazolyl, benzo[c]isoxazolyl, benzo[d]isothiazolyl, furanyl, pyrazinyl, or quinolinyl, each of which is optionally substituted.
26. The compound of claim 24 or a pharmaceutically acceptable salt thereof, wherein R 2 is cyclopentyl, cyclobutyl, cyclopropyl, cyclohexyl, azetidinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazolo[1,5-a]pyridinyl, indazolyl, thiadiazolyl, imidazo[1,5-a]pyridinyl, pyrrolo[1,2]pyridazinyl, thienyl, isoxazolyl, isothiazolyl, benzo[d]thiazolyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]isoxazolyl, benzo[c]isoxazolyl, benzo[d]isothiazolyl, furanyl, pyrazinyl or quinolinyl, each of which is unsubstituted.
27. The compound of claim 24 or a pharmaceutically acceptable salt thereof, wherein R 2 is azetidin-1-yl, azetidin-3-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,2,3-triazol-5-yl, 1,3,4-oxadiazol-2-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, pyrazolo[1,5-a]pyridin-3-yl, indazol-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, 1,3,4-thiadiazol-2-yl, pyridin-1-yl, pyridin-2-yl, pyridin- 3-yl, pyridin-4-yl, pyrimidin-2-yl, imidazo[1,5-a]pyridin-1-yl, pyrrolo[1,2-b]pyridazin-5-yl, pyrrolo[1,2-b]pyridazin-6-yl, thiophene-2-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, benzo[d]thiazol-2-yl, benzo[d]thiazol-3-yl, benzo[d]imidazol-2-yl, benzo[d]oxazol-2-yl, benzo[d]isoxazol-3-yl, benzo[d]isothiazol-3-yl, furan-3-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, pyrazin-2-yl, benzo[c]isoxazol-3-yl, or quinolin-3-yl, each of which is optionally substituted.
28. The compound of any one of claims 24, 25 and 27, or a pharmaceutically acceptable salt thereof, wherein R 2 Replaced with one or more of the following: C 1-6 Alkyl such as methyl, ethyl, propyl, isopropyl or tert-butyl; Optionally substituted C 2-6 Alkenyl such as CH=CH 2 、CH=CHC(CH 3 ) 2 OH or CH=CH-cyclopropyl; Halogens such as Br, Cl or F; CN; C 1-6 Cyanoalkyl groups such as C(CH 3 ) 2 CN; C 1-6 Haloalkyl such as CF 3 , CHF 2 , CH 2 F, CH(CH 3 )F、CH 2 CF 3 , C(CH 3 ) 2 F、C(CH 3 )F 2 , or CH 2 CHF 2 ; OH; Optionally substituted C 3-8 Cycloalkyl such as optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, or optionally substituted cyclohexyl; Optionally substituted C 3-8 Cycloalkyl(alkylene) such as optionally substituted cyclopropyl(alkylene) or optionally substituted cyclobutyl(alkylene); Optionally substituted C 3-8 Cycloalkenyl such as optionally substituted cyclohexenyl; Optionally substituted aryl such as optionally substituted phenyl; Optionally substituted aryl(alkylene) such as optionally substituted benzyl; optionally substituted heteroaryl such as optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted pyrazinyl, or optionally substituted pyridazinyl; optionally substituted heterocyclyl such as optionally substituted azetidinyl, optionally substituted piperidinyl, optionally substituted piperazinyl, optionally substituted pyrrolidinyl, optionally substituted morpholinyl, or optionally substituted 6-azaspiro[2.5]octan-6-yl; optionally substituted heterocyclyl(alkylene) such as optionally substituted morpholinyl(alkylene), piperidinyl(alkylene), optionally substituted piperazinyl(alkylene) or optionally substituted azetidinyl(alkylene); C 1-6 Hydroxyalkyl such as C(CH 3 ) 2 OH, CH(CH 3 )OH, C(CH 3 ) 2 CH 2 OH, CH 2 C(CH 3 ) 2 OH or CH(CH 2 CH 3 )OH; C 1-6 Haloalkoxy such as OCF 3 、OCH 2 CF 3 , or OCH 2 CH 2 CF 3 ; C 1-6 Haloalkoxy (alkylene) such as CH 2 OCF 3 ; C 1-6 Alkoxy groups such as methoxy or ethoxy; C 1-6 Alkoxy (alkylene) such as C (CH 3 ) 2 OCH 3 , CH 2 OCH 3 , or (CH 2 ) 2 OCH 3 ; C 1-6 Deuterated alkoxy (alkylene) such as CH 2 OCD 3 ; C 1-6 Alkylcarbonyl such as C(=O)CH 3 or CH 2 C(=O)CH 3 ; C 3-8 Cycloalkylsulfonyl such as cyclopropylsulfonyl, cyclobutylsulfonyl or cyclopentylsulfonyl; C 1-6 Alkylsulfonyl such as methylsulfonyl, ethylsulfonyl or propylsulfonyl; C 1-6 Alkylsulfonyl (alkylene) such as C(CH 3 ) 2 SO 2 CH 3 ; (CR v R x ) p NR y R z , where R v and R x are independently H or C 1-6 Alkyl; R y and R z , independently H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy (alkylene), or C (O) OC 1-6 Alkyl; and p is 0, 1, 2 or 3, such as NH 2 , NH cyclopropyl, NHCH 3 、N(CH 3 ) 2 , CH 2 N(CH 3 ) 2 , (CH 2 ) 2 N(CH 3 ) 2 , CH 2 N(CH 3 )(CH 2 CH 3 )、C(CH 3 ) 2 NH(CH 3 )、C(CH 3 ) 2 N(CH 3 ) 2 , CH 2 N(CH 3 )cyclobutyl or CH 2 N(CH 3 )(C(O)Otert-butyl); and C(O)NR y2 R z2 , where R y2 and R z2 Independently H, C 1-6 Alkyl, or C 3-6 Cycloalkyl, such as C(O)N(CH 3 ) 2 or C(O)NHcyclopropyl.
29. The compound of claim 24 or a pharmaceutically acceptable salt thereof, wherein R 2 is a heterocyclic group, optionally substituted with one or more of the following: halogen, C 1-6 haloalkyl, or optionally substituted heteroaryl.
30. The compound of claim 24 or a pharmaceutically acceptable salt thereof, wherein R 2 C 3-8 Cycloalkyl, optionally substituted with one or more of the following: halogen, C 1-6 Alkyl, C 1-6 Haloalkyl or OH.
31. The compound of claim 30 or a pharmaceutically acceptable salt thereof, wherein R 2 is unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted cyclopentyl, unsubstituted cyclohexyl, 32. The compound of claim 24 or a pharmaceutically acceptable salt thereof, wherein R 2 is aryl, optionally substituted with one or more of the following: halogen or C 1-6 Alkoxy.
33. The compound of claim 25 or a pharmaceutically acceptable salt thereof, wherein R 2 is optionally substituted pyridinyl, optionally substituted pyrimidinyl, or optionally substituted pyrazinyl.
34. The compound of claim 33 or a pharmaceutically acceptable salt thereof, wherein the pyridyl, pyrimidyl or pyrazinyl is substituted with one or more of: halogen, C 1-6 Haloalkyl, cyano, or NR y R z , where R y and R z are independently H or C 1-6 alkyl.
35. The compound of any one of claims 24, 25 and 27, or a pharmaceutically acceptable salt thereof, wherein R 2 is a heteroaryl group substituted with one or more of the following: C 1-6 Alkyl, C 1-6 Cyanoalkyl, C 1-6 Haloalkyl, or C 1-6 Hydroxyalkyl.
36. The compound of claim 35 or a pharmaceutically acceptable salt thereof, wherein R 2 Substituted with methyl, ethyl, isopropyl, tert-butyl, C(CH 3 ) 2 CN, CH(CH 3 )OH, C(CH 3 ) 2 OH, C(CH 3 ) 2 CH 2 OH, CH(CH 2 CH 3 )OH、CH 2 C(CH 3 ) 2 OH, CH 2 F. CHF 2 CF 3 , CH 2 CF 3 , CH 2 CHF 2 、CH(CH 3 )F、C(CH 3 )F 2 , or C(CH 3 ) 2 F.
37. The compound of any one of claims 24, 25 and 27, or a pharmaceutically acceptable salt thereof, wherein R 2 is a heteroaryl group substituted with C 3-8 Cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein the C 3-8 Cycloalkyl is optionally substituted with one or more of the following: halogen such as F, Cl or Br; OH; C 1-6 Haloalkyl such as CF 3 , CH 2 CF 3 or CHF 2 ; C 1-6 Alkyl such as methyl, ethyl or propyl; or C 1-6 Alkoxy groups such as methoxy, ethoxy or propoxy.
38. The compound of claim 37 or a pharmaceutically acceptable salt thereof, wherein R 2 Replace 39. The compound of any one of claims 24, 25 and 27, or a pharmaceutically acceptable salt thereof, wherein R 2 is a heteroaryl group substituted with an aryl group, such as phenyl, wherein the aryl group is optionally substituted with one or more of the following: halogen such as F, Cl or Br; C 1-6 Haloalkyl such as CF 3 , CH 2 CF 3 or CHF 2 ; C 1-6 Alkyl such as methyl, ethyl or propyl; or C 3-8 Cycloalkyl groups such as cyclopropyl, cyclobutyl or cyclopentyl.
40. The compound of claim 39 or a pharmaceutically acceptable salt thereof, wherein R 2 Replace 41. The compound of claim 28 or a pharmaceutically acceptable salt thereof, wherein R 2 is heteroaryl substituted with an optionally substituted heteroaryl, wherein the optional substitution is one or more of the following: Halogens such as F, Cl or Br; C 1-6 Haloalkyl such as CF 3 , CH 2 CHF 2 , CH 2 CF 3 or CHF 2 ; C 1-6 Alkyl such as methyl, ethyl, propyl or isopropyl; C 1-6 Alkoxy groups such as methoxy, ethoxy or propoxy; C 1-6 Haloalkoxy such as OCF 3 ; C 3-8 Cycloalkyl such as cyclopropyl, cyclobutyl or cyclopentyl; or C 3-8 Cycloalkylsulfonyl, such as cyclopropylsulfonyl, cyclobutylsulfonyl or cyclopentylsulfonyl.
42. The compound of claim 41 or a pharmaceutically acceptable salt thereof, wherein R 2 Substituted with pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl, pyrazin-3-yl, pyrazin-4-yl, pyrazin-5-yl, imidazol-4-yl, imidazol-5-yl, pyridazin-3-yl, or pyridazin-4-yl, each of which is optionally substituted.
43. The compound of claim 42 or a pharmaceutically acceptable salt thereof, wherein R 2 Replace 44. The compound of claim 42 or a pharmaceutically acceptable salt thereof, wherein R 2 Replace 45. The compound of any one of claims 24, 25 or 27, or a pharmaceutically acceptable salt thereof, wherein R 2 is a heteroaryl group substituted with an optionally substituted heterocyclic group such as an optionally substituted azetidinyl group, an optionally substituted pyrrolidinyl group, an optionally substituted piperidinyl group, an optionally substituted piperazinyl group, an optionally substituted morpholinyl group, or an optionally substituted 6-azaspiro[2.5]octan-6-yl group, or an optionally substituted heterocyclic group(alkylene group), wherein the optional substitution is one or more of the following: Halogens such as F, Cl or Br; OH; C 1-6 Haloalkyl such as CF 3 , CH 2 CF 3 or CHF 2 ; C 1-6 Alkyl such as methyl, ethyl or propyl; C 1-6 Hydroxyalkyl such as C(CH 3 ) 2 OH or CH(CH 3 )OH; C 1-6 Alkoxy groups such as methoxy, ethoxy or propoxy; C(O)O(C 1-6 alkyl), such as C(O)Omethyl, C(O)Oethyl, C(O)Opropyl, or C(O)Otert-butyl; or C 3-8 Cycloalkyl groups such as cyclopropyl, cyclobutyl or cyclopentyl.
46. The compound of claim 45 or a pharmaceutically acceptable salt thereof, wherein R 2 Replace 47. The compound of any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein R 2 for: in: R 6 and R 7 are independently H, CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Cyanoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkoxy (alkylene), C 1-6 Haloalkoxy, C 1-6 Haloalkoxy(alkylene), C 1-6 Deuterated alkoxy (alkylene), halogen, (CR v R x ) p NR y R z 、C(O)NR y2 R z2 , C 1-6 Alkylcarbonyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C 2-6 optionally substituted C 3-8 Cycloalkenyl; optionally substituted C 3-8 Cycloalkyl(alkylene); optionally substituted aryl(alkylene); optionally substituted heterocyclyl(alkylene); or C 1-6 Alkylsulfonyl; R 8 H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylcarbonyl, C 1-6 Hydroxyalkyl, (CR v R x ) p NR y R z , optionally substituted C 3-8 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted C 3-8 Cycloalkyl(alkylene); R v and R x are independently H or C 1-6 alkyl; R y and R z Independently H, C 1-6 Alkyl, C 1-6 Alkoxy (alkylene), or C 3-6 Cycloalkyl; R y2 and R z2 Independently H, C 1-6 Alkyl, or C 3-6 cycloalkyl; and p is 0, 1, 2 or 3.
48. The compound of claim 47 or a pharmaceutically acceptable salt thereof, wherein R 6 , R 7 and R 8 Each is H.
49. The compound of claim 47 or a pharmaceutically acceptable salt thereof, wherein R 6 C 1-6 Alkyl such as methyl, ethyl, isopropyl or tert-butyl, C 1-6 Haloalkyl such as CF 3 , CHF 2 , CH 2 F, CH 2 CF 3 、CH(CH 3 )F、C(CH 3 )F 2 , or C(CH 3 ) 2 F.C 1-6 Cyanoalkyl groups such as C(CH 3 ) 2 CN, or C 1-6 Hydroxyalkyl such as C(CH 3 ) 2 OH, CH(CH 3 )OH, CH(CH 2 CH 3 )OH、CH 2 C(CH 3 ) 2 OH, or C(CH 3 ) 2 CH 2 OH.
50. The compound of claim 47 or a pharmaceutically acceptable salt thereof, wherein R 6 C 3-6 Cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, optionally substituted with one or more of the following: halogen such as F, Cl or Br; OH; C 1-6 Haloalkyl such as CF 3 , CH 2 CF 3 or CHF 2 ; C 1-6 Alkyl such as methyl, ethyl or propyl; or C 1-6 Alkoxy groups such as methoxy, ethoxy or propoxy.
51. The compound of claim 50 or a pharmaceutically acceptable salt thereof, wherein R 6 for 52. The compound of claim 47 or a pharmaceutically acceptable salt thereof, wherein R 6 is aryl, such as phenyl, optionally substituted with one or more of the following: halogen such as F, Cl or Br; C 1-6 Haloalkyl such as CF 3 , CH 2 CF 3 or CHF 2 ; C 1-6 Alkyl such as methyl, ethyl or propyl; or C 3-6 Cycloalkyl groups such as cyclopropyl, cyclobutyl or cyclopentyl.
53. The compound of claim 52 or a pharmaceutically acceptable salt thereof, wherein R 6 for 54. The compound of claim 47 or a pharmaceutically acceptable salt thereof, wherein R 6 is heteroaryl such as pyridyl, pyrazolyl, pyrazinyl, pyridazinyl, imidazolyl or pyrimidinyl, optionally substituted with one or more of the following: halogen such as F, Cl or Br; C 1-6 Haloalkyl such as CF 3 , CH 2 CF 3 , CH 2 CHF 2 or CHF 2 ; C 1-6 Alkyl such as methyl, ethyl, propyl or isopropyl; C 1-6 Alkoxy such as methoxy, ethoxy or propoxy; C 1-6 Haloalkoxy such as OCF 3 ; C 3-6 Cycloalkyl such as cyclopropyl, cyclobutyl or cyclopentyl; or C 3-6 Cycloalkylsulfonyl, such as cyclopropylsulfonyl, cyclobutylsulfonyl or cyclopentylsulfonyl.
55. The compound of claim 54, or a pharmaceutically acceptable salt thereof, wherein the heteroaryl is pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, imidazol-4-yl, imidazol-5-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl, pyrazin-3-yl, pyrazin-4-yl, pyrazin-5-yl, pyridazin-3-yl, or pyridazin-4-yl, each of which is optionally substituted.
56. The compound of claim 55 or a pharmaceutically acceptable salt thereof, wherein R 6 for 57. The compound of claim 55 or a pharmaceutically acceptable salt thereof, wherein R 6 for 58. The compound of claim 47 or a pharmaceutically acceptable salt thereof, wherein R 6 is a heterocyclyl such as azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl, or a heterocyclyl(alkylene) group, wherein the heterocyclyl and heterocyclyl(alkylene) groups are each optionally substituted with one or more of the following: halogen such as F, Cl or Br; C 1-6 Haloalkyl such as CF 3 , CH 2 CF 3 or CHF 2 ; C 1-6 Alkyl such as methyl, ethyl or propyl; C 1-6 Hydroxyalkyl such as C(CH 3 ) 2 OH;C 1-6 Alkoxy such as methoxy, ethoxy or propoxy; C(O)O(C 1-6 alkyl) such as C(O)Omethyl, C(O)Oethyl, C(O)Opropyl, or C(O)Otert-butyl; or C(O)O 3-6 Cycloalkyl groups such as cyclopropyl, cyclobutyl or cyclopentyl.
59. The compound of claim 58 or a pharmaceutically acceptable salt thereof, wherein R 6 for 60. The compound of any one of claims 47 to 59, or a pharmaceutically acceptable salt thereof, wherein R 7 H, CN, C 1-6 Alkyl such as methyl, C 1-6 Haloalkyl such as CF 3 , CH 2 F. CHF 2 CF 2 (CH 3 ), or CH 2 CHF 2 , halogens such as Br or Cl, C 3-8 Cycloalkyl groups such as cyclopropyl, phenyl or pyridyl.
61. The compound of claim 47 or a pharmaceutically acceptable salt thereof, wherein R 2 for: in: R 6 For H, C 1-6 Alkyl such as methyl or tert-butyl, C 1-6 Haloalkyl such as C(CH 3 ) 2 F, C 1-6 Cyanoalkyl groups such as C(CH 3 ) 2 CN, C 1-6 Hydroxyalkyl such as C(CH 3 ) 2 OH or CH(CH 3 )OH, optionally substituted C 3-6 Cycloalkyl Optionally substituted heteroaryl such as and R 7 H, CN, C 1-6 Alkyl such as methyl, C 1-6 Alkyl halide such as CHF 2 or CF 3 , halogens such as Br or Cl, or C 3-6 Cycloalkyl groups include cyclopropyl.
62. A compound according to claim 61 or a pharmaceutically acceptable salt thereof, wherein the optionally substituted heteroaryl is substituted with one or more C 1-6 Alkyl groups such as methyl, ethyl or isopropyl.
63. A compound according to claim 61 or a pharmaceutically acceptable salt thereof, wherein the optionally substituted C 3-6 The cycloalkyl groups are substituted with one or more OH groups.
64. The compound of claim 47 or a pharmaceutically acceptable salt thereof, wherein R 2 for: in: R 6 For H, C 1-6 Alkyl such as tert-butyl, C 1-6 Haloalkyl such as C(CH 3 ) 2 F or C (CH 3 )F 2 , C 1-6 Hydroxyalkyl such as C(CH 3 ) 2 OH or CH(CH 3 )OH; and R 7 For H.
65. The compound of claim 47 or a pharmaceutically acceptable salt thereof, wherein R 2 for: in: R 6 For H, C 1-6 Alkyl such as methyl, isopropyl or tert-butyl, C 1-6 Haloalkyl such as CF 3 , CHF 2 , C(CH 3 )F 2 , or C(CH 3 ) 2 F, C 1-6 Hydroxyalkyl such as C(CH 3 ) 2 OH or CH(CH 3 )OH, optionally substituted C 3-6 Cycloalkyl Optionally substituted aryl such as Optionally substituted heterocyclic groups such as or optionally substituted heteroaryl such as 66. A compound according to claim 65 or a pharmaceutically acceptable salt thereof, wherein the optionally substituted heteroaryl is substituted by one or more of: C 1-6 Alkyl such as methyl, ethyl or isopropyl, C 1-6 Haloalkyl such as CF 3 , CH 2 CF 3 or CHF 2 , halogens such as F, C 1-6 Alkoxy such as methoxy, ethoxy or propoxy, C 3-6 Cycloalkyl such as cyclopropyl or cyclobutyl; or C 3-6 Cycloalkylsulfonyl, such as cyclopropylsulfonyl, cyclobutylsulfonyl or cyclopentylsulfonyl.
67. A compound according to claim 65 or a pharmaceutically acceptable salt thereof, wherein the optionally substituted C 3-6 Cycloalkyl and optionally substituted heterocyclyl are each substituted by one or more of the following: halogen such as F or C 1-6 Alkyl groups such as methyl.
68. A compound according to claim 65 or a pharmaceutically acceptable salt thereof, wherein the optionally substituted aryl is substituted by one or more of: halogen such as F, C 1-6 Alkyl such as methyl, or C 1-6 Haloalkyl such as CF 3 .
69. The compound of claim 47 or a pharmaceutically acceptable salt thereof, wherein R 2 for: in: R 6 and R 7 are independently H, halogen such as Cl, C 1-6 Alkyl such as methyl, C 1-6 Alkyl halide such as CHF 2 or CF 3 , or NR y R z As NH 2 ;and R 8 For H, C 1-6 Alkyl such as methyl or isopropyl, C 1-6 Alkyl halide such as CHF 2 , CH 2 CF 3 , or CF 3 , C 3-6 Cycloalkyl such as cyclopropyl, or heteroaryl such as pyridyl.
70. The compound of claim 47 or a pharmaceutically acceptable salt thereof, wherein R 2 for: in: R 6 For H, C 1-6 Alkyl such as methyl, halogen such as Cl, C 1-6 Alkyl halide such as CHF 2 or CF 3 , or C 3-6 Cycloalkyl such as cyclopropyl; and R 8 H or C 1-6 Alkyl groups such as methyl.
71. The compound of claim 70 or a pharmaceutically acceptable salt thereof, wherein R 6 and R 7 At least one of them is H.
72. The compound of any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein R 2 for: in: W is S or NR 15 ; W 1 S, O or NR 15 ; R 10 , R 11 , R 12 , R 13 and R 14 Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkoxy (alkylene), C 1-6 Hydroxyalkyl, C 1-6 Halogenated alkoxy, C 1-6 Haloalkoxy(alkylene), C 2-6 Alkenyl, CN, halogen, (CR v R x ) p NR y R z 、C(O)NR y2 R z2 , optionally substituted C 3-8 cycloalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclyl(alkylene), optionally substituted aryl, or optionally substituted heteroaryl; R v and R x are independently H or C 1-6 alkyl; R y and R z Independently H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy (alkylene), or C (O) OC 1-6 alkyl; R y2 and R z2 Independently H, C 1-6 Alkyl, or C 3-6 Cycloalkyl; p is 0, 1, 2 or 3; and R 15 H or C 1-6 alkyl.
73. The compound of claim 72 or a pharmaceutically acceptable salt thereof, wherein R 10 , R 11 , R 12 , R 13 and R 14 Each is H.
74. The compound of claim 72 or a pharmaceutically acceptable salt thereof, wherein R 10 , R 11 , R 12 and R 13 Each is H.
75. The compound of claim 72 or a pharmaceutically acceptable salt thereof, wherein R 2 for: in: R 10 , R 11 , R 12 , R 13 and R 14 Independently H, C 1-6 Alkyl such as methyl, C 3-6 Cycloalkyl such as cyclopropyl, C 1-6 Alkoxy such as methoxy, C 1-6 Alkoxy (alkylene) such as CH 2 OCH 3 or (CH 2 ) 2 OCH 3 , optionally substituted heterocyclic groups such as Optionally substituted heterocyclic (alkylene) groups such as Optionally substituted heteroaryl such as or (CR v R x ) p NR y R z As N(CH 3 ) 2 , CH 2 N(CH 3 ) 2 , or CH 2 CH 2 N(CH 3 ) 2 ; R v and R x independently H or C 1-6 alkyl; R y and R z Independently H, C 1-6 Alkyl such as methyl or ethyl, C 3-6 Cycloalkyl such as cyclobutyl, or C(O)OC 1-6 Alkyl such as C(O)O-tert-butyl; and p is 0, 1, 2 or 3.
76. The compound of claim 75, or a pharmaceutically acceptable salt thereof, wherein the optionally substituted heterocyclyl and optionally substituted heterocyclyl(alkylene) are each substituted by one or more of: halogen such as F, Cl or Br; C 1-6 Haloalkyl such as CF 3 , CH 2 CF 3 or CHF 2 ; C 1-6 Alkyl such as methyl, ethyl or propyl; OH; C 1-6 Hydroxyalkyl such as C(CH 3 ) 2 OH, C 1-6 Alkoxy such as methoxy, ethoxy or propoxy; or C 3-6 Cycloalkyl groups such as cyclopropyl, cyclobutyl or cyclopentyl.
77. The compound of claim 75 or a pharmaceutically acceptable salt thereof, wherein the optionally substituted heterocyclic group is 78. The compound of claim 75, or a pharmaceutically acceptable salt thereof, wherein the optionally substituted heteroaryl is substituted with one or more of: halogen such as F, Cl or Br; C 1-6 Haloalkyl such as CF 3 , CH 2 CF 3 or CHF 2 ; or C 1-6 Alkyl groups include methyl, ethyl, propyl or isopropyl.
79. The compound of claim 78 or a pharmaceutically acceptable salt thereof, wherein the optionally substituted heteroaryl is pyrazolyl substituted with one methyl group.
80. The compound of any one of claims 75 to 79, or a pharmaceutically acceptable salt thereof, wherein R 10 , R 13 and R 14 Each is hydrogen.
81. The compound of any one of claims 75 to 79, or a pharmaceutically acceptable salt thereof, wherein R 10 , R 11 , R 13 and R 14 Each is hydrogen.
82. The compound of any one of claims 1 to 81 which is the S-enantiomer, or a pharmaceutically acceptable salt thereof.
83. The compound of claim 1, which is a compound in Table 1, or a pharmaceutically acceptable salt thereof.
84. The compound of claim 83, which is the S-enantiomer, or a pharmaceutically acceptable salt thereof.
85. A pharmaceutical composition comprising a compound according to any one of claims 1 to 84 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
86. The pharmaceutical composition of claim 85, further comprising another therapeutic agent.
87. A method for stabilizing a mutant PAH protein comprising contacting the protein with a compound according to any one of claims 1 to 84, or a pharmaceutically acceptable salt thereof.
88. The method of claim 87, wherein the mutant PAH protein comprises at least one R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation.
89. The method of claim 87, wherein the mutant PAH protein comprises at least one R408W, Y414C, I65T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation.
90. The method of claim 87, wherein the mutant PAH protein comprises at least one R408W mutation.
91. The method of claim 87, wherein the mutant PAH protein comprises two R408W mutations.
92. A method of reducing blood phenylalanine concentration in a subject suffering from phenylketonuria comprising administering a compound of any one of claims 1 to 84, or a pharmaceutically acceptable salt thereof.
93. The method of claim 92, wherein the blood phenylalanine concentration is reduced to a concentration of less than or equal to about 600 μM.
94. The method of claim 93, wherein the blood phenylalanine concentration is reduced to a concentration of less than or equal to about 360 μM.
95. The method of any one of claims 92 to 94, in, Prior to administration of the compound, the subject's blood phenylalanine concentration is greater than about 600 μM.
96. The method of any one of claims 92 to 94, in, Prior to administration of the compound, the subject's blood phenylalanine concentration is greater than about 1200 μM.
